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Introduction 11
Introduction
The work presented in this thesis is part of the FOCUS project, ‘Female breast cancer in the 
elderly; Optimizing Clinical guidelines USing clinico-pathological & molecular data’, which 
was initiated in 2009 by a KWF program grant. The goal of the FOCUS project is to gain 
insight in breast cancer in elderly patients in order to improve care and cure in this patient 
group. The project consists of four domains; analysis of a large observational cohort of elderly 
patients; age specific analyses of clinical trial data; a prospective study investigating patient 
preferences; and a pathology study aiming to unravel differences and similarities in tumor 
biology of elderly breast cancer patients as compared to younger patients. The studies reported 
in this thesis cover analyses of observational cohort data, and age-specific analyses of clinical 
trial data.
Breast cancer is the most common malignancy diagnosed in women1. The incidence of breast 
cancer increases with age; currently, in developed countries more than 40% of breast cancer 
patients is 65 years or older at diagnosis1. In the Netherlands in 2011, 5,441 women aged 65 years 
or older were diagnosed with breast cancer2. The remaining life expectancy of persons aged 65 
is still increasing, from almost 19 years in 1980, up to more than 21 years in 2010. Moreover, 
in last decades the birth rate has decreased, resulting in a higher proportion of older persons 
in the general population3. Both an increasing life expectancy and the increasing number of 
elderly in the population will further enhance the number of elderly women confronted with 
breast cancer; 
Although a large proportion of all breast cancer patients is 65 years or older at diagnosis, 
there are no age specific guidelines for breast cancer treatment. However, elderly breast 
cancer patients differ from younger patients in several aspects. First, it is often reported 
that breast cancer in elderly patients may behave differently as compared to breast cancer in 
younger patients. Others have suggested a more aggressive as well as less aggressive disease 
in elderly patients; it has been shown that breast tumors of patients aged 70 years or older 
had slower growth rates, were genomically more stable and were more likely to be hormone 
receptor positive as compared to breast tumors in women younger than 45 years4. Of note, 
no variation with regards to hormone receptor status or histological grade was observed 
within postmenopausal patients5. On the other hand, tumor size and frequency of nodal 
involvement have been shown to increase with age5, which may be partly due to a delayed 
diagnosis. However, nodal involvement in patients over 70 years was mainly observed in 
combination with smaller tumors, which may indicate a more aggressive disease in elderly6. 
Next to potential differences in tumor biology, age-related physiological changes may affect 
drug absorption, distribution and metabolism7. Moreover, concurrent disease and medication 
use may directly affect tolerability of treatment and increase toxicity8;9. Last, the definition 
of treatment efficacy may be different in elderly patients; a higher risk of death from any 
cause and a lower remaining life expectancy as compared to younger patients may result in 
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a lower absolute benefit of anticancer therapy, while long-term adverse events may be less 
relevant. Given these differences between older and younger breast cancer patients, guideline 
recommendations for younger patients may not be applicable to elderly breast cancer patients. 
Aim of this thesis
The aim of this thesis was to improve management of breast cancer in elderly patients by 
quantifying the evidence base for treatment, and by evaluating breast cancer outcomes and 
treatment efficacy.
Overview of used patient cohorts
FOCUS cohort
Data from the FOCUS cohort were used in chapters 2, 3 and 7. The FOCUS cohort is a 
population-based cohort of all incident breast cancer patients aged 65 years or older, who were 
diagnosed in the geographically defined Comprehensive Cancer Center Region West in The 
Netherlands, between 1997 and 2004. Overall 3,672 patients were included. The nationwide 
Dutch network and registry of histopathology and cytopathology regularly submits reports of 
all diagnosed malignancies to the regional cancer registries. The national hospital discharge 
data bank, which receives discharge diagnoses of admitted patients from all Dutch hospitals, 
completes case ascertainment. Information on patient characteristics, tumor characteristics, 
treatment, follow-up and outcome were recorded for all patients. Comorbidity was defined 
as presence of comorbidity at time of diagnosis, and categorized by the 10th edition of the 
International Statistical Classification of Diseases and Related Health Problems (ICD-10). Vital 
status was established either directly from the patient’s medical record or through linkage 
with the municipal population registries, which record information on vital status (follow-
up until January 1st 2011). One of the main advantages of this cohort is that we were able 
to collect detailed information of a large number of unselected patients, reflecting the large 
heterogeneity among elderly breast cancer patients in the general population.
Netherlands Cancer Registry cohort
Data from the Netherlands Cancer Registry cohort were used in chapter 4. Patients were 
identified from the National Cancer Registry, which comprises all data from the regional 
cancer registries. Registry personnel collects data on diagnosis, staging and treatment from 
the medical records, including pathology and surgery reports, by using the registration and 
coding manual of the Dutch Association of Comprehensive Cancer Centers. Overall, 31,520 
patients with early stage breast cancer, who were diagnosed between 2005 and 2008, and who 
were younger than 65 years or who were 75 years or older at diagnosis, were included in the 
cohort. The rationale behind this age restriction was that younger patients are deemed to be 
represented in clinical in trials upon which guideline recommendations are based, whereas 
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patients aged 75 years or older are included sporadically. Vital status was established through 
linkage with the municipal population registries, which record information on vital status 
(follow-up until January 1st 2011).
TEAM trial
Data from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial were used in 
chapters 3, 5, 6 and 9. The TEAM trial is a randomized, phase 3, multinational, open-label study 
conducted in postmenopausal women with hormone receptor positive breast cancer. Overall, 
9,766 patients were randomized to receive either exemestane 25 mg once daily for 5 years, or 
tamoxifen 20 mg once daily for 2.5 to 3 years, followed by exemestane 25 mg once daily for 
2 to 2.5 years, for a total of 5 years. Patients were enrolled and included in 566 hospitals in 
Belgium, France, Germany, Greece, Japan, The Netherlands, the United Kingdom and Ireland, 
and the United States, between January 2001 and January 2006. Appropriate approvals from 
the ethical committees and written informed consent from all patients were obtained. Similar 
protocols were used in the 9 participating countries with minor differences to accommodate 
local treatment guidelines. In short, postmenopausal patients with histologically confirmed 
breast carcinoma who completed local therapy with curative intent (i.e. without evidence of 
metastatic disease) were eligible. Participants were randomized to receive endocrine treatment 
within 10 weeks of completion of surgery and chemotherapy, if indicated. Patients were 
ineligible if they had a previous malignancy with a disease-free interval of less than 5 years, 
an Eastern Cooperative Oncology Group (ECOG) performance status of more than 2, or 
significant cardiac disease or other illness interfering with study participation. Each patient’s 
medical history was taken and clinical examination was performed at baseline, with further 
investigation as clinically indicated. Patients were assessed every 3 months during the first 
year of treatment and at least once a year thereafter. Mammography was performed every year. 
Adverse events were recorded at each visit; the data were obtained from elicited responses. 
Vital status was established by medical record review or, if information was missing, through 
linkage with the municipal population registries (follow-up until October 7th, 2010). One 
of the advantages of using data from the TEAM trial, was the structured follow-up with 
ascertainment of recurrence and cause of death, which provided a unique opportunity to study 
associations between age and breast cancer outcomes.
Standard care cohort and oncogeriatric care cohort
Data from the standard care cohort and oncogeriatric care cohort were used in chapter 10. The 
standard care cohort is a population-based cohort of 104 elderly breast cancer patients who 
were treated in the Comprehensive Cancer Center West in The Netherlands. The oncogeriatric 
care cohort is a hospital-based cohort of 42 elderly patients treated at the H. Lee Moffitt Cancer 
Center and Research Institute in Tampa (Florida, United States). Patients were identified from 
the Moffitt Cancer Registry and the Total Cancer Care program.
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All female patients with primary metastatic breast cancer, who were 70 years or older at 
diagnosis, and who were diagnosed between January 1st 2008 and December 31th 2011 were 
eligible. Inclusion in the oncogeriatric care cohort was extended to January 1st 2003 to increase 
the number of eligible patients. Patients with a history of breast cancer less than five years 
prior to diagnosis of metastatic breast cancer were excluded, as these were considered to 
have recurrent disease. By means of chart review, data were collected on tumor, patient and 
treatment characteristics. For the standard care cohort, vital status and date of last follow-
up were established either directly from the patient’s medical record or through linkage of 
cancer registry data with municipal population registries, which record information on vital 
status. For the oncogeriatric care cohort, vital status and date of last follow-up were established 
directly from the patient’s medical record or through linkage of the Moffitt Cancer Registry 
data with the National Death Index. Patients who moved out of the region, were censored at 
time of last follow-up visit. Follow-up was recorded until July 1st 2012.
Outline of this thesis
This thesis is divided in three parts. The first part consists of three studies evaluating the 
evidence base for treatment of elderly breast cancer patients. It is often mentioned that elderly 
are frequently underrepresented in clinical trials, and therefore the evidence base for breast 
cancer treatment in elderly is limited. However, it remains unknown how much and which 
type of elderly patients in particular are excluded from clinical trials. In chapter 2 we quantified 
and qualified the evidence base for locoregional treatment of elderly patients with early stage 
breast cancer. The study was based on all clinical trials on locoregional treatment, which 
were included in the national guideline recommendations. Another way to evaluate whether 
treatment is evidence based, is to assess the external validity of a trial. Therefore, in chapter 3 
we compared characteristics and outcome of elderly breast cancer patients who participated 
in a trial with those of elderly breast cancer patients from the general population. Next, we 
evaluated whether adherence to national breast cancer treatment guidelines was associated 
with survival, as presented in chapter 4. Guidelines are merely based on clinical trial results; 
given a limited evidence base for treatment of elderly breast cancer patients, adherence to 
treatment guidelines may not necessarily improve outcomes in the elderly in the same way as 
it is expected in younger patients. 
The second part of this thesis consists of three studies evaluating the association between 
age at diagnosis and breast cancer outcomes. A breast cancer patient who dies from causes 
unrelated to breast cancer is no longer at risk for progression of breast cancer or death 
due to breast cancer. This so called competing risk of death is particularly present in older 
populations and may affect breast cancer specific outcomes. In chapter 5 we investigated the 
association between age at diagnosis and breast cancer death, and death due to other causes 
among patients who participated in the TEAM trial. To gain further insight in the relationship 
between age at diagnosis and breast cancer outcome, in chapter 6 we studied the incidence 
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of breast cancer recurrence and contralateral breast cancer by age at diagnosis. Results 
obtained from clinical trial data may differ from results in the general population; competing 
mortality is likely to be higher in the general population, and administered treatment, as well 
as implications of treatment, may differ from a trial population. Therefore, the association 
between age and breast cancer outcomes was also assessed in the population-based FOCUS 
cohort, as described in chapter 7.
After evaluation of the evidence base for treatment of elderly breast cancer patients, and breast 
cancer outcomes by age of diagnosis, in the third part of this thesis we studied treatment 
outcomes in more depth. Chapter 8 consists of a systematic review and meta-analysis of 
radiotherapy after breast conserving surgery in elderly patients with early stage breast cancer. 
In chapter 9 we studied the outcomes after nonpersistence of adjuvant endocrine therapy by 
age at diagnosis among patients who participated in the TEAM trial. Next to specific treatment 
outcomes, we compared two different patterns of care. Management of elderly patients treated 
in a standard care setting in The Netherlands was compared with management of those treated 
in an oncogeriatric care setting in the United States. This study was performed in primary 
metastatic patients (chapter 10). 
In chapter 11 the main conclusions of this thesis are summarized and discussed, and future 
studies and research goals are proposed.
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Treatment guidelines are merely based on randomized clinical trials, which are considered the 
evidence base for treatment of breast cancer. However, relatively few elderly are included in 
these trials. Therefore, the aim of this study was to quantify and qualify the evidence base for 
locoregional treatment of older women with early stage breast cancer.
Methods
The 66 randomized clinical trials on locoregional trials included in the national breast cancer 
guidelines comprise the evidence for locoregional treatment. Eligibility criteria of these trials 
were applied to a population-based cohort of elderly breast cancer patients. The population-
based cohort consisted of 2,662 patients aged ≥65 years at diagnosis of early stage breast cancer, 
who were diagnosed between 1997 and 2004 in the geographically defined Comprehensive 
Cancer Center Region West, in The Netherlands. For all patients we calculated the proportion 
of the randomized clinical trials from which they would be excluded due to eligibility criteria. 
Based on this proportion, the evidence base was deemed 1) present, 2) partial, or 3) limited; 
corresponding with exclusion from less than 30%; 30-60%; or more than 60% of the trials, 
respectively. 
Results
In patients aged 65-75 years, the evidence base was dependent on the number of comorbidities 
and whether patients had a previous malignancy. Contrary, the evidence base was limited for 
all patients aged 75 years or older; patients were excluded from more than 60% of the trials 
solely due to age. Overall, the evidence base for locoregional treatment was present for 35%, 
partial for 19%, and limited for 56% of elderly patients with early stage breast cancer. 
Conclusions
The evidence base for locoregional treatment is limited for the majority of elderly breast cancer 
patients, and for all patients aged 75 years or older in particular. 
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Introduction
Up to 40% of breast cancer patients is 65 years or older at diagnosis1. As breast cancer incidence 
increases with increasing age1, changing demographics and continuously increasing life 
expectancy will further enlarge the number of elderly women confronted with breast cancer. 
Recently it was shown that in postmenopausal patients, breast cancer mortality increased with 
increasing age2. Moreover, the risk of a distant recurrence in breast cancer patients aged 75 
years or older was higher than in younger postmenopausal patients, which may be attributed 
to undertreatment of elderly patients3.
The term undertreatment suggests less than optimal treatment. However, for elderly women 
with breast cancer it is largely unknown what optimal treatment is. The evidence base for 
treatment is mostly composed of randomized clinical trials. Despite comprising a large 
proportion of all breast cancer patients, elderly patients are underrepresented in these trials4;5 
because of physician factors6;7, patients factors8, but also due to exclusion criteria. Moreover, 
exclusion criteria may hamper participation of a certain type of elderly patients in particular. 
Consequently, trial results may not necessarily be extrapolated to all elderly breast cancer 
patients. 
In early stage disease9, the evidence for adjuvant chemotherapy is mostly based on the Early 
Breast Cancer Trialist’s Collaborative Group meta-analyses10;11. It is known that few women 
older than 70 years of age, and very few older than 80 were randomized into the studies 
included in these meta-analyses11, and therefore the evidence base for chemotherapy in elderly 
breast cancer patients is rather limited. It is also known that elderly breast cancer patients are 
relatively often included in clinical trials on adjuvant endocrine therapy12. However, there are 
few data on the evidence base for locoregional treatment in elderly patients with early stage 
breast cancer. 
Therefore, the aim of this study was to quantify and qualify the evidence base for locoregional 
treatment of elderly patients with early stage breast cancer. 
Methods
Early stage breast cancer includes patients with T0–T2 N0–N1 M0 breast cancer according 
to the seventh edition of the tumor node metastasis (TNM) classification9. Locoregional 
treatment includes breast surgery, axillary surgery and postoperative radiotherapy.  
The evidence base for locoregional treatment of early stage breast cancer patients was 
defined as all randomized clinical trials on locoregional treatment which are included in the 
national breast cancer guidelines. We chose to define the evidence base on the basis of the 
national breast cancer guidelines rather than on a systemic search strategy of the literature 
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to better meet the aim of the study; all randomized clinical trials which translate to clinical 
treatment decisions are incorporated in the guidelines. It was previously shown that national 
treatment recommendations in different countries exhibited a large degree of congruency13. 
Therefore, we used the Dutch guideline recommendations. In 2002, initiated by the Dutch 
Institute of Health Care Improvement CBO and the Dutch National Breast Cancer Society, 
the first national multidisciplinary guideline ‘Breast Cancer Treatment’ was implemented 
in the Netherlands14. Regular revisions ensure updated information and recommendations. 
For this study, the most recent Dutch national guidelines were used (February 2012)14. An 
overview of recommendations for locoregional treatment of early stage breast cancer, and the 
corresponding randomized clinical trials are shown in Supplementary tables 1 and 2. 
The search engines Pubmed and Medline were used to retrieve the original articles. In case of a 
systematic review or a meta-analysis of multiple randomized clinical trials, all individual trials 
were retrieved and included. In case a study was used more than once, e.g. in more than one 
recommendation or in two meta-analyses, it was included in the analyses only once.
We then examined the inclusion and exclusion criteria of each of the randomized clinical trials. 
In case the authors referred to previous publications for extensive eligibility criteria, these 
publications were retrieved. Previously, van Spall and colleagues defined reasons for excluding 
individuals from a randomized clinical trial as poorly or strongly justified15. Exclusion criteria 
were defined to be poorly justified when based on, among others; age, physical ability or 
disability, or a chronic health condition. Consequently, eligibility criteria in the current study 
were categorized into three groups; 1) age, 2) a previous malignancy, and 3) comorbid disease. 
All criteria were reported as exclusion criteria15.
Finally, we compared the exclusion criteria with a population-based cohort of breast cancer 
patients aged 65 years and older (FOCUS cohort), to see what proportion of patients would 
have been disqualified for the trials. Thereby we aimed to quantify and qualify the evidence 
base for locoregional treatment. The population-based FOCUS cohort (Female breast cancer 
in the elderly: Optimizing Clinical guidelines USing clinico-pathological & molecular data) 
comprises all consecutive incident breast cancer patients aged 65 years or older, who were 
diagnosed in the geographically defined Comprehensive Cancer Center Region West in 
The Netherlands, between 1997 and 2004. Information on patient characteristics, tumor 
characteristics, treatment, follow up and outcome were recorded for all patients. Comorbidity 
was categorized by the 10th edition of the International Statistical Classification of Diseases 
and Related Health Problems (ICD-10)16.
Statistical analyses
First, we calculated the frequency of all exclusion criteria. Second, we calculated what 
proportion of elderly patients from the population-based FOCUS cohort would have been 
proefshrift.indb   22 2-5-2014   08:13:40
Evidence base for locoregional treatment 23
disqualified for the trials, based on the exclusion criteria. There is no standard definition or 
cut-off whether there is an evidence base for treatment. Therefore we propose a qualification 
based on the proportion of randomized clinical trials, i.e. the evidence base, from which 
patients are excluded. The evidence base was deemed present in patients who are excluded 
from less than 30% of the trials, i.e. in patients who could have been included in at least 70% 
of the trials; partial in patients who are excluded from 30-60% of the trials; and limited in 
patients who are excluded from more than 60% of the trials. In patients for which an evidence 
base is deemed present, we conclude that guideline recommendations, which are based on 
these trials, can be extrapolated. To further qualify the evidence base, we evaluated which 
patients are excluded in particular. Patients were categorized based on age (65-75 years; ≥75 
years)17, the number of comorbidities they had (0-1; 2-4; ≥5 comorbidities) and whether they 
had a previous malignancy. 
Results
Population-based cohort
Overall, 2,662 patients with early stage breast cancer were included in the current study. 
Mean age was 75.7 years (standard deviation 7.3 years); 1,319 patients were 75 years or older 
at diagnosis (49.5%). Patient and tumor characteristics are shown in Table 1. The number of 
comorbid diseases varied from 0 up to 11; most patients had 0 or 1 comorbid disease. The 
most prevalent comorbidities were circulatory (e.g. heart failure, hypertension), endocrine 
(e.g. diabetes mellitus, hypothyroidism) and musculoskeletal comorbidities (e.g. arthrosis, 
osteoporosis). The majority of the patients had stage II disease (n=1,532 (58%)).
Evidence base
The evidence base for locoregional treatment comprised 181 studies, among which six meta-
analyses of 152 studies18-23. Overall, 40 studies were excluded because there was no report of 
the study methods (e.g. the results were presented at a conference or at a meeting only) or the 
study was not a randomized clinical trial. After elimination of duplicates, the evidence base for 
locoregional treatment was composed of 66 unique randomized clinical trials.  
Eligibility criteria 
Adequate breast surgery or surgery with curative intent was required for participation in 
all clinical trials. As shown in Table 2, eligibility criteria on age, a previous malignancy and 
comorbid disease were defined in 67% (44/66); 58% (38/66) and 55% (36/66) of the randomized 
clinical trials, respectively. In case eligibility criteria on age were defined, patients aged 70 years 
and older were excluded in particular. Presence of comorbid disease was defined loosely in 
the majority of the trials, e.g. as ‘a medical condition contra-indicating therapy, adherence or 
follow-up’. Therefore, consensus based definitions of comorbid disease (WW, EB) were used for 
further analyses. These are included in Table 2.
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Quantification and qualification of the evidence base
To quantify the evidence base, we calculated what proportion of elderly patients from the 
population-based FOCUS cohort would have been disqualified for the trials, based on the 
exclusion criteria. On average, elderly breast cancer patients were excluded from 52% (34/66, 
range 6% - 89%) of the randomized clinical trials which comprise the evidence base for 
locoregional treatment. Exclusion was evaluated for different groups of elderly patients, based 
on age, the number of comorbidities, and whether patients had a previous malignancy (Table 
3). Overall, the evidence base for locoregional treatment was present for 35%, partial for 19%, 
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SD: standard deviation; NMSC: non melanoma skin cancer; BCC: basal cell carcinoma
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Table 2. Frequency of exclusion criteria of 66 randomized clinical trials comprising the evidence base for locore-
gional treatment.
n













Exclusion criteria on comorbid disease (defined in 36/66 trials)*
ECOG performance status >2 6






Non-malignant systemic disease 5
Serious non-malignant systemic disease 5
Medical condition contra-indicating therapy, adherence or FU 18
BCC: basal cell carcinoma; NMSC: non melanoma skin cancer; ECOG: Eastern Cooperative Oncology Group; 
FU: follow-up. *Adds up to more than 36 because multiple criteria may apply. ECOG performance status >2: 
survival after diagnosis less than 6 months; psychiatric disorder. ECOG performance status >1: nursing home at 
time of diagnosis; survival after diagnosis <6 months; psychiatric disorder. Renal disorders: creatinin >1.5 ULN. 
Hepatic disorders: ASAT >1.5 ULN; ALAT >1.5 ULN. Cardiac disorders: myocardial infarction; heart failure plus 
one of the following disorders; valve disorder, conduction disorder, arrhythmia, peripheral arterial obstructive 
disease or cerebrovascular accident; three or more of the following conditions; heart failure, cerebrovascular 
accident, arrhythmia, valve disorder, conduction disorder, venous disease, thrombosis, hypertension. Psychiatric 
disorders: depression; severe psychiatric disorder; dementia. Hematological disorders: thrombocytes <1.5 ULN; 
leukocytes >1.5 ULN; hemoglobin <1.5 ULN. Non-malignant systemic disease: diseases of the blood and blood-
forming organs and certain disorders involving the immune mechanism (ICD10-III); endocrine, nutritional 
and metabolic diseases (ICD10-IV); diseases of the musculoskeletal system and connective tissue (ICD10-XIII); 
hypertension; peripheral arterial obstructive disease; kidney failure. Serious non-malignant systemic disease: 
survival after diagnosis less than 6 months; psychiatric disorder. Medical condition contra-indicating therapy, 
adherence or FU: survival after diagnosis less than 6 months; psychiatric disorder.
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and limited for 56% of elderly patients aged 65 years or older with early stage breast cancer. In 
patients aged 65-75 years, the evidence base was dependent on the number of comorbidities 
and whether patients had a previous malignancy. As depicted in Table 3 and in the Figure, 
an evidence base was present for patients who had 0-1 comorbid disease and no previous 
malignancy (659/1,343 or 49% of all patients aged 65-75 years); partial for those who had two 
or more comorbid disease and no previous malignancy (498/1,343 or 37% of all patients aged 
65-75 years); and limited for all patients who had a previous malignancy (186/1,343 or 14% of 
all patients aged 65-75 years). Contrary, the evidence base was limited for all patients aged 75 
years or older, irrespective of the number of comorbidities and whether they had a previous 
malignancy; they were excluded from more than 60% of the randomized clinical trials solely 
due to age. 
Table 3. Exclusion of elderly patients with early stage breast cancer from 66 randomized clinical trials comprising 
the evidence base for locoregional treatment.
Number of patients 
(n=2,662)






0-1 comorbidity 659 18 27.3 Present
2-4 comorbidities 414 25 37.9 Partial
≥5 comorbidities 84 32 48.5 Partial
Previous malignancy
0-1 comorbidity 102 43 65.2 Limited
2-4 comorbidities 72 45 68.2 Limited
≥5 comorbidities 12 45 68.2 Limited
≥75 years (n=1,319)
No previous malignancy
0-1 comorbidity 459 40 60.6 Limited
2-4 comorbidities 517 42 63.6 Limited
≥5 comorbidities 138 44 66.7 Limited
Previous malignancy
0-1 comorbidity 84 52 78.8 Limited
2-4 comorbidities 95 52 78.8 Limited
≥5 comorbidities 26 52 78.8 Limited
* The evidence base was categorized as present (exclusion from less than 30% of the trials comprising the evidence 
base); partial (exclusion from 30-60% of the trials comprising the evidence base); or limited (exclusion from more 
than 60% of the trials comprising the evidence base).
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Discussion
Summary
Overall, the evidence base for locoregional treatment was present for 35%, partial for 19%, 
and limited for 56% of breast cancer patients aged 65 years or older with early stage disease. 
The evidence base for locoregional treatment in patients aged 65-75 years was dependent on 
the number of comorbidities, and whether patients had a previous malignancy. Contrary, 
the evidence base was limited in all patients aged 75 years or older. Hence, guideline 
recommendations regarding locoregional treatment may not necessarily be valid for patients 
aged ≥75 years with early stage breast cancer. 
Under- or overestimation of results
The current study showed that breast cancer patients aged 75 years or older are excluded from 
more than 60% of the trials, and hence the evidence base was deemed limited. The evidence 
base in this group may be underestimated; theoretically, a large and representative sample 
of elderly breast cancer patients may have been included in the remaining 40% of the trials 
they were eligible for. On the other end of the spectrum, patients aged 65-75 years with 0-1 
comorbidity and no previous malignancy were excluded from only 27% of the clinical trials 
and therefore, an evidence base was deemed present. However, the evidence base in the latter 
Figure 1. Qualification of the evidence base for locoregional treatment, for different groups of elderly breast 
cancer patients.
Present evidence base (excluded from less than 30% of the trials comprising the evidence base)
Partial evidence base (excluded from 30-60% of the trials comprising the evidence base)
Limited evidence base (excluded from more than 60% of the trials comprising the evidence base)
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group of patients may be overestimated, since it is unknown how many and which type of 
elderly patients are actually included in the 73% of the trials they were eligible for. Unfortunately 
we did not have information on the number and  type of elderly patients who were actually 
included, since individual trial data were not available.
The results of the current study are likely to be underestimated in another manner. 
Disqualification of patients was assessed by eligibility criteria. However, disqualification 
is multifactorial; therefore, actual exclusion of elderly patients is expected to be higher, and 
inclusion of elderly may be even more restricted and selected. Next to eligibility criteria, 
physician factors7;8;24, patient factors7, and factors related to trial logistics may affect inclusion24. 
These factors all favor inclusion of relatively healthy volunteers25;26. From a patient view, age 
has been shown to be no significant predictor as to whether a patient would participate, once 
they have been offered a trial7;27. Moreover, as exclusion criteria on comorbid disease were 
defined loosely, we had to specify the definition to calculate exclusion of elderly patients. As 
we have chosen to use a rather conservative definition, exclusion from trials due to comorbid 
disease is likely to be underestimated. In addition, other exclusion criteria may further affect 
exclusion of elderly patients. For example, 6% of the patients in the FOCUS cohort did not 
receive breast surgery and therefore would have been disqualified for all clinical trials in this 
study.
Clinical implications
Others have published on the limited inclusion of elderly patients in clinical trials4;5;28. A 
recent literature review showed that of all clinical trials published in 2008 in five major medical 
journals, 20% excluded patients based on age4. In the remaining trials, almost half of the trials 
excluded patients with age-related diseases, which could disproportionally impact inclusion 
of elderly patients. The novelty of the current study is that we were able to actually assess 
exclusion from randomized clinical trials in a large population-based cohort of elderly breast 
cancer patients. Hence we were able not only to evaluate the magnitude of non-evidence based 
medicine in elderly breast cancer patients, but also to qualify for which patients in particular 
an evidence base for locoregional treatment is lacking.
Recently, Wolters and colleagues compared national breast cancer guidelines from the United 
States of America, Canada, Australia, the United Kingdom and Germany13. The authors 
concluded that most treatment recommendations exhibited a large degree of congruency. This 
was explained by the fact that they are based on the same evidence. Although the current study 
was based on the Dutch guideline recommendations, the study by Wolters suggests that our 
results may be valid to a large extent for locoregional treatment guidelines in other countries.
Breast cancer patients aged 75 years or older were excluded from the majority of the randomized 
clinical trials on locoregional treatment and thus, one should be aware that the evidence 
base for locoregional treatment in this population is limited. Extrapolation of trial results 
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obtained in a younger, selected population may not be justified and consequently, guidelines 
for locoregional treatment in early stage breast cancer may not be as valid in patients aged 
75 years or older. The current findings are underlined by a previous finding that guideline 
adherence in elderly patients was not associated with survival29. To enlarge the evidence base, 
and thereby to optimize treatment, efforts should be made to perform age specific studies in 
elderly patients aged 75 years or older. Moreover, relaxation of eligibility criteria that could 
hamper inclusion of these patients in particular30 and physician education6 and awareness may 
increase the number of elderly study participants.  
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Supplementary table 1. The evidence base for locoregional treatment, as included in the national guidelines.
Breast conserving surgery followed by radiotherapy is equally effective compared with mastectomy in terms of 
survival. Omission of radiotherapy after breast conserving surgery has a negative impact on locoregional control 
and survival. [1-11]. Meta-analyses [6]: [3,4,12-37]; [7]: [1,3-5,12-50]; [8]: [15,33-36,39-41,51].
A radiotherapy boost improves local control in all patients. The absolute benefit of a boost after complete 
resection declines with increasing age. [52,53]
An age of 40 years or younger is an independent predictor for a local recurrence after breast conserving surgery. 
[52-55]. Meta-analysis [54]: [56,57] 
Good cosmesis after breast conserving surgery may be obtained in at least 70% of patients. [58] 
Partial breast irradiation seems to be effective in a select group of patients with a low a priori risk for a local 
recurrence. [59] 
Patients with large tumors (>5cm) and/or extensive nodal involvement (≥ 4 nodes involved) are at a higher risk 
for a locoregional recurrence, irrespective of irradical surgery and systemic therapy. [29,60,61]
In case of a mastectomy, postoperative locregional radiotherapy decreases the risk of a locoregional recurrence 
with 2/3 and increases survival. [6,29,60-62]. Meta-analyses: [6]: [3,4,12-37]; [62]: [23,25-31,61,63,64] 
In case of a mastectomy, locoregional radiotherapy improves local control and overall survival at 15 years of 
follow up, if 5 years risk of locoregional recurrence is ≥15%. [7] Meta-analysis: [7]: [1,3-5,12-50]
In case of a mastectomy, in patients with 1 to 3 positive lymph nodes, postoperative locoregional radiotherapy 
improves locoregional control and overall survival. [29,60,61] 
Hypofractionated radiotherapy of a patient with pT1-3aN0-1M0 breast cancer with a radical resection results 
in comparable five years survival, local control and cosmesis compared to conventional radiotherapy schemes. 
[65-69]; Meta-analysis: [65]: [70,71] 
Surgery of the axillary and periclavicular lymph nodes yields similar survival, disease free survival and 
locoregional control compared with radiotherapy, in patients with clinically node negative, operable breast 
cancer. [3,48]
Surgery of the axillary lymph nodes seems to yield similar survival, disease free survival and locoregional control 
compared with radiotherapy, in patients with clinically node positive, operable breast cancer. [3] 
Risk of lymph edema and other late morbidity is higher after axillary clearance compared with radiotherapy. [72] 
For references see Supplementary table 2. 
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Despite comprising a large proportion of all breast cancer patients, elderly are underrepresented 
in clinical trials. Moreover, inclusion is likely to be selective. The aim of this study was to 
investigate to what extent elderly breast cancer patients in a randomized clinical trial are 
selected as compared to breast cancer patients from the general population. 
Methods
We compared characteristics and outcome of breast cancer patients who participated in 
a randomized clinical trial (Tamoxifen Exemestane Adjuvant Multinational trial) with 
unselected breast cancer patients of corresponding age from the general population. Dutch 
patients aged ≥65 years at diagnosis of hormone receptor positive breast cancer without distant 
metastases, with either nodal involvement, a tumor >3cm, or a 1-3cm histological grade III 
tumor, who completed local therapy were included. Analyses were stratified by age (65-75 
years; ≥75 years). Primary outcome was overall mortality.
Results
We included 1,325 breast cancer patients who participated in a trial and 1,056 breast cancer 
patients from the general population. Irrespective of age, patients who participated in the trial 
had fewer comorbid diseases, a higher socio-economic status, and smaller tumors (all p-values 
<0.001). In patients aged 65-75 years, those who participated in the trial had a similar overall 
mortality as patients from the general population after adjustment for patient, tumor, and 
treatment characteristics (hazard ratio 1.08 (95% confidence interval (CI) 0.73-1.60)). Contrary, 
in patients aged ≥75 years, those who participated in the trial had a lower overall mortality 
(multivariable hazard ratio 0.72 (95% CI 0.55-0.95)).  
Conclusion
Breast cancer trial participants aged ≥75 years do not represent elderly breast cancer patients 
of corresponding age from the general population. This may be explained by selective inclusion 
into a trial, which hampers the external validity of the trial. Hence, breast cancer trial results 
may not necessarily be extrapolated to the general elderly breast cancer patient aged ≥75 years.
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Introduction
In developed countries, over 40% of all breast cancer patients is 65 years or older1;2. Different 
factors may play a role in the evaluation of breast cancer treatment in elderly as compared to 
younger patients. Elderly suffer from a higher risk of competing mortality3 and have a lower 
remaining life expectancy. Consequently, the absolute benefit of anticancer therapy may be 
smaller, while long term adverse events may be less relevant. Moreover, concurrent disease and 
medication use may directly affect tolerability of treatment and increase toxicity4;5. Therefore, 
it is important to evaluate treatment efficacy and outcomes specifically in elderly patients, and 
not to extrapolate results which were obtained in younger patients.
Despite comprising a large proportion of all breast cancer patients, elderly are frequently 
underrepresented in clinical trials6-8. This underrepresentation might not be problematic. As 
long as the included elderly are representative of the general population of elderly breast cancer 
patients, age specific subgroup analyses can be extrapolated. However, inclusion of elderly 
patients is likely to be selective7. 
The aim of the current study was to evaluate to what extent elderly breast cancer patients in a 
trial are selected as compared to breast cancer patients from the general population. Therefore, 
characteristics and outcome of elderly breast cancer patients who participated in a large trial 
without upper age limit, were compared with those of breast cancer patients of corresponding 
age from the general population.  
Methods
We included elderly patients who participated in a clinical trial, and elderly breast cancer 
patients from the general population. To ensure a valid comparison, similar inclusion criteria 
with regards to tumor and treatment characteristics were applied to all patients. 
Patients who participated in a trial
Patients who participated in the Tamoxifen Exemestane Adfuvant Multinational trial9;10 
were eligible for inclusion in the current study. Because five-years results of the TEAM trial 
showed no significant differences in efficacy endpoints between both treatment arms9, we 
were able to conduct the current study regardless of randomized treatment. Between January 
2001 and January  2006, 9,766 postmenopausal women with hormone receptor positive breast 
cancer without distant metastases, who completed local therapy with curative intent, were 
randomized to either exemestane 25 mg daily for 5 years or to a sequential regimen consisting 
of tamoxifen 20 mg daily for 2.5–3 years, followed by exemestane 25 mg daily for 2.5–2 
years. Inclusion for patients in The Netherlands was restricted to those who either had nodal 
involvement, a tumor of >3cm, or a histological grade III tumor of 1-3cm10. 
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Patients from the general population
From the Netherlands Cancer Registry we identified all incident breast cancer patients aged 
65 years or older, who were diagnosed in the geographically defined Comprehensive Cancer 
Center Region West in The Netherlands between January 1997 and December 2004. By means 
of chart review by trained personnel, additional information on patient characteristics, tumor 
characteristics, treatment, follow-up and outcome were recorded11. 
Inclusion criteria
For a proper comparison between patients who participate in a trial and patients from the 
general population, similar inclusion criteria were applied to all patients. Hence, we restricted 
inclusion of patients who participated in a trial to patients from The Netherlands, who were 
65 years and older at diagnosis. Likewise, the inclusion criteria that were used in the trial were 
applied to patients from the general population; those who had hormone receptor positive 
disease without distant metastases, and either one of the following; a tumor size of >3cm, a 
histological grade III tumor of 1-3cm, or nodal involvement, were eligible. In addition, they had 
to have received breast surgery with curative intent.  
In all patients, prespecified forms including free text fields were used for data collection. 
Comorbidity was defined as presence of comorbidity at time of diagnosis. Comorbid diseases 
were categorized into presence or absence of the main categories included in the 10th edition of 
the International Statistical Classification of Diseases and Related Health Problems (ICD-10), 
namely endocrine, nutritional and metabolic diseases (chapter IV); mental and behavioural 
disorders (chapter V); diseases of the nervous system (chapter VI); diseases of the circulatory 
system (chapter IX); diseases of the respiratory system (chapter X); diseases of the digestive 
system (chapter XI); and diseases of the musculoskeletal and connective tissue (chapter XIII)12. 
In addition, comorbid diseases were categorized by number (0-1; 2-4; 5 or more comorbid 
diseases). Socio-economic status (SES) was assigned using an area-based measure according to 
place of residence at the time of diagnosis. The area-based SES was provided by the Netherlands 
Institute for Social Research, and is based on data concerning income, employment, and 
education13. In the current study, SES was categorized in tertiles (low, intermediate and high 
SES respectively).
Statistical analyses
Statistical analyses were performed using SPSS 20.0 (SPSS, Chicago, IL) and Stata SE 12.0. 
In line with previous publications and in line with SIOG recommendations14;15, the analyses 
were stratified by age at diagnosis (65-75 years and 75 years or older). To compare proportional 
differences in patient, tumor and treatment characteristics between patients who participated 
in a trial and patients from the general population, the Pearson χ2 test was used.  
The primary outcome was overall mortality, defined as death from any cause. Vital status 
was established either directly from the patient’s medical record or through linkage with the 
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municipal population registries (follow-up until January 1st 2011). Follow-up was truncated at 
five years to accommodate differences in total follow-up duration. Cumulative incidence of 
death was estimated by    where    is the Kaplan–Meier estimator for the probability of 
survival at time (t), based on the life tables16. Corresponding 95% confidence intervals were 
calculated as the cumulative incidence at t(x) ± 1.96 * standard error. Cox proportional hazard 
models were used to evaluate the association between covariates and overall mortality. For 
both age groups, the proportional hazard assumption was evaluated by the link test (p=0.45; 
p=0.89 respectively) and based on the analysis of the Schoenfeld residuals17 (p=0.20; p=0.75 
respectively). 
As breast cancer mortality contributes to overall mortality, disparities in breast cancer outcome 
may affect the primary endpoint. Therefore we evaluated distant breast cancer recurrence as 
secondary endpoint, which was defined as recurrence in skeleton, skin, liver, lung, brain, or 
other distant localization. We focused on distant recurrence because cause of death is more 
difficult to attribute to a certain cause with increasing age18;19, and distant recurrence is a valid 
proxy for death due to breast cancer20. Detection method of a breast cancer recurrence was 
similar for all patients. 
Cause-specific outcomes may be influenced by the risk of competing endpoints; for example, 
an individual who dies, is no longer at risk for a distant breast cancer recurrence. This risk 
of competing endpoints may be present in older populations in particular3. Therefore, distant 
breast cancer recurrence was estimated by regression analyses according to Fine and Gray21;22. 
A Fine and Gray analysis is used to assess the risk of a distant breast cancer recurrence while 
taking into account the risks of reaching other, competing endpoints. Competing endpoints 
were a locoregional recurrence (recurrence in the ipsilateral breast or chest wall, ipsilateral 
axillary or supraclavicular lymph node(s)), contralateral breast cancer, and death due to any 
cause. 
Covariates were included in the multivariable model if they were judged to be clinically 
relevant. The fully adjusted multivariable model included tumor characteristics (histological 
grade [Bloom Richardson grade I; II; III; unknown], T stage [T1,T2; T3,T4; unknown], nodal 
stage [negative; positive; unknown]), treatment characteristics (most extensive surgery [breast 
conserving surgery; mastectomy], radiotherapy [yes; no; unknown], endocrine therapy [yes; 
no], and chemotherapy [yes; no; unknown]), and patient characteristics (age [continuous], 
year of diagnosis [continuous], socio-economic status [in tertiles; unknown], and number of 
comorbidities [0-1; 2-4; ≥5]). Sensitivity analyses were performed excluding missing values. 
All statistical tests were two-sided; p values <.05 were considered to be statistically significant.
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Results
Overall, we included 1,325 breast cancer patients who participated in a trial, and 1,056 
unselected breast cancer patients from the general population. Mean age of patients who 
participated in a trial was 73.5 years, (standard deviation (SD) 5.7 years), versus 76.7 years (SD 
7.1 years) in patients from the general population (p<0.001). First, we investigated whether the 
Table 1. Patient and tumor characteristics of elderly breast cancer patients who participated in a trial, as com-
pared to those of elderly breast cancer patients from the general population.















n % n % n % n %
Socio-economic status (tertiles) <0.001 <0.001
1 (lowest) 200 23.5 205 43.9 108 22.8 250 42.4
2 177 20.8 96 20.6 106 22.4 122 20.7
3 419 49.2 165 35.3 238 50.3 217 36.8
Unknown 56 6.6 1 0.2 21 4.4 0 0
Number of comorbidities <0.001 <0.001
0-1 655 76.9 273 58.5 306 64.7 262 44.5
2-4 193 22.7 171 36.6 165 34.9 263 44.7
≥5 4 0.5 23 4.9 2 0.4 64 10.9
Presence of comorbidity
Endocrine 178 20.9 130 27.8 0.005 105 22.2 188 31.9 <0.001
Psychiatric 4 0.5 41 8.8 <0.001 7 1.5 72 12.5 <0.001
Neurological 31 3.6 38 8.1 <0.001 38 8.0 79 13.4 <0.001
Circulatory 334 39.2 225 48.2 0.002 220 46.5 334 39.2 <0.001
Respiratory 54 6.3 48 10.3 0.013 30 6.3 67 11.4 0.005
Gastro-intestinal 24 2.8 54 11.6 <0.001 16 3.4 83 14.1 <0.001
Musculoskeletal 104 12.2 86 18.4 0.002 100 21.1 167 28.4 0.008
Histological grade (BR) <0.001 <0.001
Grade 1 133 15.6 37 7.9 69 14.6 67 11.4
Grade 2 380 44.6 138 29.6 225 47.6 172 29.2
Grade 3 286 33.6 181 38.8 134 28.3 193 32.8
Unknown 53 6.2 111 23.8 45 9.5 157 26.7
T stage <0.001 <0.001
T1, T2 794 93.2 404 86.5 429 90.7 466 79.1
T3, T4 58 6.8 61 13.1 44 9.3 120 20.4
Unknown 0 0 2 0.4 0 0 3 0.5
Nodal status 0.092 0.525
Negative 269 31.6 126 27 149 31.5 181 307
Positive 583 68.4 340 72.8 322 68.1 402 68.3
Unknown 0 0 1 0.2 2 0.4 6 1
BR: Bloom Richardson.   
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phenotype of patients who participated in a clinical trial differs from the phenotype of patients 
from the general population (Table 1). In both age groups, patients who participated in a trial 
had fewer comorbid diseases and more often had a high socio-economic status. Moreover, 
patients who participated in a trial had smaller tumors. 
Second, we investigated whether treatment of patients who participated in a clinical trial differs 
from treatment of patients from the general population (Table 2). Needless to say, all patients 
who participated in the trial received endocrine therapy, whereas in both age groups 82% of 
patients from the general population received endocrine therapy, despite having hormone 
receptor positive disease and an indication for endocrine therapy. In patients aged 75 years or 
older, patients who participated in a trial more often had breast conserving surgery as the most 
extended type of breast surgery. 
Table 2. Treatment characteristics of elderly breast cancer patients who participated in a trial, as compared to 
elderly breast cancer patients from the general population.















n % n % n % n %
Most extended surgery 0.164 <0.001
BCS 383 45.0 191 40.9 114 24.1 75 12.7
Mastectomy 469 55.0 276 59.1 359 75.9 514 87.3
Radiotherapy 0.446 0.052
Yes 500 58.7 288 61.7 211 44.6 227 38.5
No 351 41.2 179 38.3 262 55.4 362 61.5
Unknown 1 0.1 0 0 0 0 0 0
Endocrine therapy <0.001 <0.001
Yes 852 100 384 82.2 473 100 480 81.5
No 0 0 83 17.8 0 0 109 18.5
Chemotherapy 0.054 <0.001
Yes 63 7.4 52 11.1 0 0 19 3.2
No 788 92.5 415 88.9 473 100 570 98.6
Unknown 1 0.1 0 0 0 0 0 0
BCS: breast conserving surgery.   
Figure 1a and b show the unadjusted cumulative incidence of death for patients who 
participated in a trial and for patients from the general population, by age at diagnosis. In 
patients aged 65-75 years, five-years cumulative incidence of death was 14% (95% CI 9-16) 
for patients who participated in a trial and 19% (95% CI 16-23) for patients from the general 
population. For patients aged 75 years or older, five-years cumulative incidence of death was 
28% (95% CI 23-32) and 48% (95% CI 44-52), respectively. 
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Table 3. Overall mortality for elderly breast cancer patients who participated in a trial, as compared to elderly 
patients from the general population, fully adjusted model.








HR (95% CI) p
Patients 0.693 0.019
General population 91 1 (reference) 281 1 (reference)
Trial participants 110 1.08 (0.73-1.60) 124 0.72 (0.55-0.95)
Socio-economic status 0.935 0.102
Low 58 1 (reference) 112 1 (reference)
Intermediate 65 0.97 (0.65-1.43) 124 1.03 (0.78-1.36)
High 69 0.90 (0.65-1.43) 162 1.27 (1.01-1.60)
Missing 9 0.87 (0.42-1.80) 7 1.74 (0.80-3.82)
Number of comorbidities 0.010 0.122
0-1 121 1 (reference) 199 1 (reference)
2-4 75 1.58 (1.18-2.11) 171 1.13 (0.92-1.40)
≥5 5 1.18 (0.47-2.93) 35 1.46 (1.00-2.12)
Histological grade (BR) <0.001 0.007
Grade 1 18 1 (reference) 50 1 (reference)
Grade 2 55 0.97 (0.57-1.65) 126 0.90 (0.65-1.26)
Grade 3 92 2.19 (1.30-3.69) 143 1.32 (0.95-1.84)
Unknown 36 1.81 (0.99-3.31) 86 0.89 (0.61-1.29)
T stage 0.656 0.002
T1, T2 169 1 (reference) 313 1 (reference)
T3, T4 31 1.22 (0.80-1.87) 91 1.56 (1.22-2.00)
Unknown - Too low numbers 1 0.70 (0.10-5.09)
Nodal stage 0.007 0.058
Negative 44 1 (reference) 112 1 (reference)
Positive 156 1.82 (1.26-2.63) 288 1.32 (1.05-1.66)
Unknown - Too low numbers 5 1.25 (0.50-3.16)
Most extensive surgery 0.001 0.518
BCS 58 1 (reference) 49 1 (reference)
Mastectomy 143 2.03 (1.35-3.04) 356 1.12 (0.80-1.57)
Radiotherapy 0.448 0.333
Yes 115 1 (reference) 148 1 (reference)
No 86 1.27 (0.88-1.84) 257 0.89 (0.70-1.13)
Unknown - Too low numbers - NA
Endocrine therapy 0.048 0.232
Yes 182 1 (reference) 347 1 (reference)
No 19 0.59 (0.35-1.00) 58 0.83 (0.61-1.13)
Chemotherapy 0.568 0.993
Yes 22 1 (reference) 10 1 (reference)
No 179 1.15 (0.71-1.88) 395 1.00 (0.52-1.91)
Unknown - Too low numbers - NA
* Hazard ratios adjusted for all other covariates mentioned in the Table, and age (continuous) and year of diagno-
sis (continuous). BR: Bloom Richardson; BCS: breast conserving surgery. Cox proportional hazard models were 
used to evaluate the association between covariates and overall mortality. All statistical tests were two-sided; p 
values <.05 were considered to be statistically significant.
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the general population (univariate HR 0.49 (95% CI 0.39-0.60)). These differences could not 
be explained by unequal distributions in patient, tumor and treatment characteristics; 
multivariable analysis consistently showed a lower overall mortality (HR 0.72 (95% CI 0.55-
0.95)). To explore whether differences in overall mortality could be explained by differences 
in breast cancer outcome, we evaluated the risk of a distant recurrence (Table 4). Irrespective 
of age, multivariable analyses did not reveal any differences. Of note, in both age groups the 
absolute number of patients who developed a distant recurrence was exceeded by the number 
of patients who died. Among patients aged 75 years or older, the number of patients who 
died during five years of follow-up was 124 and 281. Contrary, the number of patients who 
developed a distant recurrence was 54 and 74. These data confirm that in those aged 75 years 
or older, the observed difference in overall mortality between patients who participated in a 
trial and patients from the general population is likely to resemble a non-breast cancer driven 
difference in overall fitness.
Discussion
To warrant the internal validity of a clinical trial, inclusion of patients into a trial is often 
selective, even though this may compromise the external validity of the trial23. Indeed we 
Overall mortality of patients aged 65-75 years was lower for patients who participated in a 
trial (univariate HR 0.65 (95% CI 0.50-0.86)). To explore whether this difference in mortality 
could be explained by unequal distributions in patient, tumor and treatment characteristics, 
multivariable analyses were performed. The fully adjusted model (Table 3) showed that after 
adjustment for tumor, treatment and patient characteristics, the hazard ratio attenuated 
towards 1 (HR 1.08 (95%CI 0.73-1.60)). Patients aged 75 years or older who participated in a 
trial also had a lower overall mortality as compared to patients of corresponding age from 

























Figure 1. Cumulative incidence of death by age at diagnosis.
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showed that patients who participated in a clinical trial had more favourable patient and 
tumor characteristics as compared to patients from the general population. In patients aged 
65-75 years, those who participated in a trial had a similar overall mortality as patients from 
the general population after adjustment. Thus, selective inclusion can be overcome by taking 
into account patient, tumor and treatment characteristics. Selection of patients into a trial 
may be more pronounced with increasing age, given the larger heterogeneity of patients with 
increasing age. This hypothesis was confirmed in the current study; we showed that in patients 
aged 75 years or older, differences in overall mortality could not be explained by patient, tumor 
and treatment characteristics. Therefore other, unmeasured mechanisms may have played a 
role in the selection of elderly patients into a trial. 
Table 4. Risk of distant breast cancer recurrence for elderly breast cancer patients who participated in a trial, as 












HR** (95% CI) p
65-75 years 0.05 0.737
General population (n=467) 61 59 1 (reference) 1 (reference)
Trial participants (n=852) 84 62 0.72 (0.52-1.00) 0.94 (0.64-1.37)
≥75 years 0.447 0.269
General population (n=589) 74 228 1 (reference) 1 (reference)
Trial participants (n=473) 54 95 0.87 (0.66-1.24) 0.80 (0.53-1.19)
HR: Hazard ratio. * Competing events comprise intercurrent death; locoregional recurrence as first site of recur-
rence; contralateral breast cancer. ** Multivariable HRs were adjusted for histological grade, T stage, nodal stage, 
most extensive surgery, radiotherapy,  endocrine therapy, chemotherapy, socio-economic status, comorbidity, age, 
year of diagnosis. Fine and Gray regression models were used to evaluate the association between covariates and 
distant breast cancer recurrence. All statistical tests were two-sided; p values <.05 were considered to be statisti-
cally significant.
A selective inclusion of patients into a trial may vary by type of study and study drug, and is 
multifactorial. First, eligibility criteria may hamper inclusion of elderly patients in general and 
inclusion of certain elderly in particular. Patients were ineligible for the TEAM trial if they 
had a malignancy within five years preceding breast cancer diagnosis, an Eastern Cooperative 
Oncology Group performance status of more than two, or a significant cardiac disease or other 
illness interfering with study participation and adequate follow-up10. Others have published 
about the impact of eligibility criteria on the inclusion in clinical trials24. Of all clinical trials 
published in 2008 in five major medical journals, 20% excluded patients based on age7. In the 
remaining trials, almost half of the studies excluded patients with age-related diseases, which 
could disproportionally impact inclusion of certain elderly patients. As compared with other 
randomized clinical trials, the TEAM trial had relatively few eligibility criteria, without an 
upper age limitation, enabling enrolment of many elderly patients9. Therefore it is expected 
that the discrepancy between trial patients and patients from the general population will also 
be present in other breast cancer trials including elderly patients. Next to eligibility criteria 
hampering the inclusion of elderly patients, physician factors25-27, patient factors26, and factors 
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related to trial logistics may affect participation25. From a patient point of view, age has been 
shown to be no significant predictor as to whether a patient would participate, once they have 
been offered a trial26;28. 
To summarize, the lower overall mortality of patients aged 75 years or older who participated 
in a trial may be the result of selective inclusion of patients into a trial. As was shown, those who 
participated in a trial had, among others, fewer comorbid diseases. Additionally, participation 
in a trial in itself may result in a lower overall mortality. One may argue that more attention 
is being paid to treatment of comorbid disease of elderly patients who participate in a trial, as 
compared to those from the general population, which may decrease overall mortality. 
Others have published on the external validity of clinical trials23. The novelty of the current 
study is that we were able to perform a head-to-head comparison of patients participating 
in a clinical trial and patients from the general population. This way we could pinpoint 
that external validity is compromised for breast cancer patients aged 75 years or older in 
particular. Our study has some limitations. By applying identical inclusion criteria, we aimed 
to construct similar groups of patients. However, differences in design and data collection 
may have influenced our results. Although prespecified forms including free text fields were 
used for all patients, and baseline characteristics were reported extensively in the medical 
files of patients from the general population, we cannot exclude possible differences due to 
the prospective and retrospective nature of data collection. A strength of this study is that 
systematic misclassification of the primary endpoint overall mortality is unlikely; vital status 
was established through linkage with the municipal population registries for all patients. 
Regarding the secondary endpoint, the method of detection of a breast cancer recurrence 
was similar for all patients. Of note, those who participated in the trial had strict follow-up 
schemes, whereas this may not always be accomplished in general practice. Therefore, we 
cannot exclude the possibility of under diagnosis of breast cancer recurrence among patients 
from the general population. Regarding overall mortality, sample size was sufficient to detect 
a difference among patients aged 75 years or older. Among patients aged 65-75 years, given 
the confidence interval of the multivariable analysis (95% CI 0.73-1.60), we cannot exclude 
that those who participate in a trial do have a different overall mortality as compared to 
patients from the general population. Regarding the secondary endpoint, sample size may 
have been insufficient. However, it was also shown that the absolute number of patients who 
developed a distant recurrence was greatly exceeded by the absolute number of patients who 
died, especially in patients aged 75 years or older. Therefore, although the direct comparison of 
distant breast cancer recurrence between patients who participated in a trial and patients from 
the general population is possibly underpowered, the secondary endpoint does strengthen 
the main conclusion that the observed higher overall mortality in patients aged 75 years or 
older from the general population is likely to resemble a non-breast cancer driven difference in 
overall fitness.
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Clinical implications
Since treatment guidelines are mainly based on clinical trial results, the evidence base for 
treatment in patients aged 75 years or older may be limited. However, it is not likely that 
conduction of clinical trials will be sufficient to fill this ‘evidence gap’. Even in the absence of 
eligibility criteria it is expected that elderly who are included in a trial will be selected26;27;29. 
Moreover, the large heterogeneity in the elderly population makes it difficult to conduct 
clinical trials including a representative sample of the general population; even with inclusion 
of large numbers, it remains a challenge to create comparable study arms. Therefore different 
study designs may be warranted. Restriction in research topics, design, and analysis may give 
observational research the chance to be as credible as randomized evidence30. Moreover, 
observational, population-based data reflect the heterogeneity of the general population. 
Among others, international comparisons of treatment strategies, using country as an 
instrumental variable, may increase insight in adequate treatment for different groups of 
elderly breast cancer patients.  
Conclusions
Inclusion in a breast cancer trial is more selective with increasing age. Breast cancer patients 
aged 75 years or older who participate in a trial are not representative of breast cancer patients 
of corresponding age from the general population, which may hamper the external validity 
of a trial; breast cancer trial results may not necessarily be extrapolated to the general breast 
cancer patient with corresponding age.
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Elderly patients with breast cancer are underrepresented in clinical studies. Therefore, it is 
unknown whether treatment guidelines, based on clinical trials, can be extrapolated to this 
population. The aim of this study was to assess adherence to treatment guidelines by age at 
diagnosis, and to examine age-specific survival in relation to guideline adherence. 
Methods
Patients with early stage breast cancer aged younger than 65 years, or 75 years or older, 
diagnosed between 2005 and 2008, were identified from the Netherlands Cancer Registry. 
Adherence to treatment guidelines for breast and axillary surgery, radiotherapy, chemotherapy 
and endocrine therapy was determined. Nonadherence to the guidelines was defined as 
overtreatment or undertreatment. The primary endpoint was overall survival, assessed by 
means of an instrumental variable, the comprehensive cancer center region.
Results
Overall, 24,959 patients younger than 65 years and 6,561 patients aged 75 years or older were 
included. Median follow-up was 2.8 years. Compared with patients younger than 65 years, 
those aged 75 years or older were less frequently treated in concordance with guidelines: 62.0% 
(15,487 patients) versus 55.6% (3,647 patients) (p<0.001). In both age groups, most patients 
received at least three out of five treatment modalities in concordance with guidelines: 
98.8% (24,652 patients) and 93.8% (6,152 patients) respectively. Survival analysis using the 
instrumental variable showed that adherence to guidelines was not associated with overall 
survival in patients younger than 65 years (p=0.601) or those aged 75 years or older (p=0.190).
Conclusions
Adherence to treatment guidelines was affected by age at diagnosis. However, adherence to the 
guidelines was not associated with overall survival in either age group.  
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Introduction
The first national multidisciplinary guideline ‘Breast Cancer Treatment’, initiated by the Dutch 
Institute of Health Care Improvement CBO and the Dutch National Breast Cancer Society1, 
was implemented in the Netherlands in 2002. The aim was to improve breast cancer care and 
cure by providing consensus and evidence based recommendations for treatment1. Deviation 
from the guidelines is possible, but reasons should be documented. Since 2002, regular 
revisions have ensured that information and recommendations are updated.
In 2008 in the Netherlands, almost 20% of breast cancer patients was 75 years or older at time 
of diagnosis2. Elderly patients differ from younger patients in many respects. The presence 
of comorbidities and concomitant medication may interact with treatment or survival from 
breast cancer3-6. In addition, there is evidence of different tumor biology in elderly breast 
cancer patients7. Moreover, a recent study showed that, in contrast to younger patients, survival 
of elderly breast cancer patients has not improved significantly in recent years8.
Despite comprising a large proportion of those with breast cancer, elderly breast cancer 
patients have been underrepresented in trials7; it has been estimated that only 1 to 2% of the 
elderly participates in clinical trials9. Therefore, adherence to guidelines may not necessarily 
improve breast cancer cure and care in the elderly as it is expected in the younger population. 
The aim of this study was to assess adherence to national breast cancer treatment guidelines by 
age at diagnosis, and to evaluate age specific survival in relation to adherence to the guidelines. 
Previous studies have investigated the association between guideline adherence and survival in 
an observational setting10;11. However, these studies all suffer from confounding by indication12 
and so alternative methods were applied in the present analysis.
Methods
Subjects
Female patients with incident early stage breast cancer, diagnosed between 2005 and 2008, 
were identified from the Netherlands Cancer Registry database. Early stage breast cancer 
was defined as T012, N01, M0 breast cancer, i.e. a tumor size smaller than five centimeters, 
with either no axillary metastases, or one or more metastases in movable ipsilateral level I 
or II axillary lymph nodes, without distant metastasis. PALGA (Pathologisch-Anatomisch 
Landelijk Geautomatiseerd Archief), the nationwide Dutch network and registry of histo- and 
cytopathology, regularly submits reports of all diagnosed malignancies to the regional cancer 
registries. The national hospital discharge databank, which receives discharge diagnoses of 
admitted patients from all Dutch hospitals, completes case ascertainment. Registry personnel 
collects data on diagnosis, staging, and treatment from the medical records, including 
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pathology and surgery reports, by using the registration and coding manual of the Dutch 
Association of Comprehensive Cancer Centers. All data from the regional cancer registries are 
merged into the Netherlands Cancer Registry. 
Patients were categorized in age groups as discussed at the meeting of the International Society 
of Geriatric Oncology (SIOG) in 200913. Inclusion was restricted to patients aged younger 
than 65 years and patients aged 75 years or older, since patients aged younger than 65 years 
at diagnosis are frequently included in trials upon which guidelines are based, while patients 
aged 75 years or older are included sporadically9. Primary endpoint was overall survival, which 
was defined as time from diagnosis to death from any cause. Relative survival, which takes into 
account the risk of dying from other causes than breast cancer, was also evaluated. 
Guideline adherence 
Supplementary table 1 shows guideline recommendations with regards to breast and axillary 
surgery, radiotherapy, chemotherapy and endocrine therapy. Breast surgery and axillary surgery 
was recommended for all patients. Radiotherapy was recommended after a wide local excision, 
and after a mastectomy in case of non-radical surgery, involvement of the pectoral muscle, or 
positive axillary nodes at the apex. Chemotherapy was recommended in patients with nodal 
involvement, and in node negative patients with other unfavorable tumor characteristics. In 
patients aged 70 years or older, no general recommendations were given. With few exceptions, 
endocrine therapy was recommended in patients with estrogen and/or progesterone positive 
tumors.
Patients were adherent if they received treatment in concordance with guideline recom-
mendations. Nonadherence was defined as undertreatment (omission of treatment despite 
recommendation), or overtreatment (administration of treatment despite no recommendation). 
The definitions of undertreatment and overtreatment were based on guidelines at time of 
diagnosis, and did not include reasons for treatment decisions. Adherence was assessed for all 
treatment modalities, summed, and then dichotomized in 100% adherence versus less than 
100% adherence. As data on non-radicality, and localization of positive lymph nodes were not 
available, adherence with radiotherapy after a mastectomy could not be assessed and may 
therefore slightly differ from true adherence. Chemotherapy recommendations in some patients 
depend on general health. As these data were not available, adherence could not be assessed in 
these patients, and calculated adherence may again slightly differ from true adherence. 
Statistical analysis
SPSS 17.0 and STATA/SE 10.0 were used for statistical analyses. Descriptive statistics 
comprised median and interquartile range (i.q.r) and numbers (%). Pearson chi square test was 
used to compare differences in guideline adherence between age groups. A Cox proportional 
hazard model was used to assess overall survival, and reported with 95% confidence interval 
(CI). Relative survival was calculated by the Hakulinen method as the ratio of the observed 
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survival among the cancer patients and the survival that would have been expected based 
on the corresponding (age, sex and year) general population. National life tables were used 
to estimate expected survival. Relative Excess Risks of death (RER) were estimated using a 
multivariable generalized linear model with a Poisson distribution, based on collapsed relative 
survival data, using exact survival times. 
Survival was assessed for patients who were treated 100% adherent and patients who 
were treated less than 100% adherent. As observational studies suffer from confounding 
by indication, additional survival analyses by means of an instrumental variable were 
performed. An instrumental variable may serve as a substitute for randomization in non-
randomized studies, and may reduce confounding by indication under the assumptions that 
the instrumental variable is 1) associated with the exposure, 2) unrelated to the confounders 
(exclusion restriction), and 3) has no direct association with the outcome other than through 
the exposure (independence assumption)14;15. The geographically defined comprehensive 
cancer center regions (CCCRs) were used as an instrumental variable. CCCRs thus represented 
different proportions of patients who were treated 100% adherent, and were used as a substitute 
for randomization; the place of residence determines a patient’s allocation to a CCCR and 
thereby to a probability of being treated 100% adherent. Analyses were performed to explore 
potential differences in tumor characteristics among CCCRs, although no large differences 
were expected a priori. Both multivariable and stratified analyses were performed. Covariates 
were included in the multivariable model if they were judged to be clinically relevant, and 
comprised histological grade (G1; G2; G3,4), T stage (T0,1; T2), nodal stage (negative; positive), 
estrogen receptor status (negative; positive), progesterone receptor status (negative; positive) 
and age (continuous). All statistical tests were two-sided.  P values <0.05 were considered to be 
statistically significant.
Data were analyzed as intention to treat analyses; patients were categorized by theoretical 
allocation to CCCR based on postal code, which did coincide with CCCR of treatment in 
more than 95% of the patients. For survival analyses, CCCRs were ranked based on decreasing 
proportion of patients who were treated 100% adherent. 
Results
Between 2005 and 2008, 36,459 women, who were younger than 65 years or 75 years or older, 
were diagnosed with early stage breast cancer. Overall, 4,267 patients were excluded because 
of carcinoma in situ, or missing data regarding invasiveness, 649 patients because of missing 
data on estrogen and progesterone receptor status, and 23 patients because of missing data 
regarding therapy. This resulted in a study population of 31,520 patients, of whom 24,959 
were younger than 65 years (median 52.3 years) and 6,561 were 75 years or older (median 82.5 
years). Median follow-up (i.q.r) was 2.8 (1.8 to 3.9) years for all patients, 2.9 (1.9 to 3.9) years 
for patients younger than 65 years and 2.5 (1.5 to 3.5) years for patients aged 75 years or older.
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Patients aged 75 years or older more often presented with an unknown histological grade and 
unknown nodal status, with larger tumors and a positive estrogen receptor status (all p values 
<0.001). Table 1 shows treatment characteristics by age. Patients aged 75 or older less often 
underwent breast and axillary surgery, and had a lower probability of receiving radiotherapy 
and chemotherapy, while endocrine therapy was administered more frequently.
As shown in Table 2, the proportion of patients who received all five treatment modalities in 
concordance with guidelines was significantly lower in patients aged 75 years or older; 15,487 
(62.0%) patients versus 3,647 (55.6%) patients, respectively. In both age groups, the majority of 
patients received at least three out of five treatment modalities in concordance with guidelines; 
24,652 (98.7%) patients and 6,152 (93.8%) patients, respectively. 
Table 1. Treatment characteristics by age at diagnosis.
<65 years (n=24,959) ≥75 years (n=6,561) pn % n %
Most extensive surgery <0.001
Mastectomy 9,037 36.2 3,473 52.9
Wide local excision 15,805 63.3 1,677 25.6
No resection 117 0.5 1,411 21.5
Most extensive AS <0.001
ALND 9,699 38.9 2,211 33.7
SLN 14,864 59.6 2,665 40.6
None 396 1.6 1,685 25.7
Radiotherapy <0.001
Yes 16,931 67.8 1,649 25.1
No 8,028 32.2 4,912 74.9
Chemotherapy <0.001
Yes 12,22 49.0 27 0.4
No 12,739 51.0 6,534 99.6
Endocrine therapy <0.001
Yes 10,547 42.3 3,776 57.6
No 14,412 57.7 2,785 42.4
AS: axillary surgery; ALND: axillary lymph node dissection; SLNB: sentinel lymph node biopsy.
Table 2. Number of treatments in concordance with guidelines, by age at diagnosis.
<65 years (n=24,959) ≥75 years (n=6,561) pn % n %
Number of treatments <0.001
5 (100%) 15,487 62.0 3,647 55.6
4 (80%) 5,722 22.9 1,266 19.3
3 (60%) 3,443 13.8 1,239 18.9
<3 (<60%) 304 1.3 409 6.2
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Figure 1 shows the distribution of patients who were treated adherent, overtreated and 
undertreated for all treatment modalities according to the guidelines, by age at diagnosis. 
Patients aged 75 years or older had a marked lower adherence to surgical therapy 
recommendations as compared with patients who were younger than 65 years (breast surgery 
99.5% (n=24,842) versus 78.5% (n=5,150), p<0.001; axillary surgery 98.4% (n=24,563) versus 
74.3% (n=4,876), p<0.001). As surgical resection is recommended for all patients with early 
stage breast cancer, nonadherence to surgical therapy recommendations was fully explained 
by undertreatment. Adherence with endocrine therapy recommendations was slightly lower 
in patients aged 75 years or older (80.8% (n=20,167) versus 79.2% (n=5,194), p=0.003). In case 
of nonadherence, patients aged 75 years or older were overtreated more often as compared 
with patients younger than 65 years. Most patients aged 75 years or older were adherent with 
chemotherapy recommendations (73.9% (n=18,452) versus 99.6% (n=6,534), p<0.001), because 
specific chemotherapy recommendations for patients aged 70 years or older were not given.
Figure 1. Adherence to guidelines, undertreatment and overtreatment per treatment, by age at diagnosis.
Number of deaths was 762 (3.1%) in patients younger than 65 years and 1,547 (23.6%) in 
patients aged 75 years or older. By conventional survival analyses, in patients younger than 
65 years, overall survival was lower in patients who were treated less than 100% adherent 
as compared with those who were treated 100% adherent (patients who were treated 100% 
adherent functioned as reference category, univariate hazard ratio (HR) for patients who were 
treated less than 100% adherent was 1.68 (95% CI 1.46-1.94), p<0.001). In patients aged 75 years 
or older, these results were even more pronounced; HR 2.56 (95% CI 2.31-2.84), p<0.001. To 
account for unequal distribution of tumor characteristics and age, multivariable analyses were 
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In addition, survival was assessed by CCCR. The proportion of breast cancer patients who were 
treated 100% adherent varied among CCCRs in both age categories (in patients younger than 
65 years 55.4% to 66.2%, p<0.001; in patients aged 75 years or older 50.0% to 59.8%, p=0.001). 
In both age groups, CCCR was not associated with overall survival (p=0.732; p=0.905 
respectively). Multivariable analyses were performed to adjust for unequal distribution of 
tumor characteristics, which did not alter the results (Table 4). Analyses were stratified by 
T stage, N stage and histological grade, and adjusted for estrogen and progesterone receptor 
status. Again, results remained similar (data not shown). It was also studied whether CCCR was 
associated with relative survival (Supplementary table 2). Both in univariate and multivariable 
analyses the excess risk of death was similar among CCCRs. 
Additional analyses restricted to the CCCR with the lowest and highest proportion of patients 
who were treated 100% in concordance with guidelines, did not alter the results. In patients 
younger than 65 years, the HR for the region with the lowest proportion of patients who were 
treated 100% adherent was 0.93 (95% CI. 0.69-1.26), p=0.657; in patients aged 75 years or older, 
HR was 0.87 (95% CI 0.60-1.11), p=0.262. Analyses were also stratified by year of diagnosis. 
Table 3.  Overall survival by adherence to guidelines and tumour characteristics, by age at diagnosis.
<65 years ≥75 years
5-years
survival (%) HR (95% CI)* p
5-years
survival (%) HR (95% CI)* p
Adherence <0.001 <0.001
100% 95 1 (reference) 71 1 (reference)
<100% 92 1.75 (1.50-2.05) 48 1.62 (1.41-1.85)
Histological grade <0.001 0.004
G1 (well) 98 1 (reference) 76 1 (reference)
G2 (moderate) 96 1.14 (0.86-1.50) 68 1.13 (0.95-1.36)
G3, G4 (poor) 89 1.83 (1.38-2.43) 59 1.39 (1.13-1.71)
T stage <0.001 0.001
T0 88 1 (reference) 51 1 (reference)
T1 95 1.06 (0.26-4.28) 68 0.79 (0.69-0.91)
T2 91 1.69 (1.34-1.83) 56 1.25 (1.09-1.44)
N stage <0.001 0.002
Negative 95 1 (reference) 64 1 (reference)
Positive 92 1.57 (1.34-1.83) 56 1.25 (1.09-1.44)
ER <0.001 0.001
Positive 96 1 (reference) 63 1 (reference)
Negative 86 2.82 (2.25-3.54) 52 1.40 (1.14-1.72)
PR 0.014 0.002
Positive 96 1 (reference) 65 1 (reference)
Negative 89 1.32 (1.06-1.64) 55 1.30 (1.10-1.53)
Age (years) - 1.02 (1.01-1.03) <0.001 - 1.09 (1.07-1.10) <0.001
* Hazard ratios adjusted for all variables included in the model. HR: hazard ratio; CI: confidence interval; ER: 
estrogen receptor status; PR: progesterone receptor status.
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With a maximum median follow-up of 4.5 and 3.7 years respectively, similar results were 
observed (p=0.588 and p=0.335 respectively). 
Since general recommendations for chemotherapy were not available for patients aged 75 
years or older, survival analyses in this age group were repeated, in which 100% adherence 
was calculated without adherence to chemotherapy recommendations. Results were similar. 
Finally, an alternative definition of adherence was used, in which non adherence to guideline 
recommendations was defined as undertreatment only. In both age categories, again no 
difference in overall survival was observed among CCCRs (data not shown).
Table 4. Overall survival by Comprehensive Cancer Center Region, by age at diagnosis.
<65 years ≥75 years
5-years 
survival (%) HR (95% CI)* p
5-years 
survival (%) HR (95% CI)* p
CCCR** 0.601 0.190
1 (highest) 93 1 (reference) 60 1 (reference)
2 93 0.84 (0.61-1.15) 62 0.65 (0.49-0.88)
3 95 0.81 (0.55-1.18) 60 0.80 (0.59-1.08)
4 94 1.01 (0.73-1.41) 62 0.79 (0.58-1.09)
5 95 0.93 (0.66-1.32) 60 0.87 (0.63-1.20)
6 93 1.01 (0.74-1.38) 60 0.78 (0.59-1.03)
7 95 0.87 (0.62-1.22) 63 0.84 (0.63-1.13)
8 (lowest) 93 1.09 (0.73-1.61) 63 0.77 (0.57-1.05)
Histological grade <0.001 0.003
G1 (well) 98 1 (reference) 76 1 (reference)
G2 (moderate) 96 1.31 (0.99-1.72) 68 1.19 (0.90-1.42)
G3, G4 (poor) 89 2.07 (1.55-2.75) 59 1.43 (1.16-1.76)
T stage <0.001 0.004
T0 88 1 (reference) 51 -
T1 95 0.89 (0.22-3.58) 68 1 (reference)
T2 91 1.35 (0.33-5.44) 56 1.23 (1.07-1.41)
N stage <0.001 0.006
Negative 95 1 (reference) 64 1 (reference)
Positive 92 1.57 (1.34-1.84) 56 1.22 (1.06-1.40)
ER <0.001 0.004
Positive 96 1 (reference) 63 1 (reference)
Negative 86 2.62 (2.08-3.30) 52 1.36 (1.10-1.67)
PR 0.017 0.008
Positive 96 1 (reference) 65 1 (reference)
Negative 89 1.31 (1.05-1.64) 55 1.26 (1.06-1.49)
Age (years) - 1.02 (1.01-1.03) <0.001 - 1.10 (1.08-1.11) <0.001
* Hazard ratios adjusted for all variables included in the model. ** CCCR is ranked from highest to lowest propor-
tion of patients who were treated 100% adherent. HR: hazard ratio; CI: confidence interval; ER: estrogen receptor 
status; PR: progesterone receptor status.
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Discussion     
Overall adherence with breast cancer guidelines, and in particular adherence with surgical 
therapy recommendations, was lower in patients aged 75 years or older. By using an 
instrumental variable to reduce confounding by indication, comprehensive cancer center 
regions, representing a different proportion of patients who were treated 100% adherent, were 
not associated with overall survival nor with relative survival in both age categories.
A considerable number of papers have been published on adherence to breast cancer guidelines, 
in which most define nonadherence as undertreatment only16-20. Few studied guideline 
adherence by age at diagnosis. Most studies observed that increasing age was associated 
with nonadherence to either surgical treatment18;20-22, radiotherapy19;22, chemotherapy18;19 or 
endocrine therapy18. Some studies have assessed the association between guideline adherence 
and survival in an observational setting. However, these studies all suffer from confounding 
by indication12; frailty status, age, tumor characteristics or presence of comorbidity may all 
affect both adherence as well as survival. Most studies showed that adherence with guideline 
recommendations was associated with worse breast cancer outcome10;11;23;24. The authors 
did acknowledge the risk of confounding by indication, and adjusted for multiple variables. 
By conventional survival analyses, this study confirmed in both age groups a higher overall 
survival for patients who were treated 100% adherent as compared with patients who were 
treated less than 100% adherent. Even after adjustment for confounders, the results from 
the multivariable model may suffer from residual confounding by indication. Therefore, a 
conventional survival analysis may yield insufficient results in this particular field of study. 
The use of an instrumental variable may improve the quality of analyses by minimizing 
confounding by indication15;25, provided certain assumptions are met. An association was 
observed between CCCR and the proportion of patients who were treated 100% adherent. 
Further, tumor characteristics were slightly different among CCCRs. Therefore, both 
multivariable and stratified analyses were performed, which did not alter the results. Regional 
differences in background mortality may affect survival by region in another way than through 
guideline adherence. However, no major differences in background mortality, or remaining life 
expectancy among regions have been observed in elderly patients26. Since treatment allocation 
of more than 95% of the patients coincided with allocated CCCR, effect modification by 
cross-over is unlikely. There seems to be reasonable ground to justify the use of CCCR as an 
instrumental variable. Using an instrumental variable, guideline adherence was not associated 
with survival in both age groups.  
It was expected that in patients younger than 65 years, guideline adherence would be associated 
with an improved survival. The results from the present study did not confirm this hypothesis. 
The current study evaluated outcome of patients who received five treatment modalities in 
concordance with guideline recommendations, compared with patients who did not, which 
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may not be representative for outcomes of a single randomized clinical trial; most trials study 
one particular treatment at once. 
This study has some critical limitations. The proportion of patients who were treated 100% 
adherent differed 10 to 11% among regions, which might have been too small to result in 
survival differences. Virtually all patients who were treated less than 100% adherent, received 
three or more treatment modalities in concordance with guidelines. Consequently, the 
difference between adherent and nonadherent patients may have been too small to detect 
substantial survival differences. Although additional analyses stratified by year of diagnosis 
were performed, the limited follow-up time may have reduced the statistical power of the 
analyses.
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Supplementary table 1. Guideline recommendations early stage breast cancer* in The Netherlands.
Breast surgery Guideline 2005 – 2007: All.
Guideline 2008: No change.
Axillary surgery Guideline 2005 – 2007: All.
Guideline 2008: No change.
Radiotherapy Guideline 2005, 2006: Always after a wide local excision; radiotherapy may be considered 
after a mastectomy in case of a non-radical resection, involvement of pectoral muscle, or 
a positive axillary top.
Guideline 2008: No change.
Chemotherapy Guideline 2005 – 2007: <70 years, node positive #; ≤35 years (except <1cm, BR I); >35<70 
years, N0, >3cm#; >35<70 years, N0, 2-3cm, BR II#; >35<70 years, N0, >1cm, BR III#. 
In patients aged 70 years or older with nodal involvement, general recommendations 
cannot be given. Chemotherapy may be considered for those with unfavorable tumor 
characteristics.  
Guideline 2008: <70, node positive; <35 years (except ≤ 1cm BR I); ≥35<70 years, N0, 
1,1-2 cm, BR II/III; ≥35<70 years, N0, >2 cm. In patients aged 70 years or older, benefit 
of chemotherapy may be limited. It is advised to use AdjuvantOnline to calculate the 
expected benefit in individual cases. 
Endocrine therapy$ Guideline 2005 – 2007: Node positive; ≤35 years (except <1cm, BR I); >35 years, N0, ≥3cm; 
>35 years, N0, 2-3cm, BR II; >35 years, N0, >1cm, BR III.
Guideline 2008: Node positive; <35 years (except ≤ 1cm BRI); ≥ 35 years, N0, 1,1-2 cm, BR 
II/III; ≥ 35 years, N0, >2cm.
BR: Histological grade according to Bloom Richardson. * Early stage breast cancer was defined as T0-2, N0-1, 
M0 breast cancer, i.e. a tumor size smaller than five centimeters, with either no axillary metastases, or one or 
more metastases in movable ipsilateral level I or II axillary lymph nodes, without distant metastasis. # Patients 
aged 50 to 59 years in good physical state with an estrogen receptor and/or progesterone receptor positive tumor, 
and patients aged 60 to 69 years with an unfavorable prognosis. $ Patients with estrogen and/or progresterone 
receptor positive tumors only.
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p Multivariable* RER 
(95% CI)
p 
< 65 years 0.726 0.639
CCCR1 (66.2)** 95.4 (93.0-97.2) 1 (reference) 1 (reference)
CCCR2 (64.8%) 95.2 (92.7-97.0) 1.4 (0.8-2.4) 1.2 (0.7-2.1)
CCCR3 (64.2%) 96.8 (95.3-98.0) 0.9 (0.5-1.5) 0.8 (0.5-1.3)
CCCR4 (64.0%) 95.7 (94.3-96.9) 1.0 (0.6-1.7) 1.0 (0.6-1.6)
CCCR5 (63.4%) 96.5 (94.9-97.8) 1.1 (0.6-1.8) 0.9 (0.6-1.5)
CCCR6 (62.7%) 95.3 (93.5-96.7) 1.1 (0.7-1.8) 1.2 (0.7-1.9)
CCCR7 (59.6%) 96.6 (94.7-98.0) 0.9 (0.5-1.6) 1.0 (0.6-1.7)
CCCR8 (55.4%) 95.2 (93.5-96.6) 0.9 (0.5-1.5) 0.9 (0.6-1.4)
≥ 75 years 0.873 0.820
CCCR1 (59.7%)** 91.0 (76.4-100) 1 (reference) 1 (reference)
CCCR2 (58.7%) 97.5 (86.5-100) 0.3 (0.0-2.4) 0.5 (0.1-1.7)
CCCR3 (58.2%) 94.3 (85.1-100) 0.6 (0.2-2.1) 0.6 (0.2-1.7)
CCCR4 (56.4%) 95.9 (89.0-100) 0.5 (0.2-1.6) 0.9 (0.3-2.2)
CCCR5 (56.1%) 91.5 (79.0-100) 0.6 (0.2-2.4) 0.8 (0.2-2.5)
CCCR6 (55.7%) 92.1 (80.2-100) 0.5 (0.1-2.3) 0.8 (0.3-2.2)
CCCR7 (54.2%) 94.7 (85.8-100) 0.6 (0.2-1.9) 0.9 (0.3-2.5)
CCCR8 (49.9%) 98.1 (89.7-100) 0.3 (0.1-1.7) 0.5 (0.1-1.4 )
*Hazard ratios adjusted for histological grade, T stage, nodal stage, estrogen receptor, and progesterone receptor. 
** Percentage of patients treated 100% adherent. RS: relative survival; RER: relative excess risk of death.
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In addition to classical tumor related prognostic factors, patient characteristics may be 
associated with breast cancer outcome. The aim of this study was to assess the association 
between age at diagnosis and breast cancer outcome in postmenopausal women with hormone 
receptor positive breast cancer.
Methods
Patients who were enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) 
randomized clinical trial were included in the current study. Primary endpoint was disease 
specific mortality; secondary endpoints were other cause mortality and breast cancer 
recurrence. Age at diagnosis was categorized as <65 years, 65-75 years, and ≥75 years.
Results 
Overall, 9,766 patients were included; 5,349 were <65 years, 3,060 were 65-75 years, and 1,357 
were ≥75 years. Disease specific mortality as a proportion of all cause mortality decreased 
with age (78%, 56%, 36% respectively; p<0.001). Disease specific mortality increased with 
age (multivariable analyses, patients aged <65 years functioned as a reference, hazard ratio 
for patients aged 65-75 years was 1.25 (95% CI 1.01-1.54); hazard ratio for patients aged ≥75 
years was 1.63 (95% CI 1.23-2.16); p<0.001). Similarly, breast cancer recurrence and other cause 
mortality increased with age (patients aged <65 years functioned as a reference, breast cancer 
recurrence: hazard ratio for patients aged 65-75 years was 1.07 (95% CI 0.91-1.25); hazard 
ratio for patients aged ≥75 years was 1.29 (95% CI 1.05-1.60); p=0.061 – other cause mortality: 
hazard ratio for patients aged 65-75 years was 2.66 (95% CI 1.96-2.63); hazard ratio for patients 
aged ≥75 years was 7.30 (95% CI 5.29-10.07); p<0.001).  
Conclusion
Among postmenopausal women with hormone receptor positive breast cancer, increasing age 
was associated with a higher disease specific mortality.
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Introduction
Breast cancer is the leading contributor to cancer incidence and cancer mortality in women 
worldwide, with 1,383,500 new cases in 20081. In the US in 2008, 41% of these women were 65 
year or older at diagnosis2. As breast cancer incidence increases with increasing age2, changing 
demographics and continuously increasing life expectancy will further enlarge the number of 
elderly women confronted with breast cancer. 
In addition to classical tumor related prognostic factors, patient characteristics may be 
associated with breast cancer outcome; an individual who dies from causes unrelated to breast 
cancer is no longer at risk for progression of breast cancer or death due to breast cancer. The 
risk of death from another cause that is unrelated to either breast cancer or its therapy is 
termed a competing risk of death, and may be particularly present in elderly populations3. 
Observational data in breast cancer patients hint at an age specific association with mortality4. 
Observational data often lack data regarding treatment5 and in retrospective studies 
cause of death is not always traceable. Clinical trials generally do not have these problems. 
Unfortunately, elderly patients are often not included in clinical trials due to age restrictions6. 
As one of few breast cancer trials, the Tamoxifen, Exemestane, Adjuvant, Multinational 
(TEAM) trial had no upper age limit, thereby providing a unique opportunity to focus on the 
association between age and disease specific mortality in postmenopausal patients diagnosed 
with hormone receptor positive breast cancer. 
The aim of the current study was to assess disease specific mortality among age groups in 
postmenopausal patients with hormone receptor positive breast cancer. Secondarily, age 
specific other cause mortality and age specific breast cancer recurrence were evaluated.
Methods
The TEAM trial is a randomized, phase 3, multinational, open label study conducted in 
postmenopausal breast cancer patients with estrogen and/or progesterone receptor positive 
tumors. Patients were randomized to receive either exemestane 25 mg once-daily for five years 
or tamoxifen 20 mg once-daily for 2.5–3 years, followed by exemestane 25 mg once-daily for 
2.5–2 years, for a total of five years. Participants were enrolled in Belgium, The Netherlands, 
United Kingdom, Ireland, United States of America, Japan, Greece, Germany, and France 
(N=9766), and included between January 2001 and January 2006. Appropriate approvals from 
the ethical committee, and written informed consent from all patients were obtained7. The trial 
was registered with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; 
NTR 267; Ethics Commission Trial 27/2001; and UMIN, C000000057.
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Similar protocols were used in the nine countries, with minor differences to accommodate 
local treatment guidelines7;8. In short, postmenopausal patients with histologically confirmed 
breast cancer, who completed local therapy with curative intent, i.e. without evidence of 
metastatic disease, were eligible. Participants commenced endocrine treatment assigned at 
random within 10 weeks of completion of surgery and chemotherapy, if indicated. Patients 
were ineligible if they had a previous malignancy with a disease free interval of less than five 
years, an Eastern Cooperative Oncology Group (ECOG) performance status of more than 2, or 
a significant cardiac disease or other illness interfering with study participation. 
The final results of the TEAM trial showed no significant differences in efficacy endpoints 
between five years of exemestane alone versus the sequence of tamoxifen followed by 
exemestane7. Moreover, death from non breast cancer causes was comparable for both 
treatment arms7. Therefore we were able to investigate disease specific mortality for all patients 
regardless of randomized treatment. 
The design of the current post hoc analysis was developed in December 2010. The database 
was locked on October 7th 2010. Patients were categorized in three age groups (<65 years, 
65-75 years, ≥75 years) as discussed at the Meeting of the International Society of Geriatric 
Oncology (SIOG) in 20099 and in line with other publications10;11. Primary endpoint of this 
study was disease specific mortality, which was defined as time from randomization to death 
due to breast cancer, as indicated on the Case Report Form. Cause of death was ascertained 
by medical record review and categorized in one of ten prespecified groups. Classification was 
verified by the TEAM Central Statistical and Data-Center. Patients with distant metastases at 
time of death were considered to have died due to breast cancer. Overall, 7% (n=42) of deaths 
attributed to breast cancer was accounted to presence of distant metastases at time of death. 
The majority of these patients (57%, n=24) were formerly categorized as ‘unknown’ or ‘other’ 
cause of death. The secondary endpoints of this study were other cause mortality and breast 
cancer recurrence. Other cause mortality was calculated as all cause mortality minus disease 
specific mortality; breast cancer recurrence was defined as locoregional or distant breast 
cancer recurrence, or ipsi- or contralateral breast cancer. Ductal carcinoma in situ was not 
judged to be evidence of recurrence.  
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL) and R statistical 
package (R Development Core Team, 2008). To compare proportional differences among age 
categories, the Pearson chi-square test was used. Cumulative incidences of competing causes 
of death were calculated12 using the mstate package in R13. Cox proportional hazard models 
were used to evaluate associations between covariates and cause specific hazards of disease 
specific mortality and other cause mortality. Additional regression analyses according to 
Fine and Gray14 were performed in order to assess the risk of disease specific mortality and 
other cause mortality respectively, taken into account the risk of reaching the other endpoint. 
Covariates were included in the multivariable model if they were judged to be clinically 
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relevant, and comprised country, histological grade (G1; G2; G3,4), T stage (T0,Tis,T1; T2; 
T3,4), nodal stage (negative; positive), estrogen receptor (negative; positive), progesterone 
receptor (negative; positive), surgery, (mastectomy; wide local excision) radiotherapy (yes; no), 
chemotherapy (yes; no), endocrine therapy (tamoxifen followed by exemestane; exemestane) 
and persistence of endocrine therapy (discontinuation of allocated endocrine therapy because 
of either adverse events, intercurrent illness, patient refusal or other reasons;  continuation of 
allocated endocrine therapy, or having an event while on study medication). All statistical tests 
were two-sided.  P values <0.05 were considered to be statistically significant.
Results
Overall 9,766 patients (age range 35-96, median age 64 years) were included in the multinational 
TEAM trial, of which 5,349 were <65 years at diagnosis (55%, median age 58 years), 3,060 were 
65-75 years (31%, median age 69 years) and 1,357 were ≥75 years (14%, median age 79 years). 
Overall, 778 patients (8.0%) were lost to follow-up, 429 (8.0%) in patients aged <65 years, 214 
(7.0%) in patients aged 65-75 years, and 135 (9.9%) in patients aged ≥75 years.  Table 1 shows 
patient characteristics by age at diagnosis. We observed an age associated increase in larger 
tumors and estrogen receptor positive breast cancer. As shown in Table 2, the proportion of 
mastectomy increased significantly with age, whereas administration of chemotherapy, and 
administration of radiotherapy after a wide local excision an decreased. 
At database lock, median follow-up (interquartile range) from randomization was 5.1 years 
(4.3; 6.0 years) in patients aged <65 years, 5.1 years (4.2; 6.0 years) in patients aged 65-75 years, 
and 5.0 years (3.8; 5.8 years) in patients aged ≥75 years.  The number of deaths was 391 (7.3%), 
341 (11.2%), and 311 (22.9%) respectively. Figure 1 illustrates cumulative incidence of death due 
to breast cancer, non breast cancer, and all causes by age at diagnosis. Cumulative incidence 
of death due to breast cancer increased from 5.7% in patients aged <65 years, 6.3% in patients 
aged 65-75 years, to 8.3% in patients aged ≥75 years. Cumulative incidence of non breast cancer 
death was 1.6%, 4.9% and 14.6% respectively. 
Table 3 shows causes of death by age at diagnosis. Increasing age was associated with a lower 
number of deaths due to breast cancer as a proportion of all cause mortality (<65 years 78%, 
65-75 years 56%, ≥75 years 36%; p<0.001). Deaths categorized as ‘other’ (n=100) were recorded 
to have died of old age, dementia, weakness or cachexia (n=41), infection or sepsis (n=20), 
sudden death not otherwise specified (n=7), accidents (n=6), a combination of recorded reasons 
(n=6), and other infrequent causes (n=20; gastro-intestinal perforation, urogential disorders, 
malignancy related disorders, suicide). 
Univariate Cox regression analysis showed a higher risk of disease specific mortality with 
increasing age (patients aged <65 years functioned as a reference, hazard ratio (HR) for patients 
aged 65-75 years was 1.12 (95% confidence interval (CI) 0.94-1.34); HR for patients aged ≥75 
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Figure 1. Figure 1. Cumulative incidence of death due to breast cancer, non breast cancer and all causes by age 
at diagnosis. Non breast cancer death is defined as death due to all causes except breast cancer (second primary 
tumor, endometrial cancer, cardiac disorder, thromboembolism, pulmonary disorder, cerebral disorder, vascular 
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n (%) n (%) n (%)
Histological grade 0.06
G1 (well) 911 (17.0) 550 (18.0) 216 (15.9)
G2 (moderate) 2,580 (48.2) 1,537 (50.2) 679 (50.0)
G3, G4 (poor) 1,377 (25.7) 732 (23.) 329 (24.2)
Gx, unknown 481 (9.0) 241 (7.9) 133 (9.8)
T stage <0.001
T0, Tis 6 (0.1) 0 (0.0) 0 (0.0)
T1 3,291 (61.5) 1,806 (59.0) 593 (43.7)
T2 1,793 (33.5) 1,122 (36.7) 676 (49.8)
T3, T4 244 (4.6) 125 (4.1) 88 (6.5)
Tx, unknown 15 (0.3) 7 (0.2) 0 (0.0)
N stage 0.14
Negative 2,799 (52.3) 1,622 (47.1) 690 (50.8)
Positive 2,518 (47.1) 1,419 (46.4) 651 (48.0)
Unknown 32 (0.6) 19 (0.6) 16 (1.2)
Estrogen receptor <0.001
Positive 5,218 (97.6) 3,022 (98.8) 1,344 (99.0)
Negative 128 (2.4) 35 (1.1) 13 (1.0)
Unknown 3 (0.1) 3 (0.1) 0 (0.0)
Progesterone receptor 0.54
Positive 4,028 (75.3) 2,268 (74.1) 1,004 (74.0)
Negative 915 (17.1) 554 (18.1) 255 (18.8)
Unknown 406 (7.6) 238 (7.8) 98 (7.2)
Country <0.001
Belgium 265 (5.0) 106 (3.5) 43 (3.2)
France 722 (13.5) 403 (13.2) 105 (7.7)
Germany 871 (16.3) 454 (14.8) 146 (10.8)
Greece 110 (2.1) 71 (2.3) 26 (1.9)
Japan 98 (1.8) 66 (2.2) 20 (1.5)
The Netherlands 1,428 (26.7) 852 (27.8) 473 (34.9)
UK/Ireland 696 (13.0) 431 (13.5) 166 (12.2)
United States 1,159 (21.7) 695 (22.7) 378 (27.9)
UK: United Kingdom.
years was 1.66 (95% CI 1.34-2.06); p<0.001). Since tumor and treatment characteristics may be 
associated with disease specific mortality, multivariable analyses were performed in attempt to 
adjust for unequal distributions among age categories (Table 4). Overall, 8,030 (82.2%) patients 
were included in the multivariable model. Again, disease specific mortality increased with age 
(patients aged <65 years functioned as a reference, HR for patients aged 65-75 years was 1.25 
(95% CI 1.01-1.54); HR for patients aged ≥75 years was 1.63 (95% CI 1.23-2.16); p<0.001). 
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n (%) n (%) n (%)
Most extensive surgery <0.001
Mastectomy 2,120 (39.6) 1,372 (44.8) 841 (62.0)
WLE 3,222 (60.2) 1,685 (55.1) 515 (38.0)
No resection 2 (<0.1) 1 (<0.1) 0 (0.0)
Unknown 4 (0.1) 2 (0.1) 1 (0.1)
Radiotherapy <0.001
Yes 3,980 (74.4) 2,030 (66.3) 687 (50.6)
No 1,330 (24.9) 994 (32.5) 651 (48.0)
Unknown 39 (0.7) 36 (1.2) 19 (1.4)
RT in case of WLE <0.001
Yes 3,042 (94.4) 1,543 (91.6) 451 (87.6)
No 180 (5.6) 142 (8.4) 64 (12.4)
Chemotherapy <0.001
Yes 2,743 (51.3) 700 (22.9) 71 (5.2)
No 2,605 (48.7) 2,357 (77.0) 1,284 (94.6)
Unknown 1 (<0.1) 3 (0.1) 2 (0.1)
Endocrine therapy 0.38
Tam Ý Exe 2,666 (49.9) 1,546 (50.5) 655 (48.3)
Exemestane 2,682 (50.1) 1,514 (49.5) 702 (51.2)
Persistence of ET <0.001
Yes 4,142 (77.4) 2,376 (77.6) 980 (72.2)
No 1,207 (22.6) 684 (22.4) 377 (27.8)
WLE: wide local excision; RT: radiotherapy; Tam Ý Exe: tamoxifen followed by exemestane; ET: endocrine 
therapy.
Table 3. Causes of death by age at diagnosis.
<65 years (n=391) 65-75 years (n=341) ≥75 years (n=311)
n (%) n (%) n (%)
Breast cancer 303 (77.5) 192 (56.3) 113 (36.3)
Second primary tumor 35 (9.0) 50 (14.7) 31 (10.0)
Endometrial cancer 1 (0.3) 0 (0.0) 0 (0.0)
Cardiac disorder 14 (3.6) 25 (7.3) 39 (12.5)
Thromboembolism 0 (0.0) 2 (0.6) 10 (3.2)
Pulmonary disorder 5 (1.3) 12 (3.5) 14 (4.5)
Cerebral disorder 4 (1.0) 13 (3.8) 17 (5.5)
Vascular disorder 1 (0.3) 3 (0.9) 3 (1.0)
Other 17 (4.3) 26 (7.6) 57 (18.3)
Unknown 11 (2.8) 18 (5.3) 27 (8.7)
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Table 4. Disease specific mortality by age at diagnosis.
5-years death Multivariable*
HR (95% CI) pn (%)
Age <0.001
<65 years 243 (5) 1 (reference)
65-75 years 149 (6) 1.25 (1.01-1.54)
≥75 years 92 (8) 1.63 (1.23-2.16)
Histological grade (BR) <0.001
G1 27 (2) 1 (reference)
G2 191 (5) 1.86 (1.28-2.70)
G3,4 226 (10) 3.23 (2.21-4.72)
T stage <0.001
T1 151 (3) 1 (reference)
T2 282 (9) 1.91 (1.55-2.35)
T3,4 49 (12) 2.01 (1.44-2.81)
Nodal status <0.001
Negative 121 (3) 1 (reference)
Positive 360 (9) 2.31 (1.85-2.87)
Estrogen receptor <0.001
Positive 459 (6) 1 (reference)
Negative 25 (15) 2.18 (1.44-3.31)
Progesterone receptor <0.001
Positive 293 (5) 1 (reference)
Negative 138 (9) 1.64 (1.35-2.00)
Most extensive surgery <0.001
Mastectomy 316 (8) 1 (reference)
WLE 168 (4) 0.59 (0.46-0.74)
Radiotherapy 0.001
Yes 335 (6) 1 (reference)
No 146 (6) 0.68 (0.54-0.86)
Chemotherapy 0.76
Yes 213 (2) 1 (reference)
No 271 (2) 0.97 (0.77-1.20)
Endocrine therapy 0.08
Tam Ý Exe 246 (6) 1 (reference)
Exe 238 (6) 0.85 (0.71-1.02)
Persistence of ET 0.001
Persistent 425 (2) 1 (reference)
Nonpersistent 79 (2) 0.64 (0.50-0.84)
HR: Hazard ratio; CI: confidence interval. * Hazard ratios adjusted for all other covariates mentioned in the Table, 
and country. WLE: wide local excision; Tam Ý Exe: Tamoxifen followed by Exemestane; ET: endocrine therapy.
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To test the robustness of the age cut points, additional analyses were performed with age as a 
continuous variable, which confirmed an increased risk of breast cancer death per ten years 
increase in age (univariate HR per ten years was 1.20 (95% CI 1.10-1.31), p<0.001; multivariable 
HR per ten years 1.21 was (95% CI 1.08-1.36), p=0.001). Since increasing age was associated with 
larger tumors (Table 1), additional analyses were performed to exclude residual confounding by 
tumor size. Multivariable survival analyses adjusted for tumor size in centimeters instead of T 
stage revealed similar results (patients aged <65 years functioned as a reference, HR for patients 
aged 65-75 years was 1.25 (95% CI 1.01-1.55); HR for patients aged ≥75 years was 1.62 (95% CI 
1.22-2.14); p=0.003). Moreover, within strata of tumor size in centimeters, increasing age was 
consistently associated with a higher disease specific mortality (Supplementary table 1). 
As disease specific mortality may be underestimated due to increased other cause mortality 
with increasing age, we performed additional survival analyses using a Fine and Gray model, 
in which the risk of competing mortality is accounted for. Multivariable analyses yielded 
comparable results as those presented in Table 4 (patients aged <65 years functioned as a 
reference, HR for patients aged 65-75 years was 1.22 (95% CI 1.00-1.48); HR for patients aged 
≥75 years was 1.50 (95% CI 1.16-1.94); p<0.001). Additionally, one may argue that comorbidity 
in itself, independent of associated competing mortality, may result in higher disease specific 
mortality. Data on comorbidity were available for Dutch and Belgian patients (n=3142, 32%). 
Survival analyses restricted to these patients showed that estimates were not affected by 
comorbidity (Supplementary table 2). 
To investigate whether the association between age and disease specific mortality was of linear 
origin, or whether a specific turning point was present, age was categorized in seven groups 
(Supplementary table 3). Disease specific mortality was similar for patients up to 70 years of 
age. From this age onwards, disease specific mortality increased stepwise with increasing age. 
Table 5. Other cause mortality and breast cancer recurrence by age at diagnosis.
5-years events Univariate
HR (95% CI) p
Multivariable*
HR (95% CI) pn (%)
Other cause mortality <0.001 <0.001
<65 years 64 (1) 1 (reference) 1 (reference)
65-75 years 126 (5) 2.99 (2.29-3.89) 2.66 (1.96-3.63)
≥75 years 160 (14) 9.96 (7.74-12.80) 7.30 (5.29-10.07)
Breast cancer recurrence 0.002 0.061
<65 years 512 (10) 1 (reference) 1 (reference)
65-75 years 282 (10) 1.00 (0.87-1.15) 1.07 (0.91-1.25)
≥75 years 153 (13) 1.34 (1.13-1.59) 1.29 (1.05-1.60)
HR: Hazard ratio; CI: confidence interval. *Hazard ratios adjusted for country, histological grade, T stage, nodal 
stage, estrogen receptor, progesterone receptor, surgery, radiotherapy, chemotherapy, endocrine therapy and 
persistence of endocrine therapy.
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Next, we studied whether other cause mortality and breast cancer recurrence were different 
among age categories (Table 5). Mortality from other causes increased with age (multivariable 
analyses, patients aged <65 years functioned as a reference, HR for patients aged 65-75 years 
was 2.66 (95% CI 1.96-3.63); HR for patients aged ≥75 years was 7.30 (95% CI 5.29-10.07); 
p<0.001). Next, increasing age was associated with a higher risk of breast cancer recurrence 
(multivariable analyses, patients aged <65 years functioned as a reference, HR for patients aged 
65-75 years was 1.07 (95% CI 0.91-1.25); HR for patients aged ≥75 years was 1.29 (95% CI 1.05-
1.60); p=0.061).   
Discussion
The major finding in this study is that disease specific mortality is higher in older breast 
cancer patients, independent of tumor and treatment characteristics. Similarly, breast cancer 
recurrence increased with increasing age. Disease specific mortality as a proportion of all 
cause mortality decreased with age. 
Several factors were explored which potentially could have biased our findings. Increasing 
age was associated with larger tumors at diagnosis. Consequently, disease specific mortality 
would be higher in elderly patients. Multivariable analyses adjusted for treatment and tumor 
characteristics, and analyses stratified by tumor size did not alter the results. Selective 
misclassification, in which death is more often attributed to breast cancer with increasing 
age, is not likely to have biased our results, because additional analyses using the secondary 
endpoint breast cancer recurrence revealed similar results. Theoretically, this trial may have 
been subject to age specific inclusion bias, in which elderly were included with different tumors 
compared to younger patients (Table 1). However, since differences in tumor characteristics 
resemble observational data in postmenopausal patients receiving surgery15, this was not likely 
to have had a major influence.
Our finding that disease specific mortality as a proportion of all cause mortality decreased 
with age is consistent with several observational studies3;5;10;16-19. Bastiaannet et al4 found that 
within breast cancer patients the percentage of deaths attributed to breast cancer decreased 
with age. The decreased proportion of all cause mortality attributed to breast cancer may have 
led to the conclusion that disease specific mortality decreases with increasing age. Here we 
provide arguments that disease specific mortality increases with age. There are few studies 
in the literature addressing this topic. Besides, there are only little data available on disease 
specific mortality in breast cancer patients by age at diagnosis. Increased risk of disease 
specific mortality with increasing age is confirmed in two studies4;20, however others observed 
an opposite association5;17;18, or no association at all16;19;21. 
It is tempting to speculate on the underlying mechanisms which could explain the results 
presented in this study. First, elderly patients may experience undertreatment. Several studies 
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showed that elderly breast cancer patients have lower odds of receiving standard care10;22-25. 
Increased age at diagnosis predicts deviation from guidelines for surgical therapy23, adjuvant 
radiotherapy10;24;25, chemotherapy23-25 and endocrine therapy23;24. All patients included in 
this trial received surgery and endocrine therapy. A previous TEAM study analysis showed 
that patients aged ≥75 years more frequently discontinued study medication, and received 
less often subsequent therapy. However, discontinuation within the first year of follow-up was 
not associated with disease specific mortality thereafter11. Radiotherapy after a wide local 
excision was administered less frequently with increasing age (Table 1). Moreover, while 48% 
of patients aged ≥75 years had nodal involvement, only 5.2% received adjuvant chemotherapy. 
Next, elderly patients may experience overtreatment, in which adverse events of breast cancer 
therapy result in mortality attributed to breast cancer. Older patients may have an increased 
toxicity risk when treated with chemotherapy and to a lesser degree with radiotherapy26. In 
these relatively healthy elderly trial participants, breast cancer recurrence was shown to be 
higher with increasing age as well. Therefore overtreatment is not likely to play a role in our 
findings.
Breast cancer in elderly might display a more aggressive tumor biology and thereby increase 
mortality from breast cancer. In this study, elderly presented more often with larger tumors, 
however nodal status was similar over age. Although this hypothesis cannot be tested in detail 
in this study, other studies suggest the opposite. Advanced age has been associated with a 
decrease in tumor proliferative factors27, and elderly patients more often present with well 
differentiated tumors and positive hormone receptor status19;28. 
Adjustment for both treatment and tumor characteristics did not eliminate the association 
between age and disease specific mortality. Consequently, other, unknown factors might 
have contributed to our findings. Older patients might respond differently to a tumor than 
younger patients29. In addition, older patients might respond different to a certain therapy. 
Polypharmacy can cause drug interactions, and may alter pharmacokinetics of anticancer 
therapy30. 
Summarized, undertreatment, in particular undertreatment of either chemotherapy or 
radiotherapy, may explain age specific outcome in this relatively healthy population. Differences 
in tumor biology and age specific overtreatment are not likely to have influenced our findings. 
We cannot exclude a potential influence of an age specific response to either the tumor or 
anticancer therapy. 
Effects of anticancer treatment cannot be estimated as precisely in patients with a high risk 
of competing mortality. As a consequence studies may be underpowered to detect treatment 
outcome differences in these populations31. Fine and Gray analyses accounting for the higher 
competing mortality with increasing age revealed similar effect sizes; despite the fact that 
14.6% of patients aged ≥75 years died from causes other than breast cancer, estimates were 
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unaffected. These data suggest that competing mortality has to be substantial to affect disease 
specific outcome as estimated by Cox regression analysis. 
Strengths and limitations 
The major strength of this study is the ability to study a large group of breast cancer patients 
followed as part of a clinical trial on endocrine therapy. Trial data comprise highly standardized 
treatment algorithms and virtually complete follow-up. The TEAM trial had very few exclusion 
criteria, among which there was no upper age limitation. This enabled us to study age specific 
mortality.
As enrollment in the TEAM trial was restricted to postmenopausal patients with estrogen and/
or progesterone receptor positive disease, these results may not necessarily be extrapolated to 
all breast cancer patients. No data were available on compliance to non-randomized therapy. 
Although analyses were adjusted for non-randomized therapy, residual confounding and bias 
by noncompliance cannot be excluded. Although eligibility criteria of the TEAM trial were 
quite broad, it is known that trial populations generally comprise relatively healthy patients 
compared to the general population32. The results presented in this study may slightly differ 
from results in the general population.  Competing mortality is likely to be higher in the general 
population, and administered treatment as well as implications of treatment may differ from a 
trial population. Replication of the current analyses in a detailed population based study may 
reveal additional evidence for one or more explanations of the findings presented in this study. 
Conclusion
In conclusion, regardless of a higher risk of other cause mortality and independent of 
tumor and treatment characteristics, disease specific mortality increases with age among 
postmenopausal women with hormone receptor positive breast cancer. These data underline 
the need for age specific breast cancer studies, in order to improve breast cancer outcome in 
all ages. Moreover, future detailed population based and translational studies may increase 
insight in causal factors of higher disease specific mortality and breast cancer recurrence with 
increasing age. 
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Supplementary table 1. Disease specific mortality by age at diagnosis, stratified by tumor size.
5-years death Univariate
HR (95% CI) p 
Multivariable*
HR (95% CI) p n (%)
<1 cm 0.827 0.700
<65 years 3 (1) 1 (reference) 1 (reference)
65-74 years 0 (0) 0.89 (0.16-4.85) 1.29 (0.21-7.97)
≥75 years 1 (1) 1.84 (0.20-16.63) 2.82 (0.26-31.21)
1-2 cm 0.124 0.073
<65 years 58 (3) 1 (reference) 1 (reference)
65-74 years 44 (2) 1.31 (0.91-1.89) 1.52 (0.99-2.32)
≥75 years 12 (4) 1.61 (0.95-2.74) 1.86 (0.97-3.58)
2-3 cm 0.208 0.619
<65 years 80 (7) 1 (reference) 1 (reference)
65-74 years 44 (6) 0.93 (0.67-1.29) 1.01 (0.69-1.47)
≥75 years 76 (9) 1.32 (0.91-1.90) 1.24 (0.78-1.99)
3-4 cm 0.329 0.022
<65 years 50 (11) 1 (reference) 1 (reference)
65-74 years 21 (8) 0.95 (0.62-1.46) 1.11 (0.67-1.83)
≥75 years 26 (13) 1.34 (0.86-2.07) 2.15 (1.20-3.82)
4-5 cm 0.034 0.136
<65 years 15 (9) 1 (reference) 1 (reference)
65-74 years 15 (12) 1.54 (0.81-2.90) 1.48 (0.70-3.14)
≥75 years 13 (20) 2.51 (1.25-5.02) 2.32 (1.02-6.13)
≥5 cm 0.241 0.397
<65 years 19 (9) 1 (reference) 1 (reference)
65-74 years 18 (18) 1.51 (0.88-2.58) 1.53 (0.79-2.96)
≥75 years 8 (12) 0.90 (0.43-1.88) 1.02 (0.37-2.82)
HR: Hazard ratio; CI: confidence interval. * Hazard ratios adjusted for country, histological grade, nodal stage, 
estrogen receptor, progesterone receptor, surgery, radiotherapy, chemotherapy, endocrine therapy and persistence 
of endocrine therapy.
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Supplementary table 2.  Disease specific mortality in Dutch/Belgian participants, adjusted for comorbidity.
5-years death Multivariable
HR (95% CI) p n (%)
Model 1* 0.055
<65 years 135 (9) 1 (reference)
65-75 years 74 (9) 1.16 (0.86-1.57)
≥75 years 51 (11) 1.57 (1.09-2.26)
Model 2** 0.048
<65 years 135 (9) 1 (reference)
65-75 years 74 (9) 1.16 (0.86-1.58)
≥75 years 51 (11) 1.60 (1.10-2.32)
Model 3*** 0.064
<65 years 135 (9) 1 (reference)
65-75 years 74 (9) 1.16 (0.86-1.57)
≥75 years 51 (11) 1.55 (1.07-2.25)
Model 4**** 0.047
<65 years 135 (9) 1 (reference)
65-75 years 74 (9) 1.17 (0.87-1.59)
≥75 years 51 (11) 1.59 (1.10-2.31)
HR: Hazard ratio; CI: confidence interval. * Hazard ratios adjusted for country, histological grade, T stage, nodal 
stage, estrogen receptor, progesterone receptor, surgery, radiotherapy, chemotherapy, endocrine therapy and 
persistence of endocrine therapy. ** Hazard ratios adjusted for variables included in Model 1 and comorbidity 
categories (cardiac, central nervous system, endocrine, musculoskeletal comorbidities). *** Hazard ratios adjusted 
for variables included in Model 1 and number of comorbidities (continuous). **** Hazard ratios adjusted for 
variables included in Model 1 and number of comorbidities (0, 1-2, >2).
Supplementary table 3. Disease specific mortality by age at diagnosis (7 groups).
5-years death Univariate
HR (95% CI) p
Multivariable*
HR (95% CI) pn (%)
Age at diagnosis
<55 years 63 (5) 1 (reference) 1 (reference)
55-60 years 87 (5) 1.08 (0.81-1.44) 0.611 1.02 (0.74-1.41) 0.908
60-65 years 93 (5) 1.09 (0.82-1.45) 0.554 1.09 (0.79-1.51) 0.610
65-70 years 75 (5) 1.05 (0.78-1.41) 0.767 1.18 (0.84-1.65) 0.339
70-75 years 74 (7) 1.38 (1.02-1.87) 0.035 1.48 (1.04-2.11) 0.029
75-80 years 74 (9) 1.75 (1.27-2.40) 0.001 1.73 (1.17-2.56) 0.006
≥80 years 29 (7) 1.81 (1.23-2.66) 0.003 1.74 (1.11-2.74) 0.017
HR: Hazard ratio; CI: confidence interval. * Hazard ratios adjusted for country, histological grade, T stage, nodal 
stage, estrogen receptor, progesterone receptor, surgery, radiotherapy, chemotherapy, endocrine therapy and 
persistence of endocrine therapy.
proefshrift.indb   81 2-5-2014   08:13:52
82 Chapter 5
Reference List
 (1)  Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman 
D. Global cancer statistics. CA Cancer J Clin 2011.
 (2)  Surveillance Epidemiology and End Results.  2011. 
18-2-2011.  Ref Type: Online Source
 (3)  Mell LK, Jeong JH, Nichols MA, Polite BN, 
Weichselbaum RR, Chmura SJ. Predictors of 
competing mortality in early breast cancer. Cancer 
2010;116:5365-5373.
 (4)  Bastiaannet E, Liefers GJ, de Craen AJ et al. Breast 
cancer in elderly compared to younger patients in 
The Netherlands: stage at diagnosis, treatment and 
survival in 127,805 unselected patients. Breast Cancer 
Res Treat 2010;124:801-807.
 (5)  Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities 
of death from breast cancer and other causes among 
female breast cancer patients. J Natl Cancer Inst 
2004;96:1311-1321.
 (6)  Zulman DM, Sussman JB, Chen X, Cigolle CT, 
Blaum CS, Hayward RA. Examining the Evidence: A 
Systematic Review of the Inclusion and Analysis of 
Older Adults in Randomized Controlled Trials. J Gen 
Intern Med 2011.
 (7)  van de Velde CJ, Rea D, Seynaeve C et al. Adjuvant 
tamoxifen and exemestane in early breast cancer 
(TEAM): a randomised phase 3 trial. Lancet 
2011;377:321-331.
 (8)  van Nes JG, Seynaeve C, Jones S et al. Variations in 
locoregional therapy in postmenopausal patients with 
early breast cancer treated in different countries. Br J 
Surg 2010;97:671-679.
 (9)  International Society of Geriatric Oncology.  2011. Ref 
Type: Online Source
 (10)  Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards 
BK, Yates JW. Effect of age and comorbidity in post-
menopausal breast cancer patients aged 55 years and 
older. JAMA 2001;285:885-892.
 (11)  van de Water W, Bastiaannet E, Hille ET et al. 
Age-specific nonpersistence of endocrine therapy in 
postmenopausal patients diagnosed with hormone 
receptor-positive breast cancer: a TEAM study analy-
sis. Oncologist. In press.
 (12)  Putter H, Fiocco M, Geskus RB. Tutorial in biosta-
tistics: competing risks and multi-state models. Stat 
Med 2007;26:2389-2430.
 (13)  de Wreede LC, Fiocco M, Putter H. The mstate pack-
age for estimation and prediction in non- and semi-
parametric multi-state and competing risks models. 
Comput Methods Programs Biomed 2010;99:261-274.
 (14)  Fine JP, Gray RJ. A proportional hazards model for the 
subdistribution of a competing risk. Journal of theAm-
erican Statistical Association 1999;94:496-509.
 (15)  Gennari R, Curigliano G, Rotmensz N et al. Breast 
carcinoma in elderly women: features of disease 
presentation, choice of local and systemic treatments 
compared with younger postmenopasual patients. 
Cancer 2004;101:1302-1310.
 (16)  Fish EB, Chapman JA, Link MA. Competing causes 
of death for primary breast cancer. Ann Surg Oncol 
1998;5:368-375.
 (17)  Hanrahan EO, Gonzalez-Angulo AM, Giordano SH 
et al. Overall survival and cause-specific mortality of 
patients with stage T1a,bN0M0 breast carcinoma. J 
Clin Oncol 2007;25:4952-4960.
 (18)  Du XL, Fox EE, Lai D. Competing causes of death for 
women with breast cancer and change over time from 
1975 to 2003. Am J Clin Oncol 2008;31:105-116.
 (19)  Diab SG, Elledge RM, Clark GM. Tumor characteris-
tics and clinical outcome of elderly women with breast 
cancer. J Natl Cancer Inst 2000;92:550-556.
 (20)  Chapman JA, Meng D, Shepherd L et al. Competing 
causes of death from a randomized trial of extended 
adjuvant endocrine therapy for breast cancer. J Natl 
Cancer Inst 2008;100:252-260.
 (21)  Braithwaite D, Satariano WA, Sternfeld B et al. 
Long-term prognostic role of functional limitations 
among women with breast cancer. J Natl Cancer Inst 
2010;102:1468-1477.
 (22)  Allemani C, Storm H, Voogd AC et al. Variation in 
‘standard care’ for breast cancer across Europe: a 
EUROCARE-3 high resolution study. Eur J Cancer 
2010;46:1528-1536.
 (23)  Giordano SH, Hortobagyi GN, Kau SW, Theriault 
RL, Bondy ML. Breast cancer treatment guidelines in 
older women. J Clin Oncol 2005;23:783-791.
 (24)  White J, Morrow M, Moughan J et al. Compliance with 
breast-conservation standards for patients with early-
stage breast carcinoma. Cancer 2003;97:893-904.
 (25)  Eisinger F, Ronda I, Puig B, Camerlo J, Giovannini 
MH, Bardou VJ. Breast cancer guidelines--Phy-
sicians’ intentions and behaviors. Int J Cancer 
2007;120:1136-1140.
 (26)  Pallis AG, Fortpied C, Wedding U et al. EORTC 
elderly task force position paper: approach to the older 
cancer patient. Eur J Cancer 2010;46:1502-1513.
 (27)  Durbecg V, Larsimont D. Tumor biology and patholo-
gy. In: M.W.R.Reed, R.A A, eds. Management of breast 
cancer in older women. 1 ed. Springer; 2010;21-35.
 (28)  Wildiers H, Kunkler I, Biganzoli L et al. Management 
of breast cancer in elderly individuals: recommen-
dations of the International Society of Geriatric 
Oncology. Lancet Oncol 2007;8:1101-1115.
 (29)  Zitvogel L, Tesniere A, Kroemer G. Cancer despite 
immunosurveillance: immunoselection and immuno-
subversion. Nat Rev Immunol 2006;6:715-727.
 (30)  Lichtman SM, Wildiers H, Launay-Vacher V, Steer 
C, Chatelut E, Aapro M. International Society of 
Geriatric Oncology (SIOG) recommendations for the 
adjustment of dosing in elderly cancer patients with 
renal insufficiency. Eur J Cancer 2007;43:14-34.
 (31)  Latouche A, Porcher R. Sample size calculations 
in the presence of competing risks. Stat Med 2007; 
26:5370-5380.
proefshrift.indb   82 2-5-2014   08:13:52
Association between age and breast cancer mortality 83
 (32)  Lewis JH, Kilgore ML, Goldman DP et al. Participation 
of patients 65 years of age or older in cancer clinical 
trials. J Clin Oncol 2003;21:1383-1389.
proefshrift.indb   83 2-5-2014   08:13:53
proefshrift.indb   84 2-5-2014   08:13:53
6C h a p t e r
Elderly postmenopausal patients with breast 
cancer are at increased risk for distant recurrence










Anton J.M. de Craen
Rudi G.J. Westendorp
Cornelis J.H. van de Velde
Gerrit-Jan Liefers
Oncologist. 2013;18(1):8-13




For postmenopausal patients with hormone receptor positive breast cancer, breast cancer 
survival decreases with increasing age at diagnosis. The aim of this study was to assess 
the incidence of breast cancer recurrence, both locoregional and distant recurrence, and 
contralateral breast cancer, by age at diagnosis. 
Methods
Patients enrolled in the Tamoxifen Endocrine Adjuvant Multinational (TEAM) trial were 
included. Primary endpoints were locoregional recurrence, distant recurrence and contralateral 
breast cancer. Age at diagnosis was categorized as younger than 65 years, 65-75 years, and 75 
years or older. 
Results
Overall, 9,766 patients were included, of which 5,349 were younger than 65 years (reference 
group), 3,060 were 65-75 years, and 1,357 were 75 years or older. With increasing age, a 
decreased administration of radiotherapy after breast conserving surgery (94%; 92%; 88% 
respectively) and adjuvant chemotherapy (51%; 23%; 5% respectively) was observed. Risk of 
distant recurrence increased with age at diagnosis; multivariable hazard ratio for patients aged 
65-75 years was 1.20 (95% CI 1.00-1.44), hazard ratio for patients aged 75 years or older was 
1.39 (95% CI 1.08-1.79). Risks of locoregional recurrence and contralateral breast cancer were 
not significantly different across age groups.
Conclusion
Elderly breast cancer patients were at increased risk for distant recurrence. Others have shown 
that the risk of distant recurrence is mainly affected by adjuvant systemic therapy. All TEAM 
patients received adjuvant endocrine treatment, however, chemotherapy was administered less 
often in elderly patients. These findings are suggestive for consideration of chemotherapy in 
relatively fit elderly breast cancer patients with hormone sensitive disease. 
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Introduction
Breast cancer is the most common type of cancer in women in Western societies. Worldwide, 
nearly a third of all breast cancer patients are 65 years or older, and in more developed countries 
this proportion increases to over 40%1. Because of an increasing life expectancy and raised 
breast cancer incidence with increasing age, the disease will progressively affect the lives of 
elderly women2. 
Many have published on the worse prognosis of premenopausal compared with postmenopausal 
breast cancer patients3-5. However, evidence is lacking on age specific breast cancer outcome 
within postmenopausal women. Recently, we reported that breast cancer survival in 
postmenopausal patients decreased with increasing age6. To gain further insight in the relation 
between age at diagnosis and breast cancer outcome, we studied the incidence of breast cancer 
recurrence, both locoregional and distant recurrence, and contralateral breast cancer, by age at 




The TEAM trial has been described extensively in previous reports6;7. In short, 9,766 
postmenopausal women with estrogen and/or progesterone receptor positive breast cancer, who 
completed local therapy with curative intent, were randomized to receive either exemestane 25 
mg daily for five years or a sequential regimen consisting of tamoxifen 20 mg daily for 2.5–3 
years, followed by exemestane 25 mg daily for 2.5–2 years. Adjuvant chemotherapy, if indicated, 
was given before start of endocrine therapy, and radiotherapy was administered according to 
local practice. Participants commenced the assigned endocrine study treatment within 10 
weeks of completion of surgery and chemotherapy, if indicated. Patients were ineligible if they 
had a malignancy within five years preceding breast cancer diagnosis, an Eastern Cooperative 
Oncology Group (ECOG) performance status of more than two, or a significant cardiac disease 
or other illness interfering with study participation and adequate follow-up. Participants were 
enrolled in Belgium, The Netherlands, United Kingdom, Ireland, United States of America, 
Japan, Greece, Germany, and France. Similar protocols were used in the nine countries, with 
minor differences to accommodate the local treatment guidelines8. The trial was registered 
with ClinicalTrials.gov, NCT00279448, NCT00032136, and NCT00036270; NTR 267; Ethics 
Commission Trial 27/2001; and UMIN, C000000057. 
As the final results of the TEAM trial showed no significant differences in efficacy endpoints 
between both treatment arms7, we were able to investigate disease recurrence regardless of 
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randomized treatment. The database was locked on October 7th 2010; the design of the current 
post hoc analysis was developed in July 2011.  
Patients were categorized in three groups, based on age at diagnosis (younger than 65 years, 
65-75 years, and 75 years or older) as discussed at the Meeting of the International Society of 
Geriatric Oncology (SIOG) in 2009 and in line with other publications6;9;10. Study endpoints 
were 1) locoregional recurrence (recurrence in the ipsilateral breast or chest wall, recurrence 
in ipsilateral axillary or supraclavicular lymph node(s), or other locoregional localization), 2) 
distant recurrence (recurrence in bone, skin, liver, lung, brain, or other distant localization), 
and 3) contralateral breast cancer (new primary invasive tumor in the contralateral breast), 
whichever came first. In situ carcinoma was not considered to be a recurrence. For 61 patients 
with synchronously recurrent disease at more than one site, the localization most likely 
determining the prognosis was used as endpoint.
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL). Cox proportional 
hazard models were used to evaluate the association between age at diagnosis and the 
endpoints. Covariates were included in the multivariable model if they were judged to be 
clinically relevant. First, estimates were adjusted for country and tumor characteristics 
(country of residence, histological grade (Bloom Richardson grade I; II; III), T stage (T1; 
T2; T3,4), nodal stage (negative; positive), estrogen receptor status (negative; positive), and 
progesterone receptor status (negative; positive)). Next, the fully adjusted model comprised 
both tumor and treatment characteristics (country, histological grade, T stage, nodal stage, 
estrogen receptor status, progesterone receptor status, type of surgery (mastectomy; wide 
local excision), radiotherapy (yes; no), chemotherapy (yes; no), allocated endocrine therapy 
Table 1. Distribution of locoregional recurrence and distant recurrence by age at diagnosis.
<65 years 65-75 years ≥75 years p
n (%) n (%) n (%)
Locoregional recurrence 0.24
Ipsilateral breast 55 (49.1) 20 (40.8) 13 (40.6)
Chest wall 23 (20.5) 16 (32.7) 11 (34.4)
Ipsilateral lymph node(s) 16 (14.3) 5 (10.2) 6 (18.7)
Supraclavicular lymph 
node(s)
8 (7.1) 2 (4.1) 0 (0)
Other 10 (8.9) 6 (12.2) 2 (6.3)
Distant recurrence 0.50
Bone 139 (34.0) 95 (38.5) 53 (40.8)
Liver 144 (35.2) 77 (31.2) 37 (28.5)
Lung 60 (14.7) 36 (14.6) 22 (16.9)
Skin 9 (2.2) 7 (2.8) 1 (0.8)
Brain 11 (2.7) 4 (1.6) 4 (3.1)
Other 46 (11.3) 28 (11.3) 13 (10.1)
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(tamoxifen followed by exemestane; exemestane) and persistence of endocrine therapy 
(discontinuation of allocated endocrine therapy because of either adverse events, intercurrent 
illness, patient refusal or other reasons;  continuation of allocated endocrine therapy, or having 
an event while on study medication)). Patients with missing data were not included in the 
multivariable model. All statistical tests were two-sided. P values <0.05 were considered to be 
statistically significant.
Results
Overall, 9,766 patients (range 35-96, median age 64 years) were included; 5,349 were younger 
than 65 years (median 58 years), 3,060 were 65-75 years (median 69 years), and 1,357 were 
75 years or older (median 79 years). Baseline characteristics by age groups were shown in an 
earlier report6; elderly patients presented with larger tumors, without differences in nodal 
status. With increasing age, the proportion of mastectomy increased significantly, while a 
marked decrease was observed in the administration of radiotherapy following a wide local 
excision (94%; 92%; 88% respectively, p<0.001) and administration of chemotherapy (51%; 23%; 
5% respectively, p<0.001)6.
At database lock, median follow-up (interquartile range) from randomization was 5.1 years (4.2-
6.0 years), during which 1,062 first events were registered; 193 locoregional recurrences, 786 
distant recurrences and 83 contralateral breast cancers. As shown in Table 1, the distribution 
of locoregional recurrence and distant recurrence was similar across age groups. Figure 1 
shows the cumulative incidence of endpoints by age at diagnosis. Cumulative incidence of 
Table 2. Breast cancer recurrence by age at diagnosis.
5-years event Univariate
HR (95% CI) p
Multivariable*
HR (95% CI) p
Multivariable**
HR (95% CI) pn (%)
Locoregional recurrence 0.10 0.14 0.10
<65 years 100 (2) 1 (reference) 1 (reference) 1 (reference)
65-75 years 42 (1) 0.77 (0.55-1.08) 0.71 (0.49-1.04) 0.67 (0.45-0.99)
≥75 years 27 (3) 1.24 (0.84-1.84) 1.10 (0.71-1.70) 1.00 (0.61-1.63)
Distant recurrence 0.006 0.08 0.024
<65 years 378 (8) 1 (reference) 1 (reference) 1 (reference)
65-75 years 219 (8) 1.06 (0.91-1.24) 1.14 (0.96-1.36) 1.20 (1.00-1.44)
≥75 years 115 (10) 1.37 (1.13-1.68) 1.26 (1.01-1.57) 1.39 (1.08-1.79)
Contralateral breast cancer 0.73 0.79 0.75
<65 years 34 (1) 1 (reference) 1 (reference) 1 (reference)
65-75 years 21 (1) 0.98 (0.60-1.60) 0.99 (0.59-1.66) 1.03 (0.60-1.77)
≥75 years 11 (2) 1.26 (0.68-2.33) 1.24 (0.64-2.38) 1.31 (0.64-2.68)
HR: Hazard ratio; CI: confidence interval. * Hazard ratios adjusted for country, histological grade, T stage, nodal 
stage, estrogen receptor, and progesterone receptor. ** Hazard ratios adjusted for country, histological grade, 
T stage, nodal stage, estrogen receptor, progesterone receptor, surgery, radiotherapy, chemotherapy, endocrine 
therapy and persistence of endocrine therapy.
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locoregional recurrence was 2.1%, 1.6%, and 2.4% respectively; cumulative incidence of distant 
recurrence increased from 7.6% in patients younger than 65 years, 8.1% in patients aged 65-75 
years of age, to 9.6% in patients aged 75 years or older. Cumulative incidence of contralateral 
breast cancer was 0.8%, 0.8%, and 1.0% respectively.
Distant recurrence









































































Figure 1. Cumulative incidence of A) locoregional recurrence, B) distant recurrence C) and contralateral breast 
cancer by age at diagnosis.
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Table 2 shows the results of Cox regression analyses. In both univariate and multivariable 
analyses, the risk of locoregional recurrence was similar across age categories. Contrary, the 
risk of distant recurrence increased with increasing age at diagnosis. Patients aged younger 
than 65 years functioned as a reference, univariate hazard ratio (HR) for patients aged 65-75 
was 1.06 (95% confidence interval (CI) 0.91-1.24) and HR for patients aged 75 years or older was 
1.37 (95% CI 1.13-1.68). Both the partly and fully adjusted model showed comparable results; 
the fully adjusted HR for patients aged 65-75 was 1.20 (95% CI 1.00-1.44); HR for patients aged 
75 years or older was 1.39 (95% CI 1.08-1.79), p=0.024. The risk of contralateral breast cancer 
was not significantly different across age categories. 
To test the sensitivity of the endpoints, three alternative analyses were performed. The results 
of these alternative analyses were similar to the main results. First, survival analyses were 
repeated without restriction to the first site of recurrence, i.e. all events irrespective of the 
sequence of occurrence were included in the analysis. Multivariable HR for locoregional 
recurrence was 0.79 (95% CI 0.57-1.09) for patients aged 65-75 years, and 0.94 (95% CI 0.62-
1.43) for patients aged 75 years or older; multivariable HR for distant recurrence was 1.17 (95% 
CI 0.98-1.40) for patients aged 65-75 years, and 1.39 (95% CI 1.09-1.76) for patients aged 75 
years or older; and multivariable HR for contralateral breast cancer was 0.90 (95% CI 0.53-1.52) 
for patients aged 65-75 years, and 0.92 (95% CI 0.46-1.83) for patients aged 75 years or older.
Second, synchronous endpoints (n=61) were recoded as locoregional recurrence, and 
contralateral breast cancer, respectively. Multivariable HR for locoregional recurrence, for 
patients aged 65-75 years was 0.76 (95% CI 0.54-1.06), HR for patients aged 75 years or older 
was 0.92 (95% CI 0.59-1.42), p=0.260; multivariable HR for distant recurrence, for patients aged 
65-75 years was 1.20 (95% CI 0.99-1.46); HR for patients aged 75 years or older was 1.45 (95% 
CI 1.12-1.88), p=0.015; and multivariable HR for contralateral breast cancer, for patients aged 
65-75 years was 1.05 (95% CI 0.62-1.80); HR for patients aged 75 years or older was 1.46 (95% 
CI 0.73-2.94), p=0.546.
Third, contralateral breast cancer was recoded as locoregional recurrence. Multivariable HR 
for locoregional recurrence, for patients aged 65-75 years was 0.77 (95% CI 0.56-1.06); HR for 
patients aged 75 years or older was 1.08 (95% CI 0.72-1.62), p=0.164. 
Also, two additional analyses were performed to diminish selection bias. First, survival analyses 
for distant recurrence were stratified by T stage since increasing age was associated with 
larger tumors (Supplementary table 1). Although not significant, estimates were comparable 
to the main analysis. Second, survival analyses for locoregional recurrence were stratified 
by most extensive surgery since elderly patients more frequently underwent a mastectomy 
(Supplementary table 2). Again, the results remained similar.
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Discussion 
To summarize, we found that elderly breast cancer patients had a higher risk of distant 
recurrence, while the risks of locoregional recurrence and contralateral breast cancer did not 
significantly differ across age groups. Additional analyses were performed to test the robustness 
of the endpoints and to explore whether our findings may have been biased. Inclusion of three 
alternative definitions of endpoints did not alter the results. Moreover, stratified analyses by T 
stage and most extensive surgery revealed comparable estimates.  
Many have published on predictors of breast cancer recurrence in premenopausal compared 
to postmenopausal patients. Virtually all studies observed a higher risk of locoregional breast 
cancer recurrence in premenopausal compared to postmenopausal women4;5;11-14. Few studies 
addressed breast cancer recurrence within postmenopausal patients, and again most focused 
on locoregional recurrence15-18. It is tempting to speculate on the possible mechanisms which 
may explain our findings. Based on the literature, we hypothesize that locoregional recurrence 
may reflect suboptimal local19 and/or systemic20 treatment, while distant recurrence and 
contralateral breast cancer more likely reflect suboptimal systemic treatment20-23. As all 
TEAM patients received endocrine treatment, the decreased administration of chemotherapy 
with increasing age may have contributed to a higher distant breast cancer recurrence in 
elderly patients. Of note, the hazard ratio for contralateral breast cancer for patients aged 75 
years or older was comparable with the hazard ratio for distant recurrence, but the distribution 
of contralateral breast cancer was not statistically different across age groups, possibly due to 
a low number of events. 
Few have studied chemotherapy efficacy in elderly breast cancer patients. In the Early Breast 
Cancer Trialists’ Collaborative Group meta-analysis, not enough women older than 70 years 
were included to be able to draw conclusions about chemotherapy efficacy in this age group20. 
However, a review of randomized clinical trials on chemotherapy in node positive breast cancer 
patients revealed that older patients derived similar reductions in breast cancer mortality 
and recurrence compared to younger patients24. Recently, Muss et al evaluated the efficacy 
of two regimens of adjuvant chemotherapy in older women with early stage breast cancer. 
Standard chemotherapy showed to be superior to oral capecitabine, especially in patients with 
hormone receptor negative tumors. Two studies aimed to evaluate the benefit of chemotherapy 
in elderly breast cancer patients, in which chemotherapy was compared with a no treatment 
arm25;26. Both trials failed to recruit and were closed early. The investigators suggested that 
a recruitment failure was due to the inability to convince patients to accept randomization 
in which a no treatment arm was incorporated25. Our findings suggest that addition of 
chemotherapy might be of benefit in relatively fit breast cancer patients with hormone receptor 
positive breast tumors. This needs to be evaluated in future studies.
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As the association between age and distant recurrence was not eliminated by adjustment for 
both tumor and treatment characteristics, additional mechanisms may play a role, such as 
different tumor biology resulting in worse breast cancer outcome27; or interplay between tumor 
and patient characteristics including immunosenescence, which may result in a higher risk of 
disease progression28;29; or a different response to anti-cancer therapy due to interactions with 
comorbidity and polypharmacy30. 
One may argue that increasing age may be associated with a lower adherence to endocrine 
therapy and consequently may result in a higher rate of recurrence. No data were available on 
adherence by pill count. However, multivariable analyses were adjusted for nonpersistence, 
which was defined as discontinuing the assigned endocrine treatment because of adverse 
events, intercurrent illness, patient refusal, or other reasons. Previously, we reported a higher 
rate of nonpersistence of endocrine therapy with increasing age, in the Dutch and Belgian 
patients included in the TEAM study. However, both in patients aged 65-75 years as well as in 
patients aged 75 years or older, survival was not affected by nonpersistence31. The absence of a 
consistent association between nonpersistence and outcome suggests that the current findings 
cannot adequately be explained by age specific adherence. 
Strengths and limitations 
A major strength of this study is the ability to study a large group of breast cancer patients 
followed as part of a clinical trial on endocrine therapy. Trial data comprise highly standardized 
treatment algorithms and virtually complete follow-up. The TEAM trial had very few exclusion 
criteria, among which there was no upper age limitation. This enabled us to study age specific 
breast cancer recurrence. However, although eligibility criteria of the TEAM trial were 
quite broad, it is known that trial populations generally comprise relatively healthy patients 
compared to the general population32. Additionally, as enrollment in the TEAM trial was 
restricted to postmenopausal patients with hormone receptor positive disease, these results 
may not necessarily be extrapolated to all breast cancer patients.
Conclusion
In conclusion, elderly breast cancer patients included in the TEAM trial had a higher risk of 
distant recurrence. This risk may be due to underuse of chemotherapy, which therefore might 
be considered in relatively fit elderly patients. 
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Supplementary table 1.  Distant recurrence of breast cancer by age at diagnosis, stratified by T stage. 
5-years  event Univariate
HR (95% CI) p
Multivariable*
HR (95% CI) pn (%)
T1 0.12 0.11
<65 years 130 (4) 1 (reference) 1 (reference)
65-75 years 70 (4) 0.93 (0.71-1.23) 1.03 (0.74-1.42)
≥75 years 26 (5) 1.41 (0.97-2.05) 1.60 (1.01-2.51)
T2 0.54 0.14
<65 years 199 (12) 1 (reference) 1 (reference)
65-75 years 126 (13) 1.11 (0.90-1.37) 1.26 (0.98-1.62)
≥75 years 76 (13) 1.12 (0.87-1.44) 1.29 (0.93-1.80)
T3, T4 0.76 0.70
<65 years 46 (21) 1 (reference) 1 (reference)
65-75 years 23 (21) 1.11 (0.69-1.78) 1.22 (0.70-2.12)
≥75 years 13 (17) 0.86 (0.48-1.57) 1.30 (0.63-2.69)
HR: Hazard ratio; CI: confidence interval. * Hazard ratios adjusted for country, histological grade, nodal stage, 
estrogen receptor, progesterone receptor, most extensive surgery, radiotherapy, chemotherapy, endocrine therapy 
and persistence of endocrine therapy.
Supplementary table 2.  Locoregional recurrence by age at diagnosis, stratified by most extensive surgery.
5-years event Univariate
HR (95% CI) p
Multivariable*
HR (95% CI) pn (%)
Mastectomy 0.61 0.57
<65 years 54 (3) 1 (reference) 1 (reference)
65-75 years 32 (3) 0.84 (0.55-1.29) 0.80 (0.49-1.31)
≥75 years 21 (3) 1.08 (0.67-1.74) 1.06 (0.58-1.92)
Wide local excision 0.19 0.11
<65 years 46 (2) 1 (reference) 1 (reference)
65-75 years 10 (1) 0.60 (0.34-1.06) 0.49 (0.24-0.99)
≥75 years 6 (1) 1.06 (0.51-2.24) 1.07 (0.45-2.52)
HR: Hazard ratio; CI: confidence interval. * Hazard ratios adjusted for country, histological grade, T stage, nodal 
stage, estrogen receptor, progesterone receptor, radiotherapy, chemotherapy, endocrine therapy and persistence 
of endocrine therapy.
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Previously it was shown that breast cancer survival decreases with increasing age among a 
selected population of elderly who participated in a trial. However, patients who participate 
in a trial differ from patients in the general population. Therefore, the aim of this study was 
to evaluate the association between age and breast cancer outcome in an unselected group of 
elderly breast cancer patients.
Methods
We included patients of the population-based FOCUS study, which comprises all incident 
breast cancer patients aged 65 years or older at diagnosis, who were diagnosed in the South 
Western part of The Netherlands between 1997 and 2004. All patients with non-metastasized 
breast cancer who received breast surgery were included. Age was categorized as 65-75 years 
and ≥75 years. Primary outcome was relative survival, which is an approximation of disease 
specific survival and the preferred way to describe the prognosis of elderly cancer patients in 
population-based studies. In addition, the relative excess risk of death was estimated.   
Results
Overall, 3,124 patients were included (1,617 aged 65-75 years; 1,507 aged ≥75 years), with a 
median age of 74.6 years. The five-years relative survival was 92.6% (95% CI 90.5-94.5) in 
patients aged 65-75 years, and 86.4% (95% CI 82.5-90.2) in patients aged ≥75 years. The lower 
relative survival in the oldest patients corresponded with a higher relative excess risk of death 
in patients aged ≥75 years as compared to patients aged 65-75 years (multivariable relative 
excess risk of death was 1.72 (95% CI 1.21-2.44)).  
Conclusions
Breast cancer outcome, in terms of relative survival, deteriorates with increasing age among 
unselected elderly patients from the general population.
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Introduction
Breast cancer is the most frequently diagnosed malignancy in females in the Western world, 
with over 40% of new diagnoses occurring in women aged 65 years and older1. It is often assumed 
that breast cancer phenotype is less aggressive in older women. Although elderly breast cancer 
patients more often present with larger tumors2 and positive lymph nodes at diagnosis3, they 
more often have hormone receptor positive disease and lower tumor differentiation grades4. In 
addition, a higher competing risk of death among elderly, in which a patient dies from causes 
unrelated to breast cancer, may affect breast cancer mortality5.
However, recently we showed that breast cancer mortality increased with increasing age among 
9,766 postmenopausal women with hormone receptor positive breast cancer who participated 
in a randomized clinical trial6. Moreover, elderly patients had a higher risk of breast cancer 
recurrence, and distant recurrence in particular7.
Regardless of the disease and the age of the patients under study, it has been shown that 
the outlook of patients included in a clinical trial is usually better than those who do not 
participate8. In the general population, the risk of competing mortality is likely to be higher. 
In addition, both treatment9 as well as implications of treatment may differ from patients who 
participate in a trial. Therefore it remains unknown whether the association of a worse breast 
cancer outcome with increasing age is also present in unselected elderly patients from the 
general population.
The aim of this study was to evaluate the association between age at diagnosis and breast cancer 
outcome in a large, unselected, population-based cohort of elderly patients with breast cancer.
Methods
FOCUS cohort
We included patients of the population-based FOCUS study. The FOCUS study (Female breast 
cancer in the elderly; Optimizing Clinical guidelines USing clinico-pathological & molecular 
data) comprises all incident breast cancer patients aged 65 years or older at diagnosis, who 
were diagnosed in the geographically defined Comprehensive Cancer Center Region West in 
The Netherlands between 1997 and 2004. Inclusion in the cohort is based on the National 
Cancer Registry, which contains data of all incident cancer cases. The nationwide Dutch 
network and registry of histopathology and cytopathology regularly submits reports of 
all newly diagnosed malignancies to the Regional Cancer Registries. The national hospital 
discharge data bank, which receives discharge diagnoses of admitted patients from all Dutch 
hospitals, completes case ascertainment. Trained personnel reviewed charts of these patients 
and collected information on patient, tumor, treatment and outcome characteristics. Vital 
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status was established either directly from the patient’s medical record or through linkage with 
the municipal population registries, which record information on vital status (follow-up until 
January 1st 2011). Patients with in situ or invasive, non-metastatic breast cancer at diagnosis 
who received breast surgery were included in the current study. 
Outcome measures
Primary outcome measure was relative survival, which is an approximation of disease-specific 
survival. Relative survival is the preferred method for estimating disease-specific outcome in a 
population-based setting without requiring information on the cause of death10;11. 
Secondary outcome measures were time from diagnosis to occurrence of a locoregional 
recurrence, (recurrence in the ipsilateral breast or chest wall, or recurrence in ipsilateral 
axillary or supraclavicular lymph node(s); distant recurrence (recurrence in bone, skin, liver, 
lung, brain or other distant localization); or contralateral breast cancer, whichever came first. 
For patients with synchronously recurrent disease at more than one site, the localization most 
likely determining prognosis was used as endpoint. Ductal carcinoma in situ was not judged to 
be evidence of recurrence. 
Statistical analysis
Statistical analyses were performed using SPSS statistical software, version 20.0 (SPSS Chicago, 
IL) and STATA SE 12.0. Age at diagnosis was categorized as 65-74 years and ≥75 years, as 
discussed at the meeting of the International Society of Geriatric Oncology in 200912 and in 
line with other publications6;13. To compare proportional differences among age categories, the 
Pearson χ2 test was used. 
Relative survival was calculated as the observed overall survival among patients in the study, 
divided by the expected overall survival in the sex-, age-, and year matched general population, 
using the ‘strs’ command in Stata11. Expected survival was obtained from population life-tables 
according to the Ederer II method14. An estimate of the five-years relative survival of less than 
100% means that the survival of patients in the study is lower than expected, when compared 
to survival in the corresponding general population. This means that patients in the study had 
an excess risk of death, which can be attributed to breast cancer or breast cancer treatment.  
The excess risk of death can be calculated as the observed number of deaths minus the 
expected number of deaths, divided by the total person-years. To compare whether the excess 
risk of death differed by age at diagnosis, we calculated the relative excess risk of death, which 
is the excess risk of death in patients aged ≥75 years divided by the excess risk of death in 
patients aged 65-75 years. The relative excess risk of death is estimated by a multivariable 
generalized linear model with a Poisson distribution, based on collapsed relative survival data 
based on exact survival times14, and can be interpreted as the risk of death from breast cancer 
in patients aged ≥75 years as compared to the risk of death from breast cancer in patients aged 
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65-75 years. To assess the robustness of the results, the analyses were also stratified by stage 
(early stage: in situ, I, II; advanced stage: III)15. 
The relation between age at diagnosis and the secondary endpoints were evaluated by competing 
risk regression analyses according to Fine and Gray16, since cause-specific outcomes may be 
influenced by the risk of competing endpoints. For example, an individual who dies, is no 
longer at risk for breast cancer recurrence. A Fine and Gray analysis is used to assess the risk 
of locoregional recurrence, distant recurrence and contralateral breast cancer, respectively, 
taking into account the risk of reaching competing endpoints. Competing endpoints for 
locoregional recurrence were distant recurrence, contralateral breast cancer, and death; 
competing endpoints for distant recurrence were locoregional recurrence, contralateral breast 
cancer, and death;  and competing endpoints for contralateral breast cancer were locoregional 
recurrence, distant recurrence, and death. Sensitivity analyses were performed for overall 
recurrence, which was defined as either a locoregional recurrence, distant recurrence or 
contralateral breast cancer as a first event, with death as competing endpoint.
Covariates were included in the multivariable model if they were judged to be clinically relevant 
and comprised histological grade (Bloom Richardson G1; G2; G3; unknown), histological 
subtype (ductal; lobular; other), hormone receptor status (positive; negative; unknown), 
combined TNM stage (I; II; III; unknown), most extensive breast surgery (mastectomy; wide 
local excision), most extensive axillary surgery (axillary lymph node dissection; sentinel lymph 
node biopsy; none), radiotherapy (yes; no), chemotherapy (yes; no), endocrine therapy (yes; no); 
and comorbid disease (0-1; 2-4; 5 or more). All statistical tests were 2-sided. P values of less 
than 0.05 were considered to be statistically significant.
Results
Overall, 3,124 patients with a median age of 74.6 years were included (range 65–98 years); 1,617 
were 65-75 years (median age 69.8 years), and 1,507 were 75 years and older (median age 81.0 
years). Median follow-up time was 7.3 years (interquartile range 4.2-9.7 years). Patient, tumor 
and treatment characteristics by age at diagnosis are shown in Table 1. Patients aged ≥75 years 
had a higher number of comorbid diseases. Moreover, they more often had a higher stage at 
diagnosis, and more often presented with hormone receptor positive tumors. The proportions 
of patients who received a mastectomy and endocrine therapy increased with increasing age, 
whereas axillary surgery, administration of radiotherapy after lumpectomy, and chemotherapy 
decreased. 
When we compared overall survival of the patients in the current study to the expected overall 
survival as based on the corresponding general population, survival of patients in the study 
was lower than in the corresponding general population; the five-years relative survival was 
92.6% (95% CI 90.5-94.5) in patients aged 65-75 years, and 86.4% (95% CI 82.5-90.2) in patients 
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n % n %
Comorbid disease <0.001
0-1 919 56.8 602 39.9
2 to 4 584 36.1 721 47.8
≥5 114 7.1 184 12.2
Histological subtype 0.116
Ductal cancer 1,224 75.7 1,092 72.5
Lobular cancer 169 10.5 175 11.6
Other/unknown 224 13.9 240 15.9
Histological grade (BR) 0.813
Grade 1 226 14.0 195 12.9
Grade 2 492 30.4 468 31.1
Grade 3 391 24.2 358 23.8
Unknown 508 31.4 486 32.2
Hormone-receptor status <0.001
Positive 1,018 63.0 1,045 69.3
Negative 256 15.8 232 15.4
Unknown 343 21.2 230 15.3
TNM stage <0.001
In situ 137 8.5 61 4.0
I 685 42.4 373 24.8
II 627 38.8 803 53.3
III 113 7.0 204 13.5
Unknown 55 3.4 66 4.4
Most extensive breast surgery <0.001
Mastectomy 786 48.6 1,161 77.0
Wide local excision 831 51.4 346 23.0
Most extensive axillary surgery <0.001
ALND 870 53.8 913 60.6
SLNB 489 30.2 288 19.1
None 258 16.0 306 20.3
Radiotherapy after wide local excision <0.001
Yes 751 90.4 238 68.8
No 80 9.6 108 31.2
Endocrine therapy <0.001
Yes 550 34.0 704 46.7
No 1,067 66.0 803 53.3
Chemotherapy <0.001
Yes 123 7.6 37 2.5
No 1,494 92.4 1,47 97.5
BR: Bloom Richardson; ALND: axillary lymph node dissection; SLNB: sentinel lymph node biopsy.
aged ≥75 years. This is depicted in Figure 1. This means that patients in the study had an 
excess risk of death, which can be attributed to breast cancer. We calculated the excess risk 
of death of patients in the current study as the difference between the observed and expected 
number of deaths, divided by the total person-years. Among patients aged 65-75 years, 261 
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deaths occurred in 7470 person-years; among patients aged ≥75 years, 659 deaths occurred 
in 5894 person-years. The expected numbers of deaths were 147 and 496, respectively. Hence, 
the excess risk of death in patients aged 65-75 years was 15.2/1000 person-years, and 27.7/1000 
person-years in patients aged ≥75 years. To compare whether the excess risk of death differed 
between both age groups, we calculated the relative excess risk of death. As shown in Table 2, 
the relative excess risk of death for patients aged ≥75 years as compared to patients aged 65-75 
years was 1.88 (95% CI 1.25-3.83). Multivariable analyses confirmed a higher relative excess 
risk of death for patients aged ≥75 years (1.72 (95% CI 1.21-2.44)). As patients aged ≥75 years 
more often presented with a higher stage of disease, additional analyses were stratified by stage 
(Supplementary table). In patients with early stage breast cancer, again patients aged ≥75 years 
had a higher relative excess risk of death. Comparable results were observed in patients with 
advanced stage breast cancer, however these results were not statistically significant.
Table 2. Excess risk of death in elderly patients with breast cancer as compared to the corresponding general 
population, by age at diagnosis.
5-years relative 
survival %
Excess risk of 
death / 1000py
Univariate relative 








65-75 years 92.6 15.2 1 (reference) 1 (reference)
≥75 years 86.4 27.7 1.88 (1.25-2.83) 1.72 1.21-2.44)
CI: confidence interval. * Multivariable analyses were adjusted for comorbidity, combined TNM stage, hormone 
receptor status, histological subtype, histological grade, most extensive breast surgery, most extensive axillary 
surgery, radiotherapy, endocrine therapy and chemotherapy.
Figure 1. Survival of elderly patients with breast cancer as compared to the corresponding general population, by 
age at diagnosis.
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During five years of follow-up, 523 patients developed a secondary endpoint, among which 80 
developed a locoregional recurrence; 359 a distant recurrence; and 84 a contralateral breast 
cancer. Median follow-up time for recurrent disease was 5.9 years (interquartile range 2.9-7.9 
years). As shown in Figure 2, for all three endpoints, the cumulative incidence of competing 
endpoints (death or another type of recurrence) was more than twice as high in patients aged 
* Competing events for locoregional recurrence: distant recurrence, contralateral breast cancer, and death due 
to any cause. Competing events for distant recurrence: locoregional recurrence, contralateral breast cancer, 
and death due to any cause. Competing events for contralateral breast cancer: locoregional recurrence, distant 
recurrence, and death due to any cause.
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Locoregional recurrence 0.065 0.293
65-75 years 33 288 1 (reference) 1 (reference)
≥75 years 47 680 1.52 (0.97-2.37) 1.30 (0.79-2.15)
Distant recurrence 0.023 0.435
65-75 years 179 142 1 (reference) 1 (reference)
≥75 years 180 547 1.30 (1.04-1.65) 1.12 (0.84-1.49)
Contralateral breast cancer 0.061 0.487
65-75 years 53 268 1 (reference) 1 (reference)
≥75 years 31 696 0.61 (0.39-0.95) 0.80 (0.42-1.51)
* Multivariable hazard ratios adjusted for comorbidity, combined TNM stage, hormone receptor status, 
histological subtype, histological grade, most extensive breast surgery, most extensive axillary surgery, 
radiotherapy, endocrine therapy and chemotherapy.
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≥75 years as compared to those aged 65-75 years. As shown in Table 3, the risk of a distant 
breast cancer recurrence increased with increasing age in univariate analysis (hazard ratio 
for patients aged ≥75 years was 1.30 (95% CI 1.04-1.65). However, in multivariable analyses no 
significant differences were observed. Sensitivity analyses for overall recurrence did not alter 
the results (data not shown).
Discussion
The main finding of our study is that the relative survival is lower for breast cancer patients 
aged ≥75 years as compared to patients aged 65-75 years. Patients aged ≥75 years had a higher 
excess risk of death. As the excess risk of death can be attributed to breast cancer, these 
results indicate that patients aged ≥75 years had a higher risk of death from breast cancer as 
compared to patients aged 65-75 years. We found no age-specific differences in the occurrence 
of locoregional recurrence, distant recurrence or contralateral breast cancer.
The design of the current study was based on the results of clinical trial data, which demonstrated 
a higher recurrence risk and worse breast cancer survival with increasing age6;7;17. Our main 
outcome that relative survival is lower among the oldest elderly breast cancer patients is 
confirmed by a previous study in The Netherlands2, and by a population-based study in the 
United States, which showed a decreasing breast cancer specific survival18. However, other 
population-based studies have shown no association between age and breast cancer specific 
or relative survival4;19;20 or even a higher breast cancer specific survival among elderly21;22. 
An explanation for the variation in results between our study and other publications could 
be the discrepancy in choice of endpoints. In the present study, we used relative survival as 
an approximation of breast cancer specific survival. As mentioned, the relative survival is the 
ratio of observed overall survival among patients in the study and the expected overall survival 
in the age-, sex-, and year-matched background file from the general population. Assuming all 
other factors being similar in the study cohort and the background file, the relative survival 
approximates breast cancer specific survival. The major advantage of using this endpoint is 
that there is no need to know the cause of death or cancer specific death data of all patients in 
the cohort, which is often described to be biased or overestimated in cancer registry data10;23. 
In addition, in population-based studies, relative survival has been shown to be comparable to 
cancer specific survival derived from death certificates24.
It is tempting to speculate on the possible explanations of our finding that breast cancer outcome 
deteriorates with increasing age. First, elderly breast cancer patients may be undertreated. Less 
extensive treatment may be the result of careful weighing of the benefits and risk of therapy 
in patients with comorbid disease, but may also result from underestimation of the disease 
in elderly patients. As was shown, patients aged ≥75 years received less often axillary surgery, 
radiotherapy after a lumpectomy, and chemotherapy in particular. Overall, the differences in 
treatment were relatively small. Therefore it is expected that other mechanisms may play a role. 
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Although patients aged 75 years and older presented more often with more advances stages of 
disease, stratified analyse confirmed a worse breast cancer outcome in all stages. Additionally, 
it has been suggested that older patients may respond different to a tumor as well as to a certain 
therapy as compared to younger patients. Patients who are biologically older may experience 
more immunosenescence, and may thereby have an impaired immunoresponse to a tumor, 
which may impair prognosis25. Moreover, concomitant medication use and comorbid disease 
may alter pharmacokinetics of anticancer therapy26. Thus, a biologically older or frailer patient 
may be at higher risk for breast cancer events. Hence, a higher prevalence of biologically older 
or frailer patients among those aged ≥75 years may attribute to a worse breast cancer outcome. 
We expected that the lower relative survival for the oldest elderly would be accompanied 
by an increase in breast cancer recurrence. However, after adjusting for patient and tumor 
characteristics, and after taking into account the risk of competing endpoints, we observed 
no difference in the occurrence of any type of recurrence. Insufficient power due to the 
shorter follow-up time for recurrences (median 5.9 years) and the limited number of events 
may have influenced the results. Another possible explanation could be under registration or 
under diagnosis of recurrent disease in medical files, especially in the frailest patients. From a 
clinical point of view, it is understandable that in an old patient with a history of breast cancer 
who presents with back pain, it is not always desired to further investigate the possibility of 
bone metastases, because either the patient does not wish to receive any therapy or it is not 
likely that life expectancy will be increased by administering further therapy. However, there 
is no literature that reports about this issue, and it would be interesting to investigate this 
prospectively in a future study.
A major strength of this study is the unselected population-based nature and the large number 
of consecutively diagnosed patients who were included; to our best knowledge, the FOCUS-
cohort is the largest population-based cohort comprising elderly breast cancer patients with 
such detailed information. However, this study also has some limitations when interpreting 
the results. As mentioned before, due to the retrospective and observational character of the 
study we cannot exclude the possibility of under registration of recurrent disease. Next to 
breast cancer specific endpoints, it remains important to evaluate the impact of the disease and 
therapy on quality of life and daily functioning. Unfortunately, these data were not available in 
the current study. 
To conclude, breast cancer outcome, in terms of relative survival, deteriorates with increasing 
age among unselected elderly patients from the general population. Of note, this was not 
accompanied by an increased risk of breast cancer recurrence. 
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Supplementary table. Excess risk of death in elderly patients with breast cancer as compared to the corresponding 
general population by age at diagnosis, stratified by stage.
5-years relative 
survival (%)
Excess risk of 
death / 1000py
Univariate relative 




excess risk of death 
(95% CI)
p
Early stage 0.04 0.03
65-74 years 94.5 11.1 1 (reference) 1 (reference)
≥75 years 89.9 19.9 1.86 (1.03-3.36) 1.80 (1.07-2.99)
Advanced stage 0.2 0.2
65-74 years 70.7 68.7 1 (reference) 1 (reference)
≥75 years 60.1 96.4 1.39 (0.85-2.30) 1.42 (0.82-2.44)
CI: Confidence interval. * Multivariable analyses were adjusted for comorbidity, combined TNM stage, hormone 
receptor status, histological subtype, histological grade, most extensive breast surgery, most extensive axillary 
surgery, radiotherapy, endocrine therapy and chemotherapy.
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In early stage breast cancer, radiotherapy is an integral part of locoregional treatment with 
breast conserving surgery. However, few older patients are included in the clinical trials upon 
which these recommendations are based. Therefore, we performed a systematic review and 
meta-analysis to evaluate outcomes of radiotherapy after breast conserving surgery in older 
patients.
Methods
A systematic search of Pubmed and Embase was undertaken. Inclusion was restricted to 
randomized controlled trials in postmenopausal breast cancer patients. Pooled odds ratios 
were calculated for locoregional recurrence, distant recurrence and overall survival.
Results
We included 5 randomized clinical trials comprising 3,190 patients. Overall, 39% of the patients 
was ≥70 years, and most had hormone receptor positive T1 tumors without nodal involvement. 
All patients received adjuvant systemic therapy. Patients who received radiotherapy had a 
lower relative risk of locoregional recurrence (pooled OR 0.36 (95%CI 0.25-0.50)). The 5-years 
absolute risk was 2.2% (95% CI 1.6-3.1) among patients who received radiotherapy, versus 6.5% 
(95% CI 5.3-7.9) among patients who did not. The absolute risk difference was 4.3% (95% CI 
2.9-5.7), corresponding with a number needed to treat of 24. No differences were observed for 
distant recurrence or overall survival.
Conclusion
Although patients who received radiotherapy had a lower relative risk of locoregional 
recurrence, the absolute risk was low and overall survival was not affected. We propose 
that the debate should not only focus on the relative risk but also on the absolute benefit of 
radiotherapy and the number needed to treat. Both treatment options may be reasonable in 
clinical practice.
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Introduction
In early stage breast cancer, adjuvant breast irradiation is an integral part of locoregional 
treatment with breast conserving surgery in order to obtain locoregional control1. However, 
with increasing age, patients are less often included in the clinical trials upon which these 
recommendations are based. Despite comprising more than 40% of new breast cancer patients, 
older patients are underrepresented in clinical trials2. Only 1-2% is estimated to participate in 
clinical trials, and only those who are considered fit enough are included3.
Next to an underrepresentation in clinical trials, different factors may play a role in the 
evaluation of radiotherapy after breast conserving surgery in older as compared to younger 
patients. First, older patients suffer from a higher risk of competing mortality4 and have a lower 
remaining life expectancy. Consequently, the absolute benefit of anticancer therapy may be 
smaller, while long term adverse events may be less relevant. Second, concurrent disease and 
medication use may directly affect tolerability of treatment and increase toxicity of systemic 
treatment5;6. Last, relevant treatment outcomes may vary with age7. Therefore, results obtained 
in a younger trial population may not necessarily be applicable to or appropriate for older 
breast cancer patients.
The outcome of radiotherapy after breast conserving surgery specifically in older patients has 
been studied by others. However, conclusions were inconsistent8-15. Meanwhile, observational 
studies show that administration of radiotherapy after breast conserving surgery decreases 
with increasing age16;17. Also among patients included in a randomized clinical trial on 
endocrine therapy, administration of radiotherapy after breast conserving therapy decreased 
with age4. It remains unclear whether this omission of radiotherapy is appropriate or whether 
radiotherapy should be an integral part of breast conserving surgery in older patients with 
early stage breast cancer.
Therefore, we performed a systematic review and meta-analysis to assess the efficacy of 
radiotherapy after breast conserving surgery in older patients with early stage breast cancer.
Methods
The focus of this systematic review and meta-analysis was to specifically address the outcomes 
of breast conserving surgery with or without radiotherapy in older patients with early stage 
breast cancer. A systematic search of Pubmed and Embase was undertaken, using several 
different search strategies and keywords comprising early stage breast cancer, breast conserving 
surgery, and radiotherapy (Figure 1), without restriction of publication dates, until June 1st 
2013. A priori inclusion criteria were the following; studies had to be a primary research article 
specifically addressing outcomes of breast conserving surgery with and without radiotherapy 
in early stage breast cancer. At least a subgroup analysis comprising older patients was to be 
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reported. To increase the number of potentially interesting papers, older patients were defined 
as postmenopausal patients.
Studies were excluded if they were a review or meta-analysis on the subject. Published 
abstracts without complete articles were excluded because of the inability to obtain detailed 
information. All citations were independently reviewed by two of the authors (WW and EB) 
and categorized as relevant, potentially relevant, or not relevant. Citations categorized as 
relevant or potentially relevant by one of the authors, were selected for abstract review. After 
review of the abstract, potentially relevant and relevant abstracts were selected for full text 
evaluation. Upon full text evaluation, it was decided not to include any of the observational 
studies, as outcomes in observational data are prone to confounding by indication18. Therefore, 
inclusion in the current study was further restricted to randomized controlled trials. 
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Included in current study    n = 5  
- No efficacy endpoint          n = 2
- More recent publication          n = 1
proefshrift.indb   114 2-5-2014   08:14:00
Radiotherapy after breast conserving surgery 115
For each included study, we recorded study characteristics (aim; randomization; eligibility 
criteria; number of patients), and main outcomes and conclusions as reported by the authors 
(primary and secondary outcomes; conclusions; comments). Numbers of events were extracted 
to conduct a meta-analysis of the different outcomes under study. If the numbers of events 
were not available, then survival graphs or survival rates were used to estimate the numbers of 
events. All data were obtained from the intention-to-treat analyses.
STATA SE 12 was used to pool the different outcome estimates. Outcomes were analysed 
as odds ratios. The I2 statistic was used to test for heterogeneity across studies19. An I2 value 
greater than 50% was considered to represent substantial heterogeneity. Publication bias was 
tested by using funnel plots; an inverted symmetrical funnel plot assumes the absence of 
publication bias20.
Next to relative outcome measures, pooled absolute risks were calculated. The pooled absolute 
risk per study arm was calculated as Σ(number of events in study arm) / Σ(N study arm), 
including a 95% confidence interval (CI). The absolute risk difference was calculated as the 
pooled estimate of the absolute risk difference per study, including a 95% CI. Next, number 
needed to treat was calculated as 1 divided by the absolute risk difference.
Results
Results of search strategy
Overall, 1,385 unique citations were identified, of which 217 citations were selected for 
abstract review, and of those, full text evaluation was undertaken for 49 publications. Overall, 
10 publications were excluded because they were observational studies; 12 publications were 
excluded because they were no original research article; 7 were excluded because they did not 
report on a direct comparison between breast conserving surgery versus breast conserving 
surgery plus radiotherapy; 10 were excluded because no (subgroup) analysis of older patients 
was included; 2 were excluded because they were not in English; 2 were excluded because no 
primary efficacy endpoint was included; and 1 was excluded because a more recent publication 
of the same study was available21. This resulted in 5 studies which were included the current 
systematic review and meta-analysis11-13;22;23.
Description of studies
Characteristics of the included studies are shown in Table 1. The total number of patients 
included in this systematic review and meta-analysis is 3,190. The studies included patients 
between 1981 and 2005 and were published between 2004 and 2013. Inclusion in all studies 
was restricted to patients with relatively favourable tumor characteristics; the majority of 
patients had T1 tumors, without nodal involvement, and with positive hormone receptor 
status. All patients received adjuvant systemic therapy; in the majority of the studies, patients 
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received adjuvant tamoxifen; in one study patients received either tamoxifen or chemotherapy 
depending on hormone receptor status. 
As shown in Table 2, most studies restricted inclusion to postmenopausal patients.  Although 
Ford et al included patients under 70 years of age (range 25-69 years), subgroup analyses by 
menopausal status were performed and hence only the results of postmenopausal patients were 
included in the meta-analysis11. Fyles et al included patients aged 50 years or older with a median 
age of 68 years, and reported that more than 95% of the participants were postmenopausal, 3% 
were premenopausal and 2% had an unknown menopausal status12. Therefore, we decided to 
include all these patients in the meta-analysis. Although the overall median age of all studies 
could not be calculated directly, one can derive from the data that the median age was over 65 
years of age. Moreover, at least 1,254/3,190 (39%) patients were 70 years or older. 
The primary outcome of most studies was locoregional recurrence, which was defined as a 
recurrence or a secondary breast tumor in the ipsilateral breast, or a recurrence in ipsilateral 
axillary lymph nodes or infra- or supraclavicular lymph nodes11;13;22;23 (Table 3). Frequent 
secondary outcomes were distant recurrence or distant disease free survival, and overall 
survival.
Meta-analysis 
The odds ratios for locoregional recurrence, distant recurrence and overall survival are 
shown in Figure 2. All studies observed a lower risk of locoregional recurrence for patients 
who were randomized to radiotherapy in addition to breast conserving surgery. The pooled 
analyses confirmed a lower relative risk of locoregional recurrence in patients who received 
radiotherapy; OR 0.36 (95% CI 0.25-0.50). There was no substantial heterogeneity across the 
studies (I2 was 43%, p=0.130). 
Since distant disease free survival was not uniformly described in all studies, we specifically 
extracted the number of distant recurrences in order to assess the pooled risk of a distant breast 
cancer recurrence. The relative risk of a distant recurrence was not affected by radiotherapy; 
the pooled OR was 0.96 (95% CI 0.68-1.36). Overall survival was also similar for both treatment 
modalities; the pooled OR for overall survival was 0.92 (95% CI 0.74-1.15). Again, there was no 
substantial heterogeneity among the studies for both outcomes. 
Two sensitivity analyses were performed. First, the meta-analyses were repeated without the 
study results of Fyles et al12, since a minority of the patients in this study may not have been 
postmenopausal. The results were unchanged (data not shown). Second, the analyses were 
repeated without the study results of Ford et al11 and Hughes et al13, since the median follow-
up of these studies was twice as long, as compared to 4.5-5.6 years in the other studies. Instead 
we included the prior publication by Hughes et al, comprising the 5-years results21. Again, 
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the results were unchanged (data not shown). The associated funnel plots did not suggest 
significant publication bias (Supplementary figure 1).
Table 2. Age and tumor characteristics of patients in the included randomized clinical trials.
Study Age Tumor characteristics
Hughes 
(2013)




All postmenopausal; range 50-75 years; 361/749 
(48%) ≥65 years




All postmenopausal; range 46-80 years; median 
age 66 years; 587/831 (71%) ≥60 years; 293/831 
(35%) >70 years




All postmenopausal; range 44-69 years; median 
age 59 years




734/769 (95%) postmenopausal; median age 68 
years; 586/769 (76%) ≥60 years; 325/769 (42%) ≥70 
years
639/769 (83%) T1, 639/639 (100% N0, 621/769 
(81%) HR+**
ER+: estrogen receptor positive; HR+: hormone receptor positive. * Calculated for the whole population of 
pre- and postmenopausal patients; ** 127/769 (17%)  unknown hormone receptor status, 46/769 (6%) negative 
hormone receptor status.
Absolute risk
Additionally, we calculated the pooled absolute risk of locoregional recurrence, distant 
recurrence and all cause death for patients in both study arms. Since absolute risks are 
dependent on the duration of follow-up, the study by Ford et al11 and Hughes et al13 were not 
included in the calculation; the median follow-up of these studies was more than twice as much 
as compared to the other studies. For the study by Hughes et al, we used the prior publication 
in which the 5 years results were presented21. After a median follow-up of approximately 5 
years, the absolute risk of a locoregional recurrence among those who received radiotherapy 
was 2.2% (33/1,490, 95% CI 1.6-3.1), versus 6.5% (97/1,495, 95% CI 5.3-7.9) among patients who 
did not receive radiotherapy. The absolute risk difference was 4.3% (95% CI 2.9-5.7), in favour of 
those who received radiotherapy in addition to breast conserving surgery, corresponding with 
a number needed to treat of 24 to prevent one locoregional recurrence in five years.
The 5-years absolute risk of a distant recurrence was 2.7% (40/1,490, 95% CI 1.9-3.5) in patients 
who received radiotherapy, versus 2.3% (35/1,495, 95% CI 1.6-3.1) in patients who did not 
receive radiotherapy. For all cause death, the 5-years absolute risks were 7.7% in both study 
arms (115/1,490, 95% CI 6.4-9.1; 115/1,495, 95% CI 6.3-9.0).
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Figure 2. Odds ratios for locoregional recurrence, distant recurrence and overall survival.
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Discussion
Summary of results
The current systematic review and meta-analysis clearly shows a decreased risk of locoregional 
recurrence for postmenopausal patients with early stage breast cancer who received 
radiotherapy after breast conserving surgery. The absolute risk difference for a locoregional 
recurrence was 4.3% after five years, corresponding with a number needed to treat of 24. No 
differences were observed with regards to the risks of a distant recurrence, or overall survival.
The effect of radiotherapy after breast conserving surgery has been evaluated by others1;24. 
However, few specifically studied older patients, or addressed age related considerations as 
competing mortality and remaining life expectancy. We decided not to include observational 
studies, as treatment outcomes in observational studies are confounded by indication18; frailty, 
age, tumour characteristics and presence of comorbidity all affect treatment decisions as 
well as outcome. As expected, most observational studies indeed observed a higher overall, 
disease specific or other cause mortality in patients who received breast conserving surgery as 
compared to patients receiving radiotherapy in addition to breast conserving surgery8;9;25;26, 
although one study did not observe differences in overall survival between both treatment 
modalities10. With respect to locoregional recurrence, most observational studies14;15;27;28, but 
not al10 observed a higher risk for patients who received breast conserving surgery without 
radiotherapy. Recently, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
performed an age specific subgroup analysis of 7,287 node negative patients who received 
either breast conserving surgery plus or minus radiotherapy1. The relative risk reduction in 
10-years locoregional recurrence by radiotherapy remained similar over age (overall relative 
risk 0.46 (95% CI 0.41-0.51)). The current study confirms a clear statistically significant benefit 
of radiotherapy in addition to breast conserving surgery in terms of prevention of a locoregional 
recurrence, even though the included patients were considered to have a low absolute risk of 
recurrence; the median age was over 65 years, and the majority of patients had T1 tumors 
without nodal involvement, with positive hormone receptor status. 
To enhance the number of eligible studies, inclusion in the current study was permitted 
for all trials including postmenopausal patients. We are well aware of the discongruency 
between ‘postmenopausal’ and ‘older’, and the wide variation in age and phenotype among 
postmenopausal women. However, the median age of all patients in this study was over 
65 years and 39% of the patients was 70 years or older. Moreover, sensitivity analyses were 
performed to exclude potential confounding of one study in which a minority of the patients 
may not have been postmenopausal. In addition, tumor and treatment characteristics were 
comparable among the included studies, and all patients received adjuvant systemic therapy. 
Nevertheless, the variation in phenotype of the included patients in the current study limits 
explicit recommendations for advocating omission or administration of radiotherapy. Rather 
than an attempt to indicate specific subgroups of patients, for clinical guidance we propose not 
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only to focus on relative risks but also on the absolute benefit of postoperative radiotherapy 
and the number needed to treat.
A low absolute risk results in a higher number needed to treat to prevent one recurrence. The 
number needed to treat in the current study was 24. This is expected to be higher in a non-trial 
population; Smith and colleagues evaluated the number of patients needed to be irradiated 
in order to prevent one local recurrence15. Patients of advanced age or those with moderate 
to severe comorbidity were less likely to benefit from radiotherapy, with an adjusted number 
needed to treat up to 125. In addition, the EBCTCG meta-analysis showed that the absolute 
risk reduction of radiotherapy decreased significantly with increasing age, from 24.6 (95% CI 
13.2-36.0) to 8.9 (95% CI 4.0-13.8) in the oldest patients, due to a lower absolute recurrence 
rate1. This age specific decrease was also observed in other studies12;22. The more recently 
conducted randomized trials which were included in the current study seemed to observe an 
even lower locoregional recurrence rate12;13;22;23. This may be explained by the fact that studies 
included in the EBCTCG meta-analysis were mostly conducted in the 1970s and 1980s. These 
days, selection of patients may have been less precise, and hormonal status was not included in 
the selection criteria. Improvements in surgical treatment and the increased use and efficacy 
of currently available systemic treatment may have further tempered recurrence rates29 and 
thereby limit the attributive effect of radiotherapy. As mentioned, all patients included in 
the current study received adjuvant systemic therapy. To summarize, the absolute risk of a 
locoregional recurrence decreases with increasing age and decreasing fitness. Moreover, the 
absolute risk has declined in more recent years. 
As mentioned, a low absolute risk results in a higher number needed to treat. To decrease the 
number needed to treat and to personalize treatment, others have tried to identify subgroups 
of patients in which radiotherapy could be safely omitted, based on the risk of a locoregional 
recurrence. The American College of Radiotherapy Appropriateness Criteria state that for 
women older than 70 years, with hormone receptor positive breast cancer less than two 
centimetre, who receive endocrine therapy, omission of radiotherapy may be reasonable30. 
A comparable statement was included in the most recent National Comprehensive Cancer 
Network treatment guidelines on senior adult oncology31. Although in the recently updated 
recommendations of the International Society of Geriatric Oncology (SIOG) it is stated that 
after breast conserving surgery, whole breast irradiation with a boost to the tumor bed should 
be considered in all older patients, room is left to balance pro and cons in individual cases32. 
In the debate whether or not to treat older breast cancer patients with radiotherapy in 
addition to breast conserving surgery, and in the identification of subgroups of patients in 
whom radiotherapy could be safely omitted, which outcome should be leading? The clinical 
significance of the observed relative risks should be considered critically: as mentioned, the 
absolute risk of a locoregional recurrence was low, and thereby the absolute risk reduction 
is rather small. Moreover, the risk of a distant recurrence and overall survival were not 
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affected by radiotherapy. On the other hand, it was previously shown that older patients were 
less willing to exchange a prolonged survival for current quality of life7. Administration of 
radiotherapy requires frequent hospital visits, which may be impeded by decreased mobility in 
old age. Moreover, inferior cosmetic results and adverse events21 may affect quality of life. Of 
note, development and treatment of a locoregional recurrence may also impact quality of life. 
We propose that the debate should not only focus on the relative risk of a locoregional 
recurrence and on the identification of subgroups based on the relative risk of a locoregional 
recurrence, but instead should also be focused on the absolute benefit of radiotherapy and 
the number needed to treat. Both treatment options may be reasonable in clinical practice. 
The absolute recurrence risk should be discussed with respect to tumor characteristics, other 
treatment and estimated remaining life expectancy. Recently, a nomogram was developed to 
predict the absolute risk of mastectomy for a locoregional recurrence in older breast cancer 
patients in case of omission of adjuvant radiotherapy. These kind of decision tools may further 
aid in shared decision making when evaluating adjuvant treatment options33. Moreover, 
treatment options and quality of life in case of locoregional recurrence should be considered. 
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Early discontinuation of adjuvant endocrine therapy may affect outcome of treatment in breast 
cancer patients. Aim of this study was to assess age specific nonpersistence and age specific 
survival based on persistence status.
Methods 
Patients enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial were 
included. Nonpersistence was defined as discontinuing assigned endocrine treatment within 
one year of follow-up because of adverse events, intercurrent illness, patient refusal, or other 
reasons. Endpoints were breast cancer specific and overall survival. Analyses were stratified by 
age at diagnosis (<65, 65-75, ≥75 years).
Results
Overall, 3,142 postmenopausal breast cancer patients were included;  1,682 were <65 years, 951 
were 65-75 years and 509 were ≥75 years. Increasing age was associated with a higher proportion 
of nonpersistence within one year of follow-up (7.0%; 7.5%; 13.5% respectively, p<0.001). In 
patients aged <65 years, nonpersistent patients had a decreased breast cancer specific survival 
(multivariable HR 2.76 (95% CI 1.55-4.90), p=0.001) and overall survival (multivariable HR 
2.83 (95% CI 1.65-4.85), p<0.001). In patients aged 65-75 years and in patients aged ≥75 years, 
survival of persistent and nonpersistent patients was similar.
Conclusion
Nonpersistence within one year of follow-up was associated with lower breast cancer specific 
and overall survival in patients aged <65 years, but was not associated with survival in patients 
aged 65-75 years and in patients aged ≥75 years. These results suggest that extrapolation of 
outcomes from a young to an elderly breast cancer population may be insufficient and urge age 
specific breast cancer studies. 
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Introduction
Breast cancer is the most frequently diagnosed malignancy in females1. The role of adjuvant 
endocrine therapy in middle aged hormone receptor positive breast cancer patients is well 
established; five years of endocrine treatment with tamoxifen results in an 11.8% absolute 
recurrence reduction and 9.2% reduction in breast cancer mortality after 15 years of follow-up2.
Observational and non-observational studies, however, show a substantial proportion of 
nonpersistence or discontinuation during five years of endocrine therapy. A recent meta-
analysis evaluated persistence with tamoxifen or an aromatase inhibitor in clinical trials and 
reported that overall, 23-28% of patients followed for at least 4 years, discontinued endocrine 
therapy earlier than recommended3. Observational studies show a comparable or even higher 
nonpersistence percentage4-7 up to 49% nonpersistence after five years of follow-up7.
In a recent review, Ruddy et al stated that nonpersistence has been associated with an increased 
consumption of health care resources, including more physician visits, higher hospitalization 
rates and longer stays8. Moreover, nonpersistence may impede efficacy of endocrine therapy. 
To date, however, little data are published on the effects of nonpersistence in oncology8.
Especially in the elderly breast cancer population, evidence is scarce. Despite comprising a large 
proportion of all breast cancer patients, elderly breast cancer patients remain underrepresented 
in clinical trials9; an estimated 1-2% of the elderly participates in clinical trials10. Unlike many 
breast cancer trials, the Tamoxifen, Exemestane, Adjuvant, Multinational (TEAM) trial11 had 
no upper age limitation, thereby providing a unique opportunity to focus on elderly breast 
cancer patients. The aim of this study was to assess age specific nonpersistence within one year 




The TEAM trial is a randomized, adjuvant, phase 3, multinational, open label study conducted 
in postmenopausal women with estrogen and/or progesterone receptor positive breast cancer. 
Patients were randomized to receive either exemestane 25 mg once-daily for five years or 
tamoxifen 20 mg once-daily for 2.5–3  years, followed by exemestane 25 mg once-daily for 
2–2.5 years, for a total of five years. Participants were enrolled in Belgium, The Netherlands, 
United Kingdom, Ireland, United States of America, Japan, Greece, Germany and France 
(N=9,766)11. Extensive eligibility criteria have been published in earlier reports11;12. In 
short, postmenopausal patients with histologically confirmed breast adenocarcinoma, who 
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completed local therapy with curative intent, i.e. without evidence of metastatic disease, were 
eligible.
Design current study  
Figure 1 shows the flow chart of the current study. Inclusion was restricted to patients from The 
Netherlands (n=2,753) and Belgium (n=414) because of available data on comorbidity. Patients 
who never started study medication and patients with missing data regarding duration of 
randomized therapy were excluded from analyses (n=25), which resulted in a study population 
of 3,142 subjects. 
TEAM trial n = 3,167
- e Netherlands n = 2,753
- Belgium n = 414
Study population n = 3,142
- <65  years n = 1,682 
- 65 -75  years n = 951
- ≥75  years n = 509
Survival analyses n = 3,049
- <65  years n = 1,635
- 65 -75 years n = 928 
- ≥75  years n = 486
Exclusion n = 25
- Never started 
- No date last dose
Exclusion n=93 
- Endpoint <1 year of follow-up   
- <1 year of follow-up    
Persistence
Patients were categorized as persistent or nonpersistent, depending on whether they continued 
allocated treatment for at least one year. Nonpersistence was defined as discontinuation of 
allocated endocrine therapy within one year of follow-up because of adverse events, intercurrent 
illness, patient refusal not otherwise specified, or other reasons. Persistent patients continued 
allocated endocrine therapy for at least one year. Patients who died or developed a relapse within 
one year of follow-up while on study medication were considered to be persistent. Persistence 
Figure 1. Flow chart.
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status was evaluated at each follow-up visit. Patients were assessed every three months during 
the first year of follow-up and at least once-yearly thereafter. At follow-up visits, patients were 
asked whether they (dis)continued randomized therapy. In case of nonpersistence, date and 
reason of nonpersistence were recorded by the treating physician. By calculating persistence 
in the first year, persistence could be used as a fixed covariate in survival analysis following 
the first year of follow-up (landmark method)13. Alternative endocrine therapy in case of 
nonpersistence was defined as none, cross-over, or other therapy. 
Patients were categorized in three age groups (<65 years, 65-75 years, ≥75 years) according to 
recommendations at the Annual Meeting of the International Society of Geriatric Oncology 
(SIOG) in 200914. Endpoints were breast cancer specific survival and overall survival. Breast 
cancer specific survival was defined as time from randomization to death due to breast cancer, 
whereas overall survival was defined as time from randomization to death from any cause. 
Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL) and R statistical 
package (R Development Core Team, 2008). To compare proportional differences among age 
categories, the Pearson chi-square test was used. Binary logistic regression analysis was used to 
assess predictive factors for nonpersistence within one year. Kaplan-Meier curves were plotted 
and a Cox proportional hazard model was used to assess survival differences with respect to 
persistence status at one year of follow-up. Persistence was treated according to the landmark 
method, using one year of follow-up as a landmark13. Subjects who reached an endpoint within 
the first year of follow-up and subjects on study medication who had less than one year of 
follow-up could not be taken into account and were excluded from survival analyses (n=93)
(Figure 1). In line with others who investigated breast cancer outcome by adherence by means 
of a landmark analysis15, a cutoff of one year was chosen because of a considerable proportion 
of nonpersistence but occurrence of few events within one year of follow-up. Moreover, we 
aimed to exclude bias due to nonpersistence because of switch issues in the sequential arm. 
Covariates were included in the multivariable model if they were of clinical significance; 
multivariable analyses included histological grade according to Bloom Richardson (G1; G2; 
G3,4), estrogen receptor status (positive; negative), progesterone receptor status (positive; 
negative), T stage (T1; T2; T3,4), N status (negative; positive), presence of cardiac, central 
nervous system, endocrine, gastro-intestinal, genitourinary and musculoskeletal comorbidity 
(no; yes), most extensive surgery (wide local excision; mastectomy), axillary surgery (yes; no), 
radiotherapy (yes; no), adjuvant chemotherapy (yes; no) and endocrine therapy (tamoxifen 
followed by exemestane; exemestane). Because of colinearity, influence of alternative treatment 
could be assessed in nonpersistent patients only. To assess whether the association between 
nonpersistence within one year of follow-up and survival was different among age categories, 
we tested for interaction between age and persistence status at one year of follow-up. To 
assess sensitivity of the landmark, alternative cutoff points were analyzed (0.5 and 1.5 years 
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respectively). All statistical tests were two-sided. A p value less than 0.05 was considered to be 
statistically significant.
Results
Overall, 3,142 patients were included, of which 1,682 were <65 years (54%, median age 58.4 
years), 951 were 65-75 years (30%, median age 69.7 years) and 509 were ≥75 years (16%, median 
age 79.3 years). Median follow-up from randomization was 5.0, 5.0 and 4.8 years respectively. 
Baseline characteristics by age at diagnosis are shown in Table 1. Increasing age was associated 
with a different histological grade (p=0.004) and larger tumors (p<0.001), nodal status however 
was similar among age categories. The presence of one or more cardiac, central nervous system, 
endocrine, gastro-intestinal, genitourinary and musculoskeletal comorbidity increased with 
age (all p values <0.001). In addition, the proportion of mastectomy increased significantly with 
age, whereas administration of radiotherapy and chemotherapy significantly decreased (all p 
values <0.001). 
Overall, 256 subjects (8.1%) discontinued allocated endocrine therapy within one year of 
follow-up; 116 (7.4%) in the exemestane arm and 140 (8.9%) in the sequential arm (p=0.118). 
Nonpersistence within one year of follow-up increased with age (<65 years 7.0%, 65-75 years 
7.5%, ≥75 years 13.2%; p<0.001). As shown in Table 2, reasons for nonpersistence within one 
year of follow-up did not differ among age categories (p=0.561). In all age categories, presence 
of adverse events was the most frequently reported reason for nonpersistence (85%; 83%; 89% 
respectively). 
To gain insight in underlying mechanisms, we assessed predictive factors for nonpersistence 
within one year of follow-up in all age categories (Supplementary table 1a, 1b, 1c). In patients 
aged <65 years, presence of central nervous system, gastro-intestinal and genitourinary 
comorbidity, a mastectomy as most extensive surgery, and omission of radiotherapy were 
associated with nonpersistence within one year of follow-up. Multivariable analysis showed 
that gastro-intestinal comorbidity and omission of radiotherapy were independent predictive 
factors for nonpersistence within one year of follow-up. In patients aged 65-75 years, no 
predictive factors for nonpersistence could be identified. In patients aged ≥75 years, larger 
tumor size, a wide local excision as most extensive surgical treatment, and omission of 
radiotherapy were independent predictive factors for nonpersistence within one year of follow-
up. In case of nonpersistence within one year of follow-up, increasing age was associated 
with less frequent administration of alternative endocrine treatment (78.8%, 80.3% and 61.2% 
respectively; p=0.013)(data not shown). 
At database lock, the number of deaths was 173 (10.3%) in patients aged <65 years, 133 (14.0%) 
in patients aged 65-75 years, and 154 (30.3%) in patients aged ≥75 years. The number of deaths 
due to breast cancer was 146 (8.7%), 88 (9.3%) and 60 (11.8%) respectively. Figure 2 depicts 
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n % n % n %
Histological grade (BR) 0.004
Well 240 14.3 142 14.9 70 13.8
Intermediate 707 42.0 415 43.6 235 46.2
Poor 647 38.5 339 35.6 157 30.8
Unknown 88 5.2 55 5.8 47 9.2
Estrogen receptor 0.002
Positive 1,629 96.8 942 99.1 503 98.8
Negative 52 3.1 9 0.9 6 1.2
Not performed 1 0.1 0 0.0 0 0.0
Progesterone receptor 0.416
Positive 1,244 74.0 698 73.4 387 76.0
Negative 347 20.6 209 22.0 104 20.4
Not performed 91 5.4 44 4.6 18 3.5
T stage <0.001
0, is 2 0.1 0 0.0 0 0.0
1 802 47.7 443 46.2 128 25.1
2 762 45.3 442 46.5 332 65.2
3, 4 111 6.6 66 6.9 49 9.6
Unknown 5 0.3 0 0.0 0 0.0
Nodal status 0.090
Negative 486 28.9 299 31.4 168 33.0
Positive 1,194 71.0 652 68.6 339 66.6
Unknown 2 0.1 0 0.0 4 0.1
Presence of comorbidity
Cardiac 514 30.6 442 46.5 280 55.0 <0.001
CNS 151 9.0 104 10.9 79 15.5 <0.001
Endocrine 249 14.8 195 20.5 117 23.0 <0.001
Gastro-intestinal 356 21.2 272 28.6 151 29.7 <0.001
Genitourinary 466 27.7 220 23.1 145 28.5 0.020
Musculoskeletal 382 22.7 276 29.0 193 37.9 <0.001
Most extensive surgery <0.001
WLE 863 51.3 424 44.6 129 25.3
Mastectomy 818 48.7 527 55.4 380 74.7
Axillary surgery 0.285
Yes 1,341 79.7 740 77.8 413 81.1
No 341 20.3 211 22.2 96 18.9
Radiotherapy <0.001
Yes 1,201 71.4 597 62.8 243 47.7
No 478 28.4 353 37.1 266 52.3
Unknown 3 0.2 1 0.1 0 0.0
Chemotherapy <0.001
Yes 936 55.6 103 10.8 1 0.2
No 746 44.4 847 89.1 508 99.8
Unknown 0 0.0 1 0.1 0 0.0
Randomization 0.880
Tam Ý Exe 837 49.8 483 50.8 255 50.1
Exemestane 845 51.2 468 49.2 254 49.9
BR: Bloom Richardson; CNS: central nervous system; WLE: wide local excision; Tam Ý Exe: tamoxifen followed 
by exemestane.
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cumulative incidence of death due to breast cancer and death from other causes from landmark 
by persistence status at one year of follow-up, stratified by age at diagnosis. As shown in Table 
3, patients aged <65 years who were nonpersistent within one year of follow-up, had a lower 
breast cancer specific survival (multivariable hazard ratio 2.76 (95% CI 1.55-4.90); p=0.001). 
For overall survival, comparable results were observed (multivariable hazard ratio 2.83 (95% 
CI 1.65-4.85); p<0.001). On the contrary, nonpersistence within one year of follow-up was not 







n % n % n %
Reasons nonpersistence 0.561
   Adverse events 100 84.7 59 83.1 60 89.6
   Intercurrent illness 4 3.4 4 5.6 2 3.0
   Patient refusal n.o.s. 10 8.5 3 4.2 2 3.0
   Other reason 4 3.4 5 7.0 3 4.5
n.o.s.: not otherwise specified.




HR (95% CI) p
Multivariable*
HR (95% CI) p 
Breast cancer survival 0.001 0.001
<65 years
Persistent ≥1 year 94% 1 (reference) 1 (reference)
Persistent <1 year 82% 2.55 (1.51-4.33) 0.356 2.76 (1.55-4.90) 0.387
65-75 years
Persistent ≥1 year 92% 1 (reference) 1 (reference)
Persistent <1 year 94% 0.58 (0.18-1.84) 0.731 0.59 (0.18-1.94) 0.982
≥75 years
Persistent ≥1 year 90% 1 (reference) 1 (reference)
Persistent <1 year 90% 1.15 (0.52-2.56) 0.99 (0.37-2.62)
Overall survival <0.001 <0.001
<65 years
Persistent ≥1 year 93% 1 (reference) 1 (reference)
Persistent <1 year 80% 2.49 (1.51-4.09) 0.930 2.83 (1.65-4.85) 0.659
65-75 years
Persistent ≥1 year 9% 1 (reference) 1 (reference)
Persistent <1 year 66% 1.03 (0.50-2.12) 0.524 1.18 (0.57-2.47) 0.942
≥75 years
Persistent ≥1 year 76% 1 (reference) 1 (reference)
Persistent <1 year 76% 1.17 (0.72-1.90) 0.98 (0.54-1.76)
HR: Hazard ratio; CI: confidence interval. # 4-years survival from landmark onwards; *Multivariable analyses 
were adjusted for histological grade, estrogen status, progesterone status, T stage, N status, cardiac / central 
nervous system / endocrine / gastro-intestinal / genitourinary and musculoskeletal comorbidity, most extensive 
surgery, axillary surgery, radiotherapy, adjuvant chemotherapy and endocrine therapy.
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associated with breast cancer specific survival nor overall survival in patients aged 65-75 years 
(multivariable p=0.387; p=0.659 respectively) and in patients aged ≥75 years (multivariable 
p=0.982; p=0.942 respectively). 
Figure 2. Cumulative incidence of death due to breast cancer and death from other causes by persistence status at 
one year of follow-up, by age at diagnosis. A) <65 years, B) 65-75 years, C) ≥75 years.
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Additional survival analyses including an interaction term between persistence status at one 
year of follow-up and age confirmed significant interaction for breast cancer specific survival 
(p=0.031) but not for overall survival (p=0.140). To assess sensitivity of the landmark, we 
performed additional survival analyses comprising alternative landmark cutoffs (0.5 and 1.5 
years respectively), which did not alter the results (data not shown). To account for a potential 
lack of power in patients aged ≥75 years, we performed additonal survival analyses in which 
patients aged 65-75 years and patients aged ≥75 years were combined. Again, nonpersistence 
within one year of follow-up was not associated with breast cancer specific survival (univariate 
hazard ratio 0.93 (95% CI 0.49-1.77), p=0.819; multivariable hazard ratio 0.81 (95% CI 0.39-
1.69), p=0.675)). For overall survival, we observed comparable results (univariate hazard ratio 
1.29 (95% CI 0.87-1.93), p=0.206; multivariable hazard ratio 1.19 (95% CI 0.76-1.87), p=0.440)). 
Additional analyses were performed to evaluate the influence of alternative treatment in 
case of nonpersistence (data not shown). In patients who were nonpersistent, alternative 
treatment was not associated with breast cancer specific or overall survival in all age categories 
(multivariable analyses breast cancer specific survival p=0.401; p=0.576; p=0.426 respectively; 
multivariable analyses overall survival p=0.314; p=0.325; p=0.328 respectively). 
Discussion
Summary 
In this study, increasing age was associated with a higher proportion of nonpersistence within 
one year of follow-up. Patients aged <65 years who were nonpersistent within one year of 
follow-up, had a marked decreased breast cancer specific and overall survival. However, no 
differences were observed for patients aged 65-75 years as well as for patients aged ≥75 years. 
Imbedding in literature
Nonpersistence has been evaluated in other endocrine therapy trials. The Intergroup Exemestane 
Trial randomized patients to receive 2-3 years tamoxifen or 2-3 years exemestane after 3-2 years 
of tamoxifen. Treatment was stopped early in 14% of the study population. As randomization took 
place after 2-3 years of tamoxifen, early nonpersistence has not been taken into account16. Of all 
patients included in the Arimidex and Tamoxifen Alone or in Combination trial, 76% of patients 
on anastrozole and 72% of tamoxifen-treated patients were persistent nearly 47 months after 
diagnosis17. Fisher et al evaluated efficacy of five years versus more than five years of tamoxifen 
in node negative breast cancer patients. During the first five years after randomization, 23% of 
patients discontinued assigned therapy18. Five years of tamoxifen in a preventive setting showed 
a nonpersistence proportion between 24% and 36%19;20. 
Several observational studies have reported on age specific persistence. Fink et al did not 
observe a relation between age and discontinuation within two years of follow-up in a cohort 
of 516 breast cancer patients on tamoxifen4. Similar results were found in a cohort study by 
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Demissie et al6. Hershman et al studied persistence and adherence in a historical cohort of 8,769 
patients who received either tamoxifen or an aromatase inhibitor21. Persistence and adherence 
were evaluated by automated pharmacy records. Patients aged <40 years and patients aged 
≥75 years were most likely to discontinue endocrine therapy within 4.5 years of follow-up. 
Partridge studied tamoxifen adherence in a cohort of 2,378 breast cancer patients22. Adherence 
was defined as the number of days covered by filled prescription in the first year of therapy. 
Both in women both aged <45 years as well as in patients aged ≥85 years a lower adherence was 
observed. These results are consistent with a cohort study by Barron among 2,816 breast cancer 
patients aged ≥35 years on tamoxifen5. Patients aged 35-44 years and patients aged ≥75 years 
were most likely to discontinue tamoxifen within one year of follow-up. In addition, a recent 
study among 961 breast cancer patients by Owusu showed that an age of ≥75 years was an 
independent predictor of tamoxifen discontinuation before completion of five years of therapy7. 
In most observational studies, high age is associated with lower persistence5;7;21;22. Differences 
in proportions may have been affected by the use of either adherence or persistence as primary 
endpoint. Persistence is defined as the duration of time over which a patient continues to fill 
prescriptions23. A related endpoint is adherence, which is defined as whether medication is 
taken as consistently as prescribed. This can be calculated by dividing the quantity of pills 
dispensed by the total days covered by prescription22;24. Contrary to other studies, we assessed 
persistence in the first year of follow-up in order to study survival by persistence status. In 
addition, inclusion in the current study was restricted to postmenopausal patients. Moreover, 
one has to take into account that the setting of a clinical trial generally results in higher 
persistence rates23, possibly due to patient selection and attention24-26.
Exclusion of survival bias 
Since patients were not randomized to persistence status, we acknowledge the limitations 
of discussing survival by persistence status at one year of follow-up. Patients with a worse 
prognosis or higher intrinsic mortality may have had a higher tendency to become nonpersistent 
and thereby bias survival analyses. In patients aged <65 years, nonpersistent patients more 
often had central nervous system, gastro-intestinal, and genitourinary comorbidity. However, 
in patients aged ≥75 years, who had more comorbid diseases, no differences between persistent 
and nonpersistent patients were observed. Moreover, no association between persistence 
status and overall survival was demonstrated. Therefore, it is unlikely that presence of 
comorbid disease has had a major impact on the association between persistence and survival 
in the eldest patients. In addition, administration of alternative endocrine therapy in case 
of nonpersistence may have biased survival analyses. However, additional analyses did not 
indicate survival benefit for nonpersistent patients who received alternative therapy. A lack of 
power was not likely to have had a major influence on our findings; analyses in which patients 
aged 65-75 years and patients aged ≥75 years were combined, showed similar results.
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Explanation of results
It is tempting to speculate on the underlying mechanisms which could explain the results 
presented in this study. Both patients and physicians might be more likely to discontinue 
treatment with increasing patients’ age. It has been suggested that persistence in the elderly 
may be impaired by psychosocial issues such as decreased social supports and an increasing 
incidence of cognitive and functional impairment27. Sharkness et al showed that elderly 
patients with more than one chronic illness requiring the use of multiple drugs were more 
likely to be adherent28. Comparable associations have been observed for different numbers 
of prescriptions4;29. On the other hand, others observed lower adherence in patients using 
multiple drugs30-32.
Although little is known about the implications of nonpersistence, it is well known that duration 
of adjuvant endocrine therapy is strongly associated with survival of young and middle aged 
breast cancer patients2. However, evidence in elderly is lacking. Elderly might respond different 
to a certain therapy; presence of comorbidity may affect anticancer therapy33. Polypharmacy 
may cause drug interactions34 and may alter pharmacokinetics of anticancer therapy33. These 
findings hint at potential age specific therapy dynamics, but this should be investigated in 
further studies. Moreover, a higher competing risk of death with increasing age may play a role 
in assessing survival differences in elderly breast cancer patients. 
Strengths and limitations
The major strength of this study is the possibility to study a large group of incident breast 
cancer patients. Trial data comprise highly standardized treatment algorithms and virtually 
complete follow-up. The TEAM trial had very few exclusion criteria, among which there was 
no upper age limitation. This enabled us to study age specific persistence. 
As enrollment in the TEAM trial was restricted to patients with postmenopausal hormone 
receptor positive disease, these results may not be extrapolated to all breast cancer patients. 
In addition, Ziller et al reported on the inconsistency between self-reported adherence and 
true adherence based on retrospective prescription check35. A recent study by Hershman et 
al showed that 28% of patients on endocrine treatment, who were persistent at 4.5 years of 
follow-up, were nonadherent21. These results indicate that persistence may not be as sensitive 
as adherence, especially when adherence is calculated by pharmacy data or prescriptions. In 
this report, we investigated nonpersistence. However, we were unable to assess adherence in 
patients who were persistent; therefore we cannot exclude that persistence may have been 
influenced by adherence. 
Conclusion 
This study shows a higher proportion of adjuvant endocrine therapy nonpersistence within 
one year of follow-up with increasing age. Based on these data and study design we are unable 
to report on the efficacy of adjuvant endocrine therapy in elderly breast cancer patients. 
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However, we have shown that nonpersistence of adjuvant endocrine therapy within one 
year of follow-up was associated with breast cancer specific survival and overall survival in 
postmenopausal patients aged <65 years, but not in patients aged 65-75 years or in patients 
aged ≥75 years. The results presented in this study suggest that extrapolation of outcomes from 
a young, homogeneous population to a heterogeneous elderly population may be insufficient. 
Age specific breast cancer studies are needed to establish differential outcomes in young and 
elderly breast cancer patients





OR (95% CI) p
Histological grade (BR) 0.748 0.923
I 1 (reference) 1 (reference)
II 1.24 (0.69-2.24) 1.05 (0.56-1.97)
III, IV 1.12 (0.61-2.05) 0.96 (0.49-1.86)
Estrogen receptor 0.847 0.953
Positive 1 (reference) 1 (reference)
Negative 0.90 (0.32-2.55) 0.97 (0.33-2.83)
Progesterone receptor 0.813 0.585
Positive 1 (reference) 1 (reference)
Negative 1.06 (0.66-1.71) 1.15 (0.69-1.90)
T stage 0.095 0.089
1 1 (reference) 1 (reference)
2 1.53 (1.04-2.27) 1.58 (1.03-2.45)
3, 4 1.11 (0.49-2.52) 0.97 (0.37-2.57)
Nodal stage 0.856 0.384
Negative 1 (reference) 1 (reference)
Positive 0.96 (0.64-1.45) 1.34 (0.69-2.58)
Cardiac* 0.219 0.292
No 1 (reference) 1 (reference)
Yes 1.28 (0.86-1.89) 1.27 (0.81-1.99)
CNS* 0.035 0.225
No 1 (reference) 1 (reference)
Yes 1.80 (1.04-3.09) 1.46 (0.79-2.68)
Endocrine* 0.886 0.757
No 1 (reference) 1 (reference)
Yes 1.04 (0.62-1.75) 0.91 (0.51-1.63)
Gastro-intestinal* 0.011 0.030
No 1 (reference) 1 (reference)
Yes 1.71 (1.13-2.57) 1.68 (1.05-2.69)
Gentiourinary* 0.017 0.065
No 1 (reference) 1 (reference)
Yes 1.61 (1.09-2.38) 1.50 (0.98-2.32)
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OR (95% CI) p
Musculoskeletal* 0.237 0.732
No 1 (reference) 1 (reference)
Yes 1.29 (0.85-1.97) 1.09 (0.67-1.77)
Other* 0.537 0.525
No 1 (reference) 1 (reference)
Yes 1.12 (0.76-1.65) 0.86 (0.55-1.36)
Most extensive surgery 0.010 0.915
WLE 1 (reference) 1 (reference)
Mastectomy 1.65 (1.13-2.42) 1.03 (0.56-1.91)
Axillary surgery 0.465 0.341
Yes 1 (reference) 1 (reference)
No 1.18 (0.76-1.85) 1.41 (0.70-2.84)
Radiotherapy 0.001 0.040
Yes 1 (reference) 1 (reference)
No 1.87 (1.28-2.75) 1.89 (1.03-3.45)
Chemotherapy 0.898 0.839
Yes 1 (reference) 1 (reference)
No 1.03 (0.70-1.49) 1.05 (0.68-1.60)
Endocrine therapy 0.026 0.055
Tam Ý Exe 1 (reference) 1 (reference)
Exemestane 0.65 (0.44-0.95) 0.67 (0.44-1.01)
OR: odds ratio; CI: confidence interval; BR: Bloom Richardson: ER: estrogen receptor; PR: progesterone recep-
tor; CNS: central nervous system; WLE: wide local excision; Tam Ý Exe: tamoxifen followed by exemestane. * 
Presence of comorbidity. ** All covariates were included in multivariable analysis.
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OR (95% CI) p
Histological grade (BR) 0.262 0.227
I 1 (reference) 1 (reference)
II 1.49 (0.70-3.16) 1.24 (0.57-2.70)
III, IV 0.98 (0.44-2.19) 0.74 (0.31-1.77)
Estrogen receptor # #
Positive # #
Negative # #
Progesterone receptor 0.744 0.887
Positive 1 (reference) 1 (reference)
Negative 0.91 (0.51-1.61) 0.96 (0.52-1.75)
T stage 0.586 0.224
1 1 (reference) 1 (reference)
2 1.07 (0.65-1.78) 1.15 (0.65-2.01)
3, 4 1.58 (0.66-3.74) 2.35 (0.89-6.22)
Nodal stage 0.215 0.263
Negative 1 (reference) 1 (reference)
Positive 0.73 (0.44-1.20) 0.65 (0.30-1.39)
Cardiac* 0.140 0.310
No 1 (reference) 1 (reference)
Yes 0.69 (0.42-1.13) 0.75 (0.44-1.30)
CNS* 0.763 0.743
No 1 (reference) 1 (reference)
Yes 0.88 (0.39-1.98) 1.16 (0.49-2.76)
Endocrine* 0.634 0.978
No 1 (reference) 1 (reference)
Yes 0.86 (0.46-1.60) (0.52-1.97)
Gastro-intestinal* 0.721 0.870
No 1 (reference) 1 (reference)
Yes 0.91 (0.53-1.56) 0.95 (0.51-1.78)
Gentiourinary* 0.479 0.454
No 1 (reference) 1 (reference)
Yes 0.80 (0.44-1.47) 0.77 (0.40-1.52)
Musculoskeletal* 0.479 0.764
No 1 (reference) 1 (reference)
Yes 0.82 (0.47-1.43) 0.91 (0.49-1.69)
Other* 0.338 0.854
No 1 (reference) 1 (reference)
Yes 0.78 (0.47-1.30) 0.95 (0.52-1.71)
Most extensive surgery 0.168 0.356
WLE 1 (reference) 1 (reference)
Mastectomy 0.72 (0.44-1.17) 0.68 (0.31-1.53)
Axillary surgery 0.066 0.681
Yes 1 (reference) 1 (reference)
No 1.64 (0.97-2.78) 1.19 (0.53-2.66)
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OR (95% CI) p
Radiotherapy 0.543 0.581
Yes 1 (reference) 1 (reference)
No 0.85 (0.51-1.42) 1.25 (0.56-2.79)
Chemotherapy 0.606 0.173
Yes 1 (reference) 1 (reference)
No 0.83 (0.40-1.71) 0.57 (0.25-1.28)
Endocrine therapy 0.988 0.887
Tam Ý Exe 1 (reference) 1 (reference)
Exe 1.00 (0.61-1.61) 0.96 (0.58-1.61)
OR: odds ratio; CI: confidence interval; BR: Bloom Richardson: ER: estrogen receptor; PR: progesterone recep-
tor; CNS: central nervous system; WLE: wide local excision; Tam Ý Exe: tamoxifen followed by exemestane. 
* Presence of comorbidity; ** All covariates were included in multivariable analysis. # Number too low to 
estimate.
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Supplementary table 1c. Predictive factors for nonpersistence within one year of follow-up for patients aged 
≥75 years.
Univariate
OR (95% CI) p
Multivariable**
OR (95% CI) p
Histological grade (BR) 0.738 0.346
I 1 (reference) 1 (reference)
II 0.75 (0.34-1.63) 0.61 (0.27-1.41)
III, IV 0.88 (0.39-1.98) 0.95 (0.40-2.28)
Estrogen receptor 0.166 0.451
Positive 1 (reference) 1 (reference)
Negative 0.28 (0.05-1.65) 0.40 (0.04-4.37)
Progesterone receptor 0.940 0.783
Positive 1 (reference) 1 (reference)
Negative 0.98 (0.52-1.84) 0.90 (0.44-1.86)
T stage 0.513 0.021
1 1 (reference) 1 (reference)
2 0.92 (0.50-1.69) 0.82 (0.40-1.69)
3, 4 1.47 (0.61-3.56) 3.42 (1.10-10.61)
Nodal stage 0.488 0.850
Negative 1 (reference) 1 (reference)
Positive 0.83 (0.48-1.42) 1.08 (0.51-2.28)
Cardiac* 0.572 0.918
No 1 (reference) 1 (reference)
Yes 1.16 (0.69-1.96) 1.04 (0.53-2.01)
CNS* 0.828 0.744
No 1 (reference) 1 (reference)
Yes 1.08 (0.54-2.17) 1.15 (0.50-2.64)
Endocrine* 0.852 0.792
No 1 (reference) 1 (reference)
Yes 1.06 (0.58-1.94) 1.10 (0.54-2.26)
Gastro-intestinal* 0.543 0.537
No 1 (reference) 1 (reference)
Yes 1.19 (0.69-2.06) 1.24 (0.63-2.42)
Gentiourinary* 0.398 0.510
No 1 (reference) 1 (reference)
Yes 1.27 (0.73-2.20) 1.26 (0.64-2.47)
Musculoskeletal* 0.872 0.962
No 1 (reference) 1 (reference)
Yes 1.04 (0.62-1.77) 1.02 (0.52-1.98)
Other* 0.997 0.733
No 1 (reference) 1 (reference)
Yes 1.00 (0.60-1.67) 0.89 (0.46-1.73)
proefshrift.indb   143 2-5-2014   08:14:06
144 Chapter 9




OR (95% CI) p
Most extensive surgery 0.995 0.016
WLE 1 (reference) 1 (reference)
Mastectomy 1.00 (0.55-1.80) 0.24 (0.07-0.76)
Axillary surgery 0.261 0.449
Yes 1 (reference) 1 (reference)
No 1.42 (0.77-2.62) 1.40 (0.59-3.35)
Radiotherapy 0.038 0.002
Yes 1 (reference) 1 (reference)




Endocrine therapy 0.882 0.947
Tam  Ý Exe 1 (reference)
Exe 1.02 (0.56-1.85)
OR: odds ratio; CI: confidence interval; BR: Bloom Richardson: ER: estrogen receptor; PR: progesterone recep-
tor; CNS: central nervous system; WLE: wide local excision; Tam  Ý  Exe: tamoxifen followed by exemestane. * 
Presence of comorbidity; ** All covariates were included in multivariable analysis; # Number too low to estimate.
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An oncogeriatric approach may affect management of elderly breast cancer patients. However, 
little is known about oncogeriatric care in the metastatic setting. Therefore, we performed an 
international comparison of management of elderly patients with primary metastatic disease 
who were treated in two different care settings.
Methods
Patients who were ≥70 years at diagnosis of primary metastatic disease were eligible. The first 
cohort comprised a population-based cohort of 104 patients (Comprehensive Cancer Center 
West, The Netherlands), who all received standard care. The second cohort comprised a 
hospital-based cohort of 42 patients (H. Lee Moffitt Cancer Center, Florida, United States), 
who all received oncogeriatric care. 
Results
No large differences in patient and tumor characteristics were observed between both cohorts. 
Most patients in the standard care cohort received systemic therapy as primary therapy, 
whereas most patients in the oncogeriatric cohort received a combination of systemic and 
local therapy. Patients in the standard care cohort received fewer lines of treatment (mean 
number of treatments 2.1; 3.6, p<0.001), and particularly less breast surgery, chemotherapy 
and trastuzumab. Three-years overall mortality was 71% (95% CI 61-83) as compared to 58% 
(95% CI 42-75) among patients in the oncogeriatric care cohort (multivariable HR 0.63 (95% CI 
0.35-1.15), p=0.125). 
Conclusions
In primary metastatic breast cancer, oncogeriatric care intensifies treatment and might 
improve survival in elderly patients. Future studies on a larger scale should investigate the 
potential for improved survival, and whether this is accompanied by a better (preservation of) 
quality of life and functional status.
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Introduction
Over 40% of all breast cancer patients is 65 years or older at diagnosis1, and this proportion 
is expected to further increase due to increasing life expectancy2. Despite representing a 
large proportion of breast cancer patients, the elderly are frequently under accrued in clinical 
trials3, and therefore breast cancer management in older women is limited by a lack of level 1 
evidence4. Consequently, elderly are at risk for both under- and overtreatment. 
A collaborative geriatric and oncology management can optimize care in elderly patients4;5. An 
oncogeriatric approach leads to greater attention being paid to comorbidity and geriatric issues, 
which may result in a better selection of adequate treatment on an individual basis, prevention 
of complications, and a lower risk of patient deconditioning. Previously it has been shown that 
use of a comprehensive geriatric assessment may result in changes in treatment strategy6. 
Through these mechanisms, an oncogeriatric approach may improve patient outcomes. 
However, little is known about such an oncogeriatric approach in elderly with metastatic breast 
cancer7. Older women are more likely to present with more advanced disease as compared to 
younger patients4; 16.3% of patients aged 65 years and older present with distant metastases, 
versus 10.5% of patients younger than 65 years2. Therefore, we performed an international 
comparison of treatment and outcome of elderly patients with primary metastatic breast 
cancer who were treated in a standard care setting as compared to those who were treated in 
an oncogeriatric care setting. 
Methods
Cohorts
The study flowchart is shown in Figure 1. Two patient cohorts were constructed. Cohort 
1 comprised a population-based cohort of elderly breast cancer patients treated in the 
Comprehensive Cancer Center West in The Netherlands, who all received standard care 
(standard care cohort). Patients were identified from the Dutch Cancer Registry. Cohort 2 
comprised a hospital-based cohort of elderly patients treated at the H. Lee Moffitt Cancer 
Center and Research Institute in Tampa, Florida, United States. All patients received 
oncogeriatric care (oncogeriatric care cohort). Patients were identified from the Moffitt Cancer 
Registry and the Total Cancer Care program. 
All women with primary metastatic breast cancer, who were 70 years or older at diagnosis, 
and diagnosed between January 1st 2008 and December 31th 2011 were eligible. To increase 
the power of the analysis, inclusion in the oncogeriatric care cohort was extended to January 
1st 2003. Patients with a history of breast cancer less than five years prior to diagnosis of 
metastatic breast cancer were excluded, as these were considered to have recurrent disease. By 
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means of chart review, data were collected on tumor, patient and treatment characteristics. For 
the oncogeriatric care cohort, vital status and date of last follow-up were established directly 
from the patient’s medical record or through linkage of the Moffitt Cancer Registry data with 
the National Death Index. Patients who moved out of the region were censored at time of 
last follow-up visit. For the standard care cohort, vital status and date of last follow-up were 
established either directly from the patient’s medical record or through linkage of cancer 
registry data with municipal population registries, which record information on vital status. 
Follow-up was recorded until July 1st 2012.
Description of care
In the standard care cohort, no structured oncogeriatric approach was present. Irrespective 
of age at diagnosis, patients were discussed in multidisciplinary meetings, and treatment 
was based on national guidelines. Contrary, in the oncogeriatric care cohort a structured 
oncogeriatric approach was provided for all patients. Patients were seen in the Senior Adult 
Oncology Program and underwent a geriatric screening at first visit to evaluate functional 
status, mood and cognition, nutritional status and quality of life6;8. Any adverse finding 
prompted further evaluation and possible interventions6. All patients were discussed in a 
multidisciplinary meeting with a focus on geriatric parameters. Moreover, risk scores were 
used to predict benefit and toxicity from systemic therapy in order to personalize treatment9. 
Statistical analysis
SPSS version 20.0 (SPSS, Chicago, Illinois, USA) was used for statistical analyses. Continuous 
data were presented as mean (standard deviation, SD). Differences in patient and tumor 
characteristics between the cohorts were analyzed by means of Pearson’s χ2 test or the Fisher 
Exact test in the event of low numbers in any cell. 
As the majority of patients with metastatic breast cancer die from breast cancer, the primary 
outcome of interest was overall mortality. A Cox proportional hazards model was used to assess 
Female patients aged ≥70 years with primary metastatic breast cancer
Patients treated at the H. Lee Moffitt Cancer Center, 
Tampa, Florida, US
Oncogeriatric Care Cohort (n=42)
Senior Adult Oncology Program; geriatric screening 
(functional status, mood and cognition, nutritional status 
and quality of life) with interventions in case of 
abnormalities; multidisciplinary meetings with focus 
on geriatric parameters; risk scores to predict treatment 
toxicity and benefit.
Patients treated in the Comprehensive Cancer Center 
Region West, e Netherlands
Standard Care Cohort (n=104)
Standard care according to national guidelines. 
Figure 1. Flow chart.
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the association between care setting and overall mortality, with results reported as hazard ratio 
(HR) with 95% confidence interval (CI). Covariates were included in the multivariable model 
if they were judged to be clinically relevant, and comprised age (continuous) and the year of 
diagnosis (continuous). All statistical tests were two-sided. A p value of <0.05 was considered 
statistically significant.
Instrumental variable
Differences in overall mortality were evaluated by means of cohort as an instrumental 
variable. An instrumental variable can be used as a substitute for randomization in non-
randomized studies, and may reduce confounding by indication under the assumptions that 
the instrumental variable is associated with the exposure, unrelated to the confounders and 
has no direct association with the outcome other than through the exposure10;11. Thus, cohort 
membership was used as an instrumental variable, as a surrogate for type of care. The two 
geographically distinct cohorts represent different settings of care. The place of residence 
determines a patient’s allocation to the cohort and thereby determines the probability of 
being treated in a standard or in an oncogeriatric care setting. The interpretation of the results 
strongly depends on the valid use of the instrumental variable. Therefore, sensitivity analyses 
and investigations were performed to assess whether the assumptions of the instrumental 
variable were met. 
The standard care cohort is a population-based cohort in which all patients in a certain 
geographic area, who met the inclusion criteria, were included.  Since the oncogeriatric care 
cohort is a hospital-based cohort, patients might be selected due to selective (self) referral. 
To assess whether patients included in the oncogeriatric care cohort were representative of 
the regional patient population, patient characteristics were compared with those treated in 
the other health facilities in the catchment area of the hospital (Pasco, Polk, Hillsborough, 
Pinellas, Hernando, Manatee, and Sarasota county). These data were retrieved from the Florida 
Cancer Data System (FCDS), Florida’s statewide, population-based cancer registry12. All cancer 
cases seen in any health facility must be reported to FCDS within six months of diagnosis, 
as mandated by Florida statutes. Next, a comparison was made between the characteristics 
of patients who resided in the catchment area of the H. Lee Moffitt Cancer Center versus 
characteristics of patients who resided outside the catchment area.  
Results
Table 1 shows patient and tumor characteristics in both cohorts. Patients in the standard care 
cohort were older (p<0.001). Other patient characteristics and tumor characteristics were 
similar for patients in both cohorts.  
Overall, 13/104 patients in the standard care cohort and 1/42 patients in the oncogeriatric care 
cohort did not receive any treatment. As shown in Figure 2, primary therapy was categorized 
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as systemic therapy, local therapy, or a combination of systemic and local therapy. Patients in 
the standard cohort who received treatment, most often received a form of systemic therapy 
as primary therapy (49/91). Of these, the vast majority received endocrine therapy (43/49). 
Contrary, patients in the oncogeriatric cohort who received treatment, most often received a 
combination of systemic therapy and local therapy (23/41). In both cohorts, very few patients 
received local therapy of the breast or metastasis as primary therapy. 






n % n %
Age, years (mean, SD) 81.1 5.8 76.1 5.2 <0.001 <0.001
Comorbidities (number) 0.590 0.590
0-1 33 31.7 10 23.8
2-4 53 51 25 59.5
≥5 18 17.3 7 16.7
Polypharmacy 0.194 0.194
Yes 67 64.6 22 52.4
No 37 35.6 20 47.6
Localization metastases 0.518 0.741
Visceral 21 20.2 11 26.2
Non visceral 49 47.1 18 42.9
Both 30 28.8 13 31
Unknown 4 3.8 0 0
T stage 0.793 0.574
0,1,2 45 43.3 24 57.1
3,4 45 43.3 16 38.1
Unknown 6 5.8 2 4.8
N stage 0.567 0.833
Negative 27 26 10 23.8
Positive 67 64.4 30 71.4
Unknown 10 9.6 2 4.8
Hormone receptor status 0.050 0.333
Negative 18 17.3 5 11.9
Positive 75 72.1 37 88.1
Unknown 11 10.6 5 11.9
Her2Neu overexpression 0.087 0.609
No 72 69.2 32 76.2
Yes 13 12.5 8 19
Unknown 19 18.3 2 4.8
SD: standard deviation. * p value excluding missing data.
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Patients in the standard care cohort less often received chemotherapy as primary therapy, 
irrespective of hormone receptor status, and less often received trastuzumab (Table 2). Contrary, 
they more often received endocrine therapy as monotherapy (41% versus 21%, p=0.024). In 
case patients received endocrine therapy as part of primary therapy, an aromatase-inhibitor 
was prescribed most frequently in both cohorts: 62/81 patients in the standard care cohort 
were treated with an aromatase-inhibitor (letrozole n=46; anastrozole n=15; exemestane n=1), 
and 31/32 patients in the oncogeriatric care cohort received an aromatase-inhibitor (letrozole 
Table 2. Treatment characteristics of patients treated in a standard care setting versus an oncogeriatric care 
setting.
Standard care (n=104) Oncogeriatric care (n=42)
p
% n % n
Primary therapy 
Local therapy 
Surgery breast 16 15.4 11 26.2 0.158
Radiotherapy breast 8 7.7 5 11.9 0.521
Surgery metastasis 2 1.9 4 9.5 0.057
Radiotherapy metastasis 26 25 11 26.2 0.881
Systemic therapy
Endocrine therapy 81 77.9 32 76.2 0.829
in HR + patients* 72 96 32 86.5 0.113
in HR – patients* 5 27.8 0 0 0.545
Chemotherapy 6 5.8 8 19 0.025
in HR + patients* 1 1.3 5 13.5 0.015
in HR – patients* 4 22.2 3 60 0.142
Trastuzumab 4 3.8 6 14.3 0.034
Any therapy**
Local therapy
Surgery breast 19 18.3 17 40.5 0.010
Radiotherapy breast 10 9.6 8 19 0.162
Surgery metastasis 7 6.7 5 11.9 0.327
Radiotherapy metastasis 33 31.7 16 38.1 0.562
Systemic therapy
Endocrine therapy 81 77.9 34 81 0.824
in HR + patients* 72 96 34 91.1 0.395
in HR – patients* 5 27.8 0 0 0.545
Chemotherapy 10 9.6 17 40.5 <0.001
in HR + patients* 5 6.7 14 37.8 <0.001
in HR – patients* 4 22.2 3 60 0.142
Trastuzumab 4 3.8 6 14.3 0.034
* Percentages were calculated based on the number of patients per subgroup. HR + patients: patients with positive 
hormone receptor status; HR – patients: patients with negative hormone receptor status. ** Any breast cancer 
therapy received between date of diagnosis until death or end of follow up, including primary therapy.
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n=14; anastrozole n=10; and exemestane n=7). Additionally 13/81 patients in the standard 
care cohort received tamoxifen, and 6/81 patients received another form of endocrine therapy. 
In case patients received chemotherapy as part of primary therapy, the majority of patients 
in the standard care cohort received mono-chemotherapy (4/6), whereas patients from the 
oncogeriatric care cohort most often received a poly-chemotherapy regimen (6/8). 






























Local therapy only (breast/metastasis)
Over the whole course of disease, patients in the standard care cohort received a lower number 
of treatments as compared to patients in the oncogeriatric care cohort (mean number of 
treatments was 2.1 (SD 1.8) versus 3.6 (SD 2.1), p<0.001), and received less often breast surgery, 
chemotherapy and tratuzumab in particular (Table 2). Comparable results were observed 
when the analysis was restricted to therapy received during the first two years of follow-up 
(data not shown). In both cohorts, progression of disease was the most frequent reason for 
another line of therapy.
Median follow-up among patients censored at July 1st 2012 was 2.1 years for patients in the 
standard care cohort, and 2.0 years for patients in the oncogeriatric care cohort. Figure 3 shows 
the cumulative incidence of death for both cohorts. For patients in the standard care cohort, 
three-years overall mortality was 71% (95% CI 61-83), as compared to 58% (95% CI 42-75) in 
the oncogeriatric care cohort, corresponding with a univariate HR of 0.62 (95% CI 0.38-1.02). 
Adjustment for year of diagnosis and age at diagnosis yielded comparable results (multivariable 
HR 0.63 (95% CI 0.35-1.14)). 
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Since patients in the oncogeriatric care cohort may be selected by (self) referral, we 
performed two sensitivity analyses. First, we compared patient characteristics of patients in 
the oncogeriatric care cohort with corresponding patients who were treated in other health 
facilities in the catchment area of the oncogeriatric care cohort (Supplementary table 1). Mean 
age of patients who were treated in other health facilities was 79.6 years (SD 6.4); as compared 
to 76.0 years (SD 5.2) for those who were included in the oncogeriatric care cohort (p=0.001). 
Otherwise, no marked differences were observed, which indicates that despite a possible 
selection of patients, patients in the oncogeriatric care cohort seem to be a representative patient 
sample. Second, we compared characteristics of patients who resided outside the catchment 
area of the H. Lee Moffitt Cancer Center with characteristics of patients who resided in the 
catchment area (Supplementary table 2). Patients who resided outside the catchment area were 
more often married; otherwise no marked differences were observed. 




HR (95% CI) p
Multivariable*
HR (95% CI) p
Cohort 0.057 0.125
Standard care 62 (71) 1 (reference) 1 (reference)
Oncogeriatric care 19 (58) 0.62 (0.38-1.02) 0.63 (0.35-1.14)
HR: Hazard ratio; CI: confidence interval. * Multivariable analyses were adjusted for age and year of diagnosis.  

















Figure 3. Cumulative incidence of death from all causes for patients treated in a standard care setting versus 
patients treated in an oncogeriatric care setting. 




Elderly patients with primary metastatic breast cancer who were treated in a standard 
care setting received a lower number of treatments, and in particular less often received 
chemotherapy, trastuzumab and local breast surgery, as compared to those treated in an 
oncogeriatric care setting. Moreover, our findings suggest that oncogeriatric care may be 
beneficial in elderly breast cancer patients with primary metastatic disease in terms of overall 
survival, although cautious interpretation is warranted given the relatively low number of 
patients and the older age profile in the standard care cohort.
Instrumental variable
Randomized controlled trials are the preferred way to study specific treatment efficacy and 
should therefore be encouraged. However, the large heterogeneity of the elderly population 
renders difficult the conduct of clinical trials that are truly representative of that population. 
Eligibility criteria aimed at increasing the internal validity of a study, favor inclusion of 
relatively healthy participants, which tenders to weaken the external validity of the study13. 
Some authors have argued that even if all limits on eligibility were removed, the elderly who 
would be included in a trial would be a selected group14;15. Therefore different study designs 
may be warranted to obtain evidence based medicine in this large and growing population of 
patients. One option is the use of an instrumental variable in observational studies (e.g. regions 
within the same country or with similar settings, but with a different treatment approach).
In regular observational studies, the evaluation of treatment or treatment strategies is 
hampered by confounding by indication; frailty, age, tumor characteristics and presence of 
comorbidity might all affect both treatment and survival. An instrumental variable serves as 
a proxy for randomization and might thereby improve the quality of analyses in observational 
studies by minimizing confounding by indication16, provided that certain assumptions are 
met. The instrumental variable has to be associated with the exposure of interest, should 
be unrelated to the confounders and must not have a direct association with the outcome 
other than through the exposure10;11. With regards to exposure, both cohorts represent a 
different care setting, which is displayed in the organization of care as well as in differences 
in administration of treatment. Next, the instrumental variable should not be related to the 
confounders, in other words, patients in both cohorts should be comparable. A priori we did 
not expect large differences in patient and tumor characteristics between patients diagnosed 
with metastatic disease in The Netherlands and the United States. As shown in Table 1, 
indeed no large differences were observed between both cohorts, except for age at diagnosis. 
Therefore, results were adjusted for age at diagnosis. Last, other than through care setting, 
there should be no direct association between the instrumental variable and overall mortality. 
Differences in background mortality might affect survival in other ways than through care 
setting. However, no major differences in background mortality or remaining life expectancy 
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were observed between the cohorts. In The Netherlands, women who were aged 65 years in 
2007-2010 had an average remaining life expectancy of 21.2 years. For women aged 75 years 
the remaining life expectancy was 13.2 years17. This is comparable with the life expectancy 
of elderly women in the United States. White women who were aged 65 years in 2008-2009 
had an average remaining life expectancy of 20.0-20.4 years. For women aged 75 years, the 
remaining life expectancy was 12.6-12.9 years18. Next, the year of diagnosis is associated with 
birth cohort and might thereby possibly affect life expectancy. To account for the different 
inclusion periods between the cohorts, the results were adjusted for year of diagnosis. Third, 
patients in the oncogeriatric care cohort were observed to be comparable to patients treated 
in other health facilities in the region, and are therefore deemed to be a representative sample. 
In summary, there seemed to be reasonable grounds for justifying the use of two cohorts with 
different care settings as an instrumental variable. 
Treatment differences
The main finding of this study is the less intensive treatment of patients in the standard care 
cohort. The current study does not allow separating the various reasons for a more intense 
management of patients in the oncogeriatric care cohort. A greater familiarity of the staff 
with the management and treatment of older breast cancer patients, the use of a geriatric 
assessment, a multidisciplinary coordination of care, the proactive use of preventive measures 
against complications, and the use of risk scores to predict treatment toxicity might all have 
contributed. 
One of the most prominent treatment differences is the proportion of patients receiving 
chemotherapy. Others investigated chemotherapy effectiveness in elderly patients. A 
retrospective study based on the Surveillance Epidemiology End Results database among 
1,519 patients aged 66 years and older with metastatic hormone receptor negative breast 
cancer, revealed that 33% received chemotherapy within 6 months of their diagnosis. 
Chemotherapeutic treatment was associated with a better overall survival, and age did not 
modify the survival effect of chemotherapy19. However, these results should be interpreted 
with caution, as they are prone to confounding by indication. A recent meta-analysis showed a 
similar relative benefit from adjuvant chemotherapy in older women as compared to younger 
patients20, however the risk of toxicity increased with age21. Chemotherapy tolerability has 
also been investigated; in a study among 397 patients aged 60 years or older with metastatic 
breast cancer, women were randomized to either gemcitabine or epirubicin. Side effect wise, 
elderly patients tolerated chemotherapy well22. Moreover, older patients did not differ from 
their younger counterparts in their acceptance of chemotherapy, although they seemed to be 
less willing to trade survival for current quality of life23. 
Another marked treatment difference between both cohorts is the proportion of patients who 
received local therapy. Different studies suggest a beneficial effect of upfront breast surgery in 
metastasized breast cancer. A pooled analysis of 12 retrospective studies showed that patients 
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who underwent upfront surgery had a 35% higher survival24. Again, these results are prone 
to confounding by indication; it has been shown that patients who receive surgery have more 
favourable characteristics25. 
It is not expected that differences in treatment were explained by differences in treatment 
guidelines. Recently, Wolters and colleagues compared the national breast cancer guidelines 
of different countries and concluded that most treatment recommendations exhibited a 
large degree of congruency. This was explained by the fact that they are based on the same 
evidence26. Moreover, it is not expected that insight in oncogeriatric care, if applied, differed 
between both areas, since oncogeriatric guidelines are the result of collaborative efforts of 
experts from both Europe and the United States4;27.
In addition, it is not expected that differences in treatment were explained by differences in 
standard care strategies between the United States and The Netherlands, beyond guideline 
recommendations. An international comparison between the United States and Europe has 
not shown a different willingness of patients to receive chemotherapy28. Unfortunately we were 
unable to confirm this hypothesis, since no information was present for elderly patients with 
primary metastatic breast cancer who were treated in a standard care setting in the United 
States. Since neither patients nor guidelines are different between both cohorts, different care 
setting is likely largely responsible for survival differences. Different care setting might include 
differences in multidisciplinary management, supportive or preventive measures, as well as 
differences in specific treatment, all of which support the use of oncogeriatric care.
Survival differences
A second finding of this study was that patients in the oncogeriatric care cohort seemed to 
have a lower overall mortality. However, cautious interpretation is warranted, as patients in 
the standard care cohort did have a somewhat older age profile. This may be the result of 
small demographic differences between the geographic areas of both cohorts17;29. In addition, 
although we constructed two cohorts of unselected nature, inclusion in the oncogeriatric 
care cohort may have been affected by selective (self) referral of patients to the H. Lee Moffitt 
Cancer Center. However, sensitivity analysis showed no gross differences between patients who 
received oncogeriatric care, and patients who received standard care in other health facilities 
in the catchment area of the hospital. Of note, multivariable analyses were adjusted for age at 
diagnosis, which did not alter the results. Moreover, since we focused on different care settings 
for elderly patients with primary metastatic breast cancer, the number of eligible patients 
is limited, which hampers the power of the analyses. Therefore, the potential for improved 
survival by oncogeriatric care needs to be investigated on a larger scale.
Both a more intensive primary treatment as well as more subsequent treatment during the first 
year of follow-up might have contributed to the lower overall mortality among patients in the 
oncogeriatric care cohort. Moreover, oncogeriatric care might not only result in more intensive 
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treatment, but also in a better selection of treatment for individual patients. Additionally, 
a greater attention being paid to comorbidity and geriatric issues may have prevented 
complications and functional decline, with the net effect of improved overall survival. 
Survival versus quality of life 
A review on metastatic breast cancer in the elderly states that in addition to controlling 
symptoms, care should include determination of comorbidity, assessment of functional status 
and patients’ preferences30. In a setting with limited life expectancy due to both advanced age 
as well as advanced disease it remains a challenge to balance the benefit from therapy and the 
risk of adverse events which may impede quality of life or survival. Maintaining quality of life 
is one of the main aims in metastatic breast cancer27. From the oncogeriatric care setting we 
may deduce a greater attention for functional status and quality of life; however, no data on 
preservation of quality of life or functional status were available. Therefore, it is important to 
further investigate whether the deemed improved survival in the oncogeriatric care cohort is 
accompanied by a better (preservation of) quality of life, or contrary, counterbalanced by a 
decrease in quality of life because of treatment burden. 
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Supplementary table 1. Characteristics of patients in the oncogeriatric cohort as compared to those who were 
treated in other health facilities in the catchment area of the oncogeriatric care cohort (H. Lee Moffitt Cancer 
Center and Research Institute).
Oncogeriatric care (n=42) Other care*  (n=341)
p 
n % n %
Marital status 0.199
Married 17 40.5 95 27.9
Other# 25 59.5 242 71
Unknown 0 0 4 1.2
Insurance 0.457
Uninsured 1 2.4 3 0.9
Private 4 9.5 17 5
Medicare^ 37 88.1 305 89.4
Other governmental^^ 0 0 9 2.6
Unknown 0 0 7 2.1
Race 0.672
White 312 91.5 40 95.2
Non white 27 7.9 2 4.8
Unknown 2 0.6 0 0
Ethnicity 0.984
Hispanic 16 4.7 2 4.8
Non-hispanic 325 95.3 40 95.2
* Patients treated at other health facilities in the catchment area of the oncogeriatric care cohort. # widowed, 
divorced, single, separated. ^ plus or minus supplement. ^^ TRICARE, Veterans Affairs etc.
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Supplementary table 2. Characteristics of patients in the oncogeriatric cohort who reside inside versus outside 
the catchment area of the H. Lee Moffitt Cancer Center and Research Institute.
In catchment area (n=26) Outside catchment area (n=16)
p
n % n %
Comorbidities (number) 0.937
0-1 6 23.1 4 25
2-4 16 61.5 9 56.2
5 or more 4 15.4 3 18.8
Marital status 0.001
Married 5 19.2 12 75
Other# 21 80.8 4 25
Education 0.634
Less than high school 7 26.9 3 18.8
Some high school 10 38.5 6 37.5
More than high school 4 15.4 5 31.2
Unknown 5 19.2 2 12.5
Insurance 0.109
Uninsured 0 0 1 6.2
Private 1 3.8 3 18.8
Medicare^ 25 96.2 12 75
Other governmental^^ 0 0 0 0
Race 0.722
White 25 96.2 15 93.8
Non white 1 3.8 1 6.2
Unknown 0 0 0
Ethnicity 0.517
Hispanic 2 7.7 0 0
Non-hispanic 24 92.3 16 100
# widowed, divorced, single, separated; ^ plus or minus supplement; ^^ TRICARE, Veterans Affairs etc.
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Summary
The three main conclusions of this thesis are that there is a limited evidence base for treatment 
of elderly women with breast cancer; that elderly women with breast cancer have a worse 
prognosis as compared to younger patients; and that the evaluation of treatment efficacy in 
elderly women with breast cancer differs from the evaluation in younger patients. 
I. Limited evidence base for treatment of elderly women with breast cancer 
In the first part of this thesis, we investigated the evidence base for treatment of elderly breast 
cancer patients. Not only were we able to confirm an underrepresentation of elderly breast 
cancer patients in clinical trials, we were also able to pinpoint for which elderly patients an 
evidence base for treatment is lacking in particular. In chapter 2 we quantified the evidence 
base for locoregional treatment, based on the proportion of clinical trials from which elderly 
breast cancer patients are excluded. An evidence base for locoregional treatment in patients 
aged 65-75 years was dependent on their phenotype. Contrary, there was a limited evidence 
base for all patients aged 75 years or older. These results were supported by the findings in 
chapter 3, in which we evaluated the external validity of a clinical trial on endocrine therapy. 
Breast cancer patients aged 65-75 years who participated in a clinical trial were comparable 
with breast cancer patients from the general population of corresponding age, in terms of 
overall survival. However, with increasing age, inclusion in a clinical trial was more selected on 
fitness; trial participants aged 75 years or older did not represent elderly breast cancer patients 
from the general population. Hence, trial results may not necessarily be extrapolated to elderly 
breast cancer patients aged 75 years or older. Third, it was investigated whether adherence to 
guideline recommendations is associated with outcome (chapter 4). In line with the previous 
findings, we observed that guideline adherence was not associated with overall survival or 
with relative survival in patients aged 75 years or older. These results confirmed our hypothesis 
that non-evidence based guidelines do not improve breast cancer outcome. Surprisingly, we 
did not find an association between guideline adherence and breast cancer outcome in younger 
patients either. 
There are two explanations for this absence of an association in both age groups; it is truly not 
there, or it is there but we fail to observe it (Figure 1). A true absence of an association may 
be explained by the fact that trials usually focus on the efficacy of one particular treatment. 
No trials have been performed comparing complete guideline adherence versus incomplete 
guideline adherence. In early stage breast cancer, both options may result in similar survival 
after five years of follow-up. 
Other than a true absence of an association, we may fail to observe a true association. First, 
the study may have been underpowered. The contrast in adherence proportion among regions 
may have been too small (10%), or the contrast between adherent and nonadherent patients 
may have been too small; most patients who were not treated completely in accordance with 
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the guidelines received at least three out of five therapies in accordance with the guidelines. 
Second, confounding may blur the association in case patient or tumor characteristics, which 
may impact survival, differed among regions. However, background mortality and remaining 
life expectancy were similar among regions, and the analyses were adjusted for small differences 
in tumor characteristics. Third, bias may occur if a certain type of patients seeks medical help 
in another region than the region of residence. However, this was not the case in our study. In 
addition, information bias may occur when assessment of vital status differs across regions. 
However, vital status is established through linkage with the municipal population registries 
nationwide. Summarized, it seems likely that there is a true absence of an association, although 
we cannot exclude that a lack of power may have contributed to our findings.  
II. Elderly women with breast cancer have a worse prognosis 
In in the second part of this thesis, we studied breast cancer outcomes in elderly patients. In 
patients who participated in a trial, we investigated the association between age at diagnosis 
and death from breast cancer and death due to other causes (chapter 5). As expected, we 
observed a higher risk of death due to other causes with increasing age. Surprisingly, we also 
observed a higher risk of breast cancer death in patients with higher age. To gain further 
insight in the relationship between age at diagnosis and breast cancer outcome, we studied the 
risk of breast cancer recurrence in the same cohort of patients (chapter 6). We found that with 
increasing age, patients had a higher risk of a distant recurrence, while the risks of locoregional 
recurrence and contralateral breast cancer were not different across age groups. 
In the previous section we showed that elderly breast cancer patients who are included in a 
clinical trial may not represent elderly breast cancer patients from the general population. 
Therefore, the association between age and breast cancer outcome was also assessed in the 
population-based FOCUS cohort (chapter 7). Again we observed a worse breast cancer outcome 
with increasing age; patients aged 75 years or older had a lower relative survival as compared 
to younger patients. Of note, this was not accompanied by an increased risk of distant breast 
Figure 1. No association between guideline adherence and survival; explanations and solutions.
It is not there It is there but we fail to observe it 
No association observed
BiasConfoundingLack of power
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cancer recurrence. The latter observation is probably explained by an age specific under 
diagnosis or under registration of recurrence; compliance with follow-up may differ in the 
general population as compared to compliance of patients who participate in a trial. Moreover, 
if a recurrence is detected outside the hospital, the patient and/or general practitioner may 
decide not to refer the patient to the hospital, and thus the recurrence is not recorded in the 
patient’s hospital chart and consequently not reported in the cohort.
It is tempting to speculate on the underlying mechanisms of the surprising observation that 
breast cancer outcomes detoriate with increasing age. In general, patient, tumor and treatment 
characteristics may affect cancer outcome. Increasing age may affect breast cancer outcome by 
changes in tumor, patient and treatment characteristics (Figure 2). 
Figure 2. Relation between increasing age and prognosis.
Increasing age
Tumor characteristics Patient characteristics Treatment characteristics
Breast cancer outcome
BA C
As indicated by A, increasing age is associated with different tumor characteristics. Others have 
found a more frequent occurrence of hormone receptor positive breast cancer with increasing 
age1;2, although this difference seems to be most pronounced in premenopausal versus 
postmenopausal women; within postmenopausal patients no large differences in hormone 
receptor status have been observed3;4. One may also speculate that it is not the tumor, but the 
surroundings of the tumor, i.e. the patient, that change with increasing age, and thereby may 
affect tumor characteristics and tumor phenotype. There is evidence that a patient’s cellular 
immune response is able to control tumor development and progression, a process called 
immonosurveillance5. The mechanisms involved in immunosurveillance have been shown to 
alter with increasing age6. The functional decline in immune system with ageing is commonly 
defined as immunosenescence7. Thus, immunosenescence may impair immunosurveillance, 
which may result in increased cancer development and progression with increasing age6.
As indicated by B in the Figure, increasing age is associated with certain patient characteristics. 
An individual who dies from other causes is no longer at risk for breast cancer death and 
therefore, death due to other causes is considered a competing endpoint. Competing endpoints 
may be particularly present in older populations8. If one is interested in causation (‘does age 
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cause breast cancer death’), a Cox regression analysis may be suitable, since one would like to 
know the risk of death from breast cancer if a patient would not have died from other causes. 
In Cox regression estimations, patients who are lost to follow-up or experience a competing 
endpoint are censored; the assumption for censoring is that patients who are censored would 
in theory have the same probability to develop the outcome of interest as those who are still 
in the risk set. For prediction, or treatment decisions (‘do I need to treat the breast cancer 
of this patient or will she die from something else before she will die from breast cancer’), 
a Cox regression analysis is not suitable, since one would like to know the risk of breast 
cancer death in the presence of the risk of other causes of death. In the presence of competing 
endpoints, the cause-specific cumulative incidence is overestimated in the conventional 
analysis9. Alternatively, in a Fine and Gray analysis the risk of breast cancer death is calculated 
in the presence of the risk of a competing event10. As described in chapters 5-7, Fine and Gray 
analyses did not substantially alter the results, which suggests that competing mortality needs 
to be substantial to significantly alter the results of Cox regression estimates. 
As indicated by C, increasing age may affect treatment and thereby affect breast cancer 
outcome. It has been shown repeatedly that elderly patients receive less extensive treatment 
as compared to younger patients11. Consequently, they may suffer from undertreatment. The 
finding that elderly patients in the TEAM trial had a higher risk of a distant recurrence is 
suggestive for undertreatment with chemotherapy in particular. Next to undertreatment, 
treatment efficacy may change in elderly patients due to interactions between anticancer 
therapy and concurrent medication or comorbidity. Concurrent disease and medication use 
may affect tolerability of treatment and increase toxicity12;13, which may result in suboptimal 
dosage of anticancer treatment. Moreover, drug absorption, distribution and metabolism can 
be affected by age-related physiological changes14. 
III. Different treatment efficacy in older women with breast cancer
In the third part of this thesis, specific treatment and treatment strategies were evaluated. 
As reported in chapter 8, we evaluated the efficacy of radiotherapy in addition to breast 
conserving surgery in elderly patients with early stage breast cancer. A systematic review 
and meta-analysis of five randomized clinical trials showed a decreased risk of locoregional 
recurrence in favour of patients who received radiotherapy after breast conserving surgery. 
However, the absolute risk difference for a locoregional recurrence was low, and no differences 
were observed with regards to the risk of a distant recurrence, or overall survival. Therefore, 
omission of radiotherapy seems to be a reasonable option in elderly breast cancer patients. 
As reported in chapter 9, we evaluated the outcome of patients who discontinued endocrine 
therapy. Patients younger than 65 years who discontinued endocrine therapy within one year 
of follow-up, had a worse overall and breast cancer specific survival after this first year. These 
results are in line with other studies showing a higher efficacy of five years of endocrine therapy 
as compared to one year of endocrine therapy15. Surprisingly, no association was observed 
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Figure 3. Explanations for the absence of an observed association.
It is not there It is there but we fail to observe it 
No association in the elderly observed
Age specific mechanisms Confounding BiasLack of power




between nonpersistence of endocrine therapy within one year and outcome after this year 
in patients aged 65 years or older. Again, there are two explanations for this absence of an 
association in the elderly; it is truly not there, or we fail to observe it (Figure 3).
If the association is truly not there, the explanation must be sought in age specific mechanisms 
or biology. As mentioned, absorption, distribution and metabolism of both types of endocrine 
treatment can be affected by age-related physiological changes14, comorbidity or concurrent 
medication use. In addition, the quantitative expression of hormone receptors on the tumor 
surface may decline with age, or there may be less substrate for the hormone receptors with 
increasing age; both may hamper the absolute benefit of endocrine therapy. Of note, these 
suggestions are of hypothetical nature only, as there is no evidence to support them. 
Alternatively, a lack of power, bias and confounding can blur a true association. In all three 
scenarios, these factors should be age specific, as the failure to observe an association would be 
present in the elderly only. In case of a lack of power, the number of patients in the oldest age 
category may have been too small. Second, competing mortality may decrease power because it 
negatively affects both the numerator and the denominator. In case of confounding, age specific 
treatment characteristics may have blurred the association. For example, administration 
of chemotherapy may decrease the risk of breast cancer death, but may also predict early 
discontinuation. A negative effect of early discontinuation may be counterbalanced by the 
positive effect of chemotherapy, with the net effect of no association between discontinuation 
and breast cancer death. Of note, no therapy was shown to predict early discontinuation of 
endocrine therapy. Second, tumor characteristics may confound the association; if patients 
with favourable tumor characteristics are more likely to discontinue endocrine treatment, a 
negative effect of early discontinuation could be counterbalanced by the positive effect of tumor 
characteristics. However, no tumor characteristics were predictive for  early discontinuation. 
Third, the association may be confounded by patient characteristics. One may argue that those 
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who discontinue therapy within one year are healthier and have fewer comorbid diseases. 
Patients with fewer comorbid disease may be aged to a lesser extent, and consequently have a 
better preserved immune system function, and hence a better breast cancer outcome. Again, 
a negative effect of early discontinuation may be counterbalanced by the positive effect of 
fewer comorbid diseases, with the net effect of no association. However, evidence is lacking 
on the association between comorbidity and immunosensecence, and indicators of general 
health, i.e. comorbidity, were not predictive for discontinuation. Information bias, or systematic 
misclassification can occur when elderly who discontinue within one year, are also less 
compliant with follow-up visits. Consequently, there may be under registration of breast cancer 
recurrence and breast cancer death, thereby counterbalancing the higher risk of breast cancer 
death due to discontinuation. However, vital status was checked with the municipal population 
registries, so in the case of information bias we would still observe a higher overall risk of death 
in patients who discontinued endocrine therapy within one year. This was not the case.
In conclusion, despite the possibility of a lack of power, so far the results hint at evidence 
of absence rather than absence of evidence. The data appear to be robust and indicate that 
discontinuation of endocrine therapy within one year in patients aged 75 years or older is truly 
not as detrimental as in younger postmenopausal patients. Although the latter study design 
was unfit to report on the efficacy of adjuvant endocrine therapy in elderly breast cancer 
patients, these findings warrant further age specific studies. Few randomized clinical trials 
addressed the efficacy of endocrine therapy specifically in elderly patients. In one trial, a benefit 
of extended adjuvant endocrine therapy of letrozole treatment after five years of tamoxifen was 
only observed in patients younger than 60 years. However, no significant interaction between 
age and treatment efficacy was observed16. In 1993, Cummings et al reported on a clinical trial 
among 168 women aged 65 years or older, with mostly hormone receptor positive tumors, who 
were randomized to two years of tamoxifen or a placebo. After a median follow-up of 10 years, 
patients allocated to tamoxifen had a lower risk of a distant recurrence17. A meta-analysis 
including 2,805 patients aged 70 years or older with estrogen receptor positive disease, who 
were allocated to about five years of tamoxifen or to a control arm, showed a lower recurrence 
risk for those allocated to tamoxifen18. Of note, elderly patients comprised 3% of all patients 
included in the meta-analysis (2,805/105,623) and little was known about the phenotype of 
included elderly patients. Moreover, the majority of the trials included in the meta-analysis 
was conducted in the 1970s and 1980s; therapy regimens other than the randomized treatment 
have changed considerably since. Therefore, it remains subject of further investigation whether 
the association between nonpersistence and breast cancer outcome in the elderly it is truly not 
there, or whether we failed to observe it.
Other treatment modalities
In the current thesis, not all treatment modalities were evaluated. Based on current literature, 
short notes are provided for breast surgery and chemotherapy. A Cochrane review investigating 
surgery versus primary endocrine therapy for operable breast cancer in women aged 70 years 
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or older concluded that primary endocrine therapy should only be offered to women with 
hormone receptor positive disease who are unfit for surgery, and to those who refuse surgical 
treatment19. Although the risk of postoperative complications seems to increase with increasing 
age20, the majority of older patients tolerate surgery and anaesthesia with very low morbidity 
and virtually non-existent mortality21. A recent meta-analysis on adjuvant chemotherapy 
stated that age did not much affect the proportional risk reductions with taxane-based or 
anthracycline-based chemotherapy; elderly may have had somewhat greater immediate 
hazards from chemotherapy, but appeared to have similar reduction as younger women with 
regards to breast cancer outcomes. However, the gain in life expectancy from a given absolute 
reduction in the risk of death from breast cancer decreased with increasing age22.
Oncogeriatric care
Next to specific treatment, collaborative oncogeriatric management can optimize care and 
outcomes in elderly patients23;24. Therefore, we compared two different treatment strategies in 
elderly breast cancer patients. Chapter 10 describes the international comparison of treatment 
and outcome of elderly patients with primary metastatic breast cancer, who were treated in 
a standard care setting in The Netherlands, as compared to those who were treated in an 
oncogeriatric setting in the United States. We observed that patients who were treated in an 
oncogeriatric care setting were treated more extensively. Although not statistically significant, 
overall survival was deemed higher in the oncogeriatric care cohort, which was suggestive 
for a beneficial effect of oncogeriatric care in elderly breast cancer patients with metastatic 
disease. It needs yet to be determined whether this increase in survival is accompanied by a 
better (preservation of) quality of life and functional status, and whether similar results can be 
obtained in patients with early stage disease. 
Reflection 
Trial data versus population-based data
The work presented in this thesis indicates that elderly patients who participate in a clinical trial 
do not always represent breast cancer patients from the general population of corresponding 
age. However, some of the studies in this thesis comprise posthoc analyses of trial data. One 
may question to what extent these results can be extrapolated to the general population. 
With regards to outcome, we observed a worse breast cancer outcome with increasing age, 
both in a trial setting as well as in a population-based cohort. Contrary, the higher risk of a 
distant recurrence in elderly trial patients could not be confirmed in the population-based 
cohort. This may be due to both under diagnosis and under registration in the latter cohort, 
as pointed out above. Another posthoc analysis of trial data comprised the association 
between early nonpersistence and breast cancer outcome thereafter. It is known that trial 
patients are generally more compliant with therapy as compared to patients in the general 
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population25, but observational data confirm that higher age is predictive for nonpersistence 
and noncompliance26.  
Calendar age 
In geriatric oncology, it is recommended that treatment decisions are not (solely) based on 
calendar age, but rather on biological age or functional status. It is still being debated how 
biological age should be assessed and defined. Nevertheless, all our studies make use of 
calendar age rather than biological age. Therefore, one may question to which extent the results 
presented in this thesis are useful for daily practice. Although calendar age does not cover the 
whole spectrum of phenotypic variety in the elderly, it is strongly related with comorbidity, 
functional status and remaining life expectancy27. Until a definition and categorization of 
biological age is developed, calendar age may be appropriate to use as a proxy for biological 
age, whether or not in combination with another measurement of functional status, like 
comorbidity, polypharmacy or performance status. 
Outcome measures
In this thesis, the outcomes under study are overall survival and breast cancer outcomes. 
With increasing age, it is more difficult to establish cause of death to a single cause28. Relative 
survival can be used as a valid alternative of breast cancer specific survival29. Regardless of 
which survival endpoint is used, relevance of endpoints may differ between older and younger 
patients. Elderly are less likely to trade current quality of life for a prolonged survival30. Hence, 
maintenance of functional status, or preservation of quality of life may be more relevant 
outcomes that breast cancer specific survival. Unfortunately no data were available on quality 
of life or follow up of functional status.  
In addition, the evaluation of treatment efficacy may differ depending on the outcome measure. 
As observed for radiotherapy after breast conserving surgery and adjuvant chemotherapy, the 
relative risk reduction was similar across age groups, while the absolute risk difference declined 
with increasing age. This is depicted in Figure 4. A smaller absolute risk difference corresponds 
with a larger number needed to treat to prevent one endpoint. The dotted lines resemble the 
hypothetical cut-off in absolute risk difference and numbers needed to treat, where treatment 
efficacy is considered not efficient anymore. This cut-off may vary per treatment and per 
patient. The number needed to treat may be a more useful instrument to evaluate whether 
a certain treatment is worthwhile, as compared to relative risk measures. Moreover, risks of 
serious adverse events should be included in evaluation of treatment efficacy. The delicate 
balance between absolute benefits of a certain therapy and potential impairment in functional 
status or quality of life due to adverse events, calls for patients and their peers to be actively 
involved in decision-making, and to take into account the patient’s personal preferences with 
regards to risk of recurrent disease, functional status and risk of adverse events.




The next phase in oncogeriatric research in breast cancer is aimed at individualized, tailored 
treatment. The key for appropriate care in the heterogeneous elderly breast cancer population 
is to predict who will die with and from breast cancer. As depicted in Figure 5, those who 
have a high risk of dying from breast cancer, i.e. those with a high risk of recurrent disease, 
should receive adequate anti-cancer therapy, aiming at minimal residual disease. However, 
those who will likely to die with breast cancer, i.e. those who have a low risk of recurrent 
disease and a higher risk of competing mortality, should receive adequate supportive care and 
optimal treatment of comorbid diseases, in order to maintain functional status and optimize 
quality of life. The X-axis of the Figure is yet undetermined as it needs to be investigated which 
combination of patient characteristics and tumor characteristics will predict breast cancer 
outcome best.
The online tool “Adjuvant Online” is frequently used as support for adjuvant treatment decisions 
in breast cancer. However, Adjuvant Online predictions have been shown to be less accurate 
in elderly patients31. Moreover, Adjuvant Online only predicts breast cancer recurrence and 
mortality, and does not include outcomes such as functional status. Maintaining functional 
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status can make the difference between independent living and institutionalization, which may 
be more relevant in elderly patients than sec additional years added to survival. A prediction 
model based on patient and tumor characteristics, with relevant outcomes for elderly, can be 
used as a decision support tool when evaluating treatment options in elderly breast cancer 
patients. Moreover, such a model will aid in individualized treatment, taking into account the 
large heterogeneity in the elderly.
Treatment 
Currently, recommendations for management of breast cancer in elderly are limited by a lack 
of evidence23, although the magnitude of this lack of evidence varies per type of treatment. To 
specifically assess treatment efficacy, conducting randomized controlled clinical trials in the 
elderly is inevitable. In some cases alternative designs, for example the use of an instrumental 
variable, may function as a surrogate for randomization in observational studies. Innovative 
designs may further enlighten efficacy and tolerability of treatment in elderly patients. As 
suggested by Martine Extermann, one could think of Phase I like studies; instead of increasing 
the dose of a certain treatment, one may increase the frailty status of patients receiving the 
treatment in order to assess tolerability of a certain therapy. Next to cancer specific treatment, 
supportive treatment is being investigated. Recently, the prospective study ‘Climb Every 
Mountain’ was initiated, in which elderly breast cancer patients undergo a geriatric assessment 
at diagnosis and during follow-up, to evaluate cognitive function, psychosocial issues and 
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physical activity. Aim of the study is to assess which domain is at highest risk for detoriation, 
and to identify predictive factors for detoriation. Afterwards, an intervention study will be 
conducted, aimed at preservation of the domain most at risk. In addition to treatment, the 
prospective study ‘FOCUS on preferences’ aims to unravel patient preferences with regards 
to surgical treatment, and to quantify the minimum expected benefit of adjuvant systemic 
therapy in order to opt for systemic treatment.  
Clinical implications 
The work presented in this thesis primarily gained insight in the unknown unknowns. For 
example, we did not know whether the prognosis of elderly patients would be different as 
compared to younger patients. Now we know that elderly not only have a higher risk of non 
breast cancer death, but also have a higher risk of breast cancer death as well as a higher risk of 
distant disease recurrence. But we still do not know why. The question how to optimize breast 
cancer care and cure in elderly patients is yet unanswered. How to act in ignorance? Until the 
evidence gap is filled, the following remarks may be useful for clinical practice.
In line with the adagio ‘primum non nocere’, one should treat first what kills first. An older 
breast cancer patient who is likely to die from her breast cancer, or who is at high risk for 
disease recurrence, is a candidate for extensive anti-cancer treatment. On the other hand, 
treatment of an elderly breast cancer patient who will more likely die from other causes, i.e. 
with breast cancer should rather be focused on supportive care and optimal treatment of 
comorbid diseases. These outcome predictions can be based on the combination of tumor and 
patient characteristics. 
A similar relative risk reduction of a certain treatment, may translate in only a minor absolute 
risk difference in elderly patients as compared to in younger patients. Therefore, elderly patients 
and their peers should be actively involved in decision-making, by discussing the absolute 
benefits and risks of different treatment options. In addition, the goals of treatment and the 
relevance of possible outcomes should be discussed. 
A collaborative geriatric and oncology management may optimize care in elderly patients. A 
form of geriatric assessment and multidisciplinary meetings specifically addressing the needs 
of elderly patients may improve patient outcome.
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Introductie
Dit proefschrift maakt deel uit van het FOCUS-onderzoek (Female breast cancer in the elderly; 
Optimizing Clinical guidelines USing clinico-pathological & molecular data), wat gerealiseerd 
is middels een programmasubsidie van het Koningin Wilhelmina Fonds. Het doel van het 
FOCUS-onderzoek is om de behandeling en uitkomsten van oudere patiënten met borstkanker 
te verbeteren. Waarom onderzoek doen bij ouderen, en in het bijzonder bij oudere vrouwen 
met borstkanker? Borstkanker is de meest voorkomende vorm van kanker bij vrouwen en meer 
dan 40% van de borstkankerpatiënten is 65 jaar of ouder ten tijde van diagnose1;2. Hoewel 
oudere borstkankerpatiënten in meerdere opzichten verschillen van jongere patiënten, zijn er 
geen leeftijdsspecifieke richtlijnen voor de behandeling van oudere patiënten. Omdat er tot 
voor kort nauwelijks onderzoek verricht werd in deze grote en groeiende groep patiënten, is het 
dus onduidelijk hoe deze patiënten behandeld moeten worden.
Doel van het proefschrift
Het doel van dit proefschrift is de zorg te verbeteren voor oudere patiënten met borstkanker, 
door het gebrek aan bewijs voor behandeling te kwantificeren, de borstkankeroverleving van 
oudere patiënten te onderzoeken en leeftijdsspecifieke effecten van verschillende behandelingen 
te evalueren.
Gebruikte cohorten
Voor dit proefschrift zijn verschillende observationele patiëntcohorten samengesteld. Ook is 
gebruik gemaakt van gegevens van patiënten die deelnamen aan een grote klinische trial. 
FOCUS-cohort 
Data uit het FOCUS-cohort zijn gebruikt in hoofdstuk 2, 3 en 7. Het FOCUS-cohort is een 
observationeel cohort van alle vrouwen in de regio West van het Integraal Kankercentrum 
Nederland, die tussen 1997 en 2004 gediagnosticeerd werden met borstkanker en 65 jaar 
of ouder waren ten tijde van de diagnose. In totaal werden 3.762 patiënten geïncludeerd. 
Middels statusonderzoek werden gedetailleerde gegevens verzameld over tumor-, patiënt- en 
behandelkarakteristieken, alsook follow-up en overleving.
Nederlandse Kankerregistratie cohort 
Data van dit cohort zijn gebruikt in hoofdstuk 4. De Nederlandse Kankerregistratie verzamelt 
gegevens over de diagnose, stagering en behandeling van alle patiënten met kanker in Nederland. 
In totaal werden 31.520 vrouwen geïncludeerd die tussen 2005 en 2008 gediagnosticeerd 
werden met vroeg stadium borstkanker, en ten tijde van diagnose jonger waren dan 65 jaar of 
ouder dan 75 jaar. 
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TEAM trial 
Data van de TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial zijn gebruikt in 
hoofdstuk 3, 5, 6 en 9. De TEAM trial is een fase-3 studie in 9 landen, waarin tussen 2001 
en 2006 9.766 borstkankerpatiënten gerandomiseerd werden voor twee verschillende vormen 
van endocriene therapie. Patiënten ontvingen 5 jaar exemestaan, of 2.5 jaar tamoxifen gevolgd 
door 2.5 jaar exemestaan. Postmenopauzale vrouwen met hormoonreceptorpositieve tumoren 
zonder afstandsmetastasen, die lokale therapie hadden afgerond, werden geïncludeerd. 
Standaard zorg- en oncogeriatrische zorg cohort
Data van dit cohort zijn gebruikt in hoofdstuk 10. Voor het standaard zorg cohort werden 
gegevens gebruikt van alle vrouwen van 70 jaar en ouder die tussen 2008 en 2011 werden 
gediagnosticeerd met een primair gemetastaseerd mammacarcinoom in de regio West van 
het Integraal Kankercentrum Nederland (n=104). Vergelijkbare criteria werden toegepast voor 
inclusie in het oncogeriatrische zorg-cohort;  vrouwen van 70 jaar en ouder die tussen 2003 en 
2011 in het H. Lee Moffitt Cancer Center and Research Institute in Tampa (Florida, Verenigde 
Staten) werden gediagnosticeerd met een primair gemetastaseerd mammacarcinoom, werden 
geïncludeerd (n=42). Middels statusonderzoek werden gedetailleerde gegevens verzameld over 
tumor-, patiënt- en behandelkarakteristieken, alsook follow-up en overleving.
Overzicht van het beschreven onderzoek
Beperkte bewijsvoering voor de behandeling van oudere borstkankerpatiënten 
Dit proefschrift bestaat uit drie delen; in het eerste deel wordt aangetoond dat de behandeling van 
borstkanker bij ouderen non-evidence based is. In hoofdstuk 2 wordt beschreven dat de meeste 
ouderen worden uitgesloten van deelname aan klinische trials. Voor borstkankerpatiënten van 
65-75 jaar hangt het af van hun patiëntkarakteristieken hoe vaak zij worden uitgesloten van 
klinische trials waarop behandelrichtlijnen zijn gebaseerd. Borstkankerpatiënten van 75 jaar 
of ouder daarentegen worden alleen op basis van kalenderleeftijd uitgesloten van deelname 
aan de meerderheid van de klinische trials. In hoofdstuk 3 wordt onderzocht in hoeverre 
oudere borstkankerpatiënten in een klinische trial geselecteerd zijn ten opzichte van oudere 
borstkankerpatiënten in de algemene bevolking. Met name patiënten van 75 jaar of ouder 
die geïncludeerd worden in een klinische trial, zijn gezonder en hebben derhalve een betere 
algemene overleving dan hun leeftijdsgenoten in de algemene bevolking. Trialresultaten die 
zijn gebaseerd op een selecte groep ouderen zijn dus mogelijk niet extrapoleerbaar naar oudere 
borstkankerpatiënten in de algemene bevolking. Dit wordt bevestigd in hoofdstuk 4, waarin 
aangetoond wordt dat het naleven van behandelrichtlijnen die grotendeels zijn gebaseerd op 
klinische trials, niet geassocieerd is met een betere overleving van oudere borstkankerpatiënten.
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Oudere borstkankerpatiënten hebben een slechtere prognose
In het tweede deel van dit proefschrift wordt de prognose van oudere borstkankerpatiënten 
onderzocht. Het is een veel gehoorde opvatting dat borstkanker bij ouderen een minder grote 
bedreiging voor de gezondheid vormt in vergelijking met borstkanker bij jongere vrouwen. 
De prognose van oudere postmenopauzale borstkankerpatiënten blijkt echter slechter te zijn 
dan die van jongere patiënten. In hoofdstuk 5 worden de doodsoorzaken onderzocht van 
postmenopauzale patiënten die participeerden in de TEAM trial. Zoals verwacht neemt met 
het stijgen van de leeftijd de kans toe om te overlijden aan niet aan borstkanker gerelateerde 
oorzaken. Oudere patiënten hebben echter ook een grotere kans te overlijden aan borstkanker. 
In hoofdstuk 6 wordt de associatie tussen leeftijd en het optreden van een borstkankerrecidief 
onderzocht. De slechtere prognose van oudere patiënten wordt in deze studie bevestigd; het 
risico op afstandsmetastasen neemt toe met het stijgen van de leeftijd. Omdat in het eerste deel 
van dit proefschrift wordt gesteld dat resultaten uit een klinische trial niet altijd van toepassing 
zijn op oudere patiënten uit de algemene bevolking, wordt in hoofdstuk 7 de relatie tussen 
leeftijd en borstkankerprognose ook onderzocht in een cohort oudere borstkankerpatiënten 
uit de algemene bevolking. Wederom wordt aangetoond dat oudere borstkankerpatiënten een 
hoger risico hebben om aan borstkanker gerelateerde oorzaken te overlijden. In deze studie 
wordt dit echter niet ondersteund door een toename van het risico op afstandsmetastasen; dit 
is mogelijk het gevolg van onderdiagnose of onderregistratie. 
Er zijn verschillende mogelijke verklaringen voor een hogere borstkankersterfte bij oudere 
borstkankerpatiënten, zoals weergegeven in Figuur 1. Zoals aangegeven met A, is een toenemende 
leeftijd geassocieerd met bepaalde tumorkarakteristieken. Hoewel oudere patiënten zich 
vaker presenteren met hormoonreceptorpositieve borsttumoren3, blijkt dit verschil het meest 
uitgesproken tussen pre- en postmenopauzale patiënten4. Het is ook mogelijk dat de tumor zich 
anders gedraagt omdat de omgeving van de tumor, oftewel de patiënt, verandert; een slechter 
werkend immuunsysteem op hogere leeftijd kan mogelijk het risico op tumorontwikkeling en 
-metastasering vergroten5. Zoals aangegeven met B, is toenemende leeftijd ook geassocieerd 
met bepaalde patiëntkarakteristieken. Borstkankerspecifieke uitkomsten kunnen beïnvloed 
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worden door ‘competing mortality’; het risico om aan andere, niet aan borstkanker gerelateerde 
oorzaken te overlijden alvorens men aan borstkanker zou overlijden. Dit risico neemt toe met 
het stijgen van de leeftijd en kan zo borstkankerspecifieke uitkomsten beïnvloeden6. Tenslotte 
kan een toenemende leeftijd invloed hebben op behandelkarakteristieken, zoals aangegeven 
met C. Het is bekend dat ouderen vaker minder uitgebreid worden behandeld; mogelijk worden 
zij in sommige gevallen onderbehandeld7. Daarnaast kunnen comorbide aandoendingen en het 
gelijktijdig gebruik van andere medicatie de werkzaamheid van antikankertherapie negatief 
beïnvloeden8.
Andere evaluatie van de effectiviteit van behandeling 
In het derde deel van dit proefschrift wordt de werkzaamheid van verschillende therapieën 
en behandelstrategieën bij ouderen onderzocht. Een systematisch literatuuronderzoek en 
meta-analyse naar de effectiviteit van radiotherapie na borstsparende chirurgie bij oudere 
borstkankerpatiënten toont aan dat ook bij ouderen het relatieve risico op een locoregionaal 
recidief wordt verlaagd door radiotherapie (hoofdstuk 8). De absolute risicoreductie is 
echter klein, en het aantal te behandelen mensen om één recidief te voorkomen neemt 
toe met het stijgen van de leeftijd. Daarnaast beïnvloedt radiotherapie niet het risico op 
afstandsmetastasen en borstkankersterfte. Het achterwege laten van radiotherapie lijkt 
dan ook een reële optie en dient met de patiënt besproken te worden. In hoofdstuk 9 wordt 
onderzocht wat de associatie is tussen het vroegtijdig stoppen met endocriene therapie en 
de algemene overleving en borstkankerspecifieke overleving. Postmenopauzale patiënten die 
jonger zijn dan 65 jaar en binnen een jaar stoppen met endocriene therapie, hebben na dit jaar 
een slechtere algemene en borstkankerspecifieke overleving. Bij oudere patiënten wordt echter 
geen relatie gevonden tussen het vroegtijdig stoppen met endocriene therapie en overleving. 
De opzet van deze studie is niet geschikt om conclusies te trekken over de effectiviteit van 
endocriene therapie bij ouderen, maar suggereert wel dat het zinvol is hier nader onderzoek 
naar te doen. Naast de effectiviteit van specifieke therapie is ook gekeken naar verschillende 
zorgstrategieën (hoofdstuk 10). Een internationale vergelijking tussen Nederlandse patiënten 
met primair gemetastaseerde borstkanker die standaard zorg ontvingen, en patiënten in de 
Verenigde Staten die behandeld werden in een oncogeriatrisch centrum, suggereert dat een 
oncogeriatrische benadering van oudere borstkankerpatiënten resulteert in betere uitkomsten. 
Vervolgonderzoek moet aantonen of dit gepaard gaat met een beter behoud van functioneren 
en kwaliteit van leven, en of deze relatie ook aantoonbaar is in patiënten met borstkanker in 
een vroeg stadium.
Reflectie
Patiënten in een trial versus patiënten in de algemene populatie
Eén van de bevindingen in dit proefschrift is dat oudere patiënten in een trial niet representatief 
zijn voor oudere borstkankerpatiënten in de algemene bevolking. Toch is een aantal van de 
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onderzoeken in dit proefschrift uitgevoerd bij oudere patiënten die participeerden in een 
klinische trial. Men kan zich afvragen of de in deze studies beschreven resultaten ook van 
toepassing zijn op oudere patiënten uit de algemene bevolking. Wat betreft de studies over de 
prognose van oudere borstkankerpatiënten, werd ook bij patiënten uit de algemene bevolking 
gevonden dat het risico op borstkankersterfte toeneemt met de leeftijd. Dat dit niet gepaard 
ging met een hoger risico op afstandsmetastasen is mogelijk het gevolg van leeftijdsspecifieke 
onderdiagnose en -rapportage in een observationeel cohort. 
Kalenderleeftijd versus biologische leeftijd
In de geriatrische oncologie wordt geageerd tegen het gebruik van kalenderleeftijd als (enige) 
criterium voor het aanbevelen of onthouden van behandeling; de grote heterogeniteit binnen 
de ouderen vraagt om andere criteria, zoals biologische leeftijd of functionele status. De studies 
in dit proefschrift zijn echter allemaal verricht met kalenderleeftijd als variabele. Hoewel dit 
niet volledig overeenkomt met biologische leeftijd, is kalenderleeftijd wel sterk geassocieerd 
met comorbiditeit en resterende levensverwachting. Totdat er een eenduidige definitie van 
biologische leeftijd is ontwikkeld kan kalenderleeftijd, al dan niet in combinatie met andere 
factoren, gebruikt worden in onderzoek.
Uitkomstmaten
De in dit proefschrift gebruikte eindpunten zijn algemene overleving en borstkankerspecifieke 
eindpunten. Naast levensverlenging zijn er echter andere, wellicht relevantere uitkomstmaten 
voor oudere patiënten. Zo is bekend dat zij minder geneigd zijn kwaliteit van leven in te 
leveren voor een langere overleving9. Helaas waren andere uitkomsten zoals behoud van 
functioneren, zelfstandigheid of kwaliteit van leven niet voorhanden voor de in dit proefschrift 
gepresenteerde studies. 
Naast de overweging welke uitkomstmaat relevant is voor oudere patiënten, is het ook 
belangrijk om onderscheid te maken in de weergave van de uitkomstmaat. Zoals geobserveerd 
voor radiotherapie na borstsparende therapie, kan met toenemende leeftijd het relatieve 
risico gelijk blijven, terwijl het absolute risicoverschil tussen wel of niet behandelen afneemt. 
Dit is weergegeven in Figuur 2. Hoe kleiner het absolute risicoverschil, hoe groter het aantal 
mensen dat behandeld moet worden om één uitkomst, bijvoorbeeld een borstkankerrecidief, 
te voorkomen. Het absolute risicoverschil, of de ‘number needed to treat’ is wellicht relevanter 
om in te schatten of een behandeling de moeite waard is. De stippellijn is het hypothetische 
afkappunt wanneer een bepaalde behandeling niet meer efficiënt geacht wordt. Dit afkappunt 
kan variëren per behandeling en per patiënt. Omdat elke behandeling bijwerkingen heeft, is het 
bovendien belangrijk dit absolute risicoverschil af te wegen tegen het risico op bijwerkingen en 
de mogelijke gevolgen hiervan. De voorkeur en afwegingen van de patiënt ten aanzien van het 
risico op een borstkankerrecidief, algemeen functioneren en behoud van kwaliteit van leven 
dienen meegenomen te worden in de besluitvorming rondom de behandeling. Het is daarom 
aan te raden om patiënten en hun naaste omgeving actief hierbij te betrekken.




De volgende stap in de geriatrische oncologie is gericht op geïndividualiseerde, op maat 
gesneden therapie. Gegeven de grote heterogeniteit binnen de ouderen is het moeilijk, zo niet 
onmogelijk, om algemene richtlijnen te formuleren over de behandeling van ouderen met 
borstkanker. Men dient datgene te behandelen waaraan men verwacht dat de patiënt het eerst 
zal overlijden. Wanneer voorspeld kan worden wie aan of juist met borstkanker overlijdt, kan 
de behandeling hier op aangepast worden (Figuur 3). Patiënten die op basis van tumor- en 
patiëntkarakteristieken een hoog risico hebben op terugkeer van de ziekte, hebben baat bij 
een adequate, uitgebreide borstkankerbehandeling. Patiënten die daarentegen een laag risico 
hebben op terugkeer van de ziekte, en een hoger risico hebben om aan andere, niet aan 
borstkanker gerelateerde oorzaken te overlijden, kunnen beter ondersteunend behandeld 
worden, met focus op het behoud van functioneren en adequate behandeling van eventuele 
andere comorbide aandoeningen. De ontwikkeling van een predictiemodel kan gebruikt 
worden als ondersteuning van de keuze om een bepaalde behandeling al dan niet in te zetten.
Behandeling
Vanwege het gebrek aan bewijs voor een adequate borstkankerbehandeling moet verder 
onderzoek gedaan worden naar de effectiviteit van de verschillende behandelopties, specifiek 
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bij ouderen. Hiervoor kunnen verschillende studie-opzetten gebruikt worden, waaronder 
gerandomiseerde klinische trials en internationale vergelijkingen van behandelstrategieën. 
Naast antikankerbehandeling dient ook ondersteunende behandeling onderzocht te worden; 
recent is de ‘Climb Every Mountain’ studie opgezet, waarin gekeken wordt welke functies met 
name achteruitgaan na de diagnose en behandeling van ouderen, met als doel gericht te kunnen 
interveniëren. Aanvullend op het onderzoek naar de effectiviteit van behandeling wordt 
onderzoek verricht naar de voorkeur van oudere patiënten voor verschillende behandelopties 
(‘Focus on Preferences’).
Conclusies
De drie conclusies van dit proefschrift zijn dat er gebrekkige bewijsvoering is voor de 
behandeling van oudere patiënten met borstkanker; dat oudere patiënten met borstkanker 
een slechtere prognose hebben dan jongere patiënten; en dat het effect van therapie alsook de 
evaluatie van effectiviteit bij ouderen anders is dan bij jongeren.
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Het onderzoek dat gepresenteerd is in dit proefschrift heeft ertoe geleid dat we beter weten 
wat we niet weten; zo weten we nu dat ouderen een slechtere borstkankerprognose hebben. We 
weten echter nog steeds niet waarom dat zo is. De vraag hoe de behandeling en uitkomsten van 
oudere borstkankerpatiënten geoptimaliseerd kunnen worden, is dus nog niet beantwoord. 
Hoe te handelen in onwetendheid? De volgende aanbevelingen kunnen bruikbaar zijn voor de 
dagelijkse praktijk:
Behandel als eerste datgene dat de meeste invloed op de gezondheid en overleving heeft. 
Patiënten die een hoog risico hebben op een borstkankerrecidief, hebben baat bij een adequate 
en uitgebreide borstkankerbehandeling. Patiënten met een laag risico op terugkeer van de 
ziekte en een hoger risico om aan andere oorzaken te overlijden, kunnen beter ondersteunend 
behandeld worden, met focus op behoud van functioneren en adequate behandeling van 
eventuele andere comorbide aandoeningen.
Oudere patiënten en hun naaste omgeving dienen actief betrokken te worden in de 
besluitvorming rondom de behandeling.  Bij de evaluatie van het effect van therapie dient niet 
alleen gekeken te worden naar relatieve risicomaten, maar ook naar absolute risicoreductie en 
het aantal mensen dat behandeld moet worden om één borstkankereindpunt te voorkomen, 
alsook naar andere uitkomstmaten zoals kwaliteit van leven en behoud van functioneren. 
Een oncogeriatrische benadering van ouderen met borstkanker kan de zorg en uitkomsten van 
oudere patiënten verbeteren.
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Dankwoord
Dit proefschrift had niet gerealiseerd kunnen worden zonder alle patiënten die bereid zijn 
geweest mee te doen aan de verschillende studies. Ik ben hen heel veel dank verschuldigd. 
Onderzoek doe je nooit alleen. Ik wil iedereen bedanken voor alles dat er, direct of heel indirect, 
toe heeft geleid dat ik dit onderzoek heb kunnen doen, en daarbij een ontzettend leuke tijd heb 
gehad, waardoor uiteindelijk dit proefschrift tot stand is gekomen. 
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